File_Name	Text	ICD-O code
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	afectación de médula ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	infiltración ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	neuroblastoma estadio IV (afectación de médula ósea	9500/6
dev-set1-to-publish/cantemist-norm/cc_onco861.ann	RC medular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	Melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco716.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	Angioma	9120/0
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	Carcinosarcoma	8980/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	carcinoma sarcomatoide	8033/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	carcinosarcoma	8980/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	mesotelioma	9050/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	neoplásicas	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	sarcomatoide	8033/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumor heterogéneo	8000/1/H
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	carcinoma escamoso de células claras	8084/3
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	Infiltración pleural por neoformación maligna	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	Carcinosarcoma pulmonar estadio IV (pulmonares	8980/6
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	tumor indiferenciado	8000/34
dev-set1-to-publish/cantemist-norm/cc_onco11.ann	enfermedad a nivel de sistema nervioso central	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco106.ann	T2N2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco106.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco106.ann	recidiva pleuropulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco563.ann	adenocarcinoma de colon moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial	8120/3
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	tumoraciones	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial pTa GII	8120/32
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma mixto urotelial	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial con diferenciación glandular T1 de bajo grado	8120/31
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial, de bajo grado de la OMS	8120/31
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	tumoración papilar	8000/1/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	variante tipo nested de carcinoma urotelial	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	tumoración papilar	8000/1/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial tipo nested	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial infiltrante de vejiga tipo nested	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial infiltrante de alto grado tipo nested	8120/34/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	carcinoma urotelial infiltrante de variante tipo nested	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco43.ann	variante histológica tipo nested del carcinoma urotelial	8120/3/H
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	metástasis de carcinoma renal de células claras	8310/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	carcinoma renal de células claras de 6 cm de diámetro máximo, grado 2 de Fhurman	8310/32
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	metástasis de adenocarcinoma de células claras	8310/6
dev-set1-to-publish/cantemist-norm/cc_onco224.ann	lesión osteolítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	CPNM	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	Carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	carcinoma escamoso	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metástasis de carcinoma escamoso	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	metástasis de un carcinoma escamoso	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	infiltración pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	lesión tumoral en el músculo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	infiltración tumoral de la pleura	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	enfermedad a nivel pulmonar y hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	cáncer pulmonar de células no pequeñas	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco740.ann	cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico	8046/6
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	Carcinoma tímico	8586/3
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	carcinoma tímico	8586/3
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	carcinoma tímico	8586/3
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	carcinoma tímico	8586/3
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	glioblastoma multiforme	9440/3
dev-set1-to-publish/cantemist-norm/cc_onco608.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	masa pélvica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	implante en cúpula vaginal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco500.ann	Adenocarcinoma de colon derecho pT4bN2aM1	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	cáncer de mama metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	metástasis por carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	cutánides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco695.ann	Metástasis cerebelosa de carcinoma ductal infiltrante	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	carcinoma renal de células claras	8310/3
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	carcinoma renal de células claras grado 3 de Fuhrman	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco246.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	adenocarcinoma de pulmón (T2BN0M1b	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	lesión frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	enfermedad cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	lesión frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco708.ann	masa retroperitoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	Lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	adenocarcinoma pobremente diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	carcinoma lobulillar	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	carcinoma lobulillar	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	carcinoma lobulillar infiltrante	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	implante tumoral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	Carcinoma lobulillar de mama IV con afectación ósea	8520/6
dev-set1-to-publish/cantemist-norm/cc_onco533.ann	infiltración colónica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	macroadenoma hipofisario	8272/0
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	nódulo en región supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	metástasis de carcinoma de alto grado	8010/64
dev-set1-to-publish/cantemist-norm/cc_onco450.ann	tumor mamario oculto luminal (TxN2M1)	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	melanoma metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	pT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	melanoma diseminado	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco404.ann	lesión resecada del músculo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	Masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	afectación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	cáncer microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	linfoma	9590/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	masa prevertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	neuroblastoma	9500/3
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	tumor desmoide	8821/1
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	metastásis ósea de neuroblastoma	9500/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	Afectación metastásica de la médula ósea de las vértebras sacras	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	metástasis ósea de neuroblastoma	9500/6
dev-set1-to-publish/cantemist-norm/cc_onco66.ann	recaída de neuroblastoma, a nivel óseo	9500/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	Lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	Masa suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	carcinoma de célula pequeña	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	enfermedad a nivel cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	enfermedad sistémica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	implantes pleurales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	linfangitis carcinomatosa	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	progresión pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	progresión pleuropulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	carcinoma microcítico de pulmón enfermedad extendida	8041/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	carcinoma pobremente diferenciado tipo oat-cell	8041/33
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	adenopatías patológicas mediastínicas, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	nódulos hiperecogénicos hepáticos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	Carcinoma microcítico de pulmón enfermedad extendida	8041/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	T4N3M1c	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	lesión de 6 mm a nivel mesencefálico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	tumor microcítico	8002/1
dev-set1-to-publish/cantemist-norm/cc_onco681.ann	RP ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	angiosarcoma cardiaco (11,3 x 10,8 cm) estadio IV (metástasis	9120/6
dev-set1-to-publish/cantemist-norm/cc_onco127.ann	nodulares pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	metástasis por adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesión de cavidad oral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesión en cavidad oral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesión en trígono retromolar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	enfermedad ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesión en hemisacro	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco674.ann	lesión en cavidad oral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	adenocarcinoma bien diferenciado	8140/31
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco402.ann	lesiones ocupantes de espacio en parénquima hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	lesión ocupante de espacio a nivel cerebeloso	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	Adenocarcinoma colorrectal estadio IV (SNC	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	adenocarcinoma de sigma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	lesiones ocupantes de espacio en hemicerebelo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco631.ann	recaída cerebelosa	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	Adenocarcinoma gástrico pobremente diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	implante peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco428.ann	T4N3M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	adenocarcinoma endometrioide	8380/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	adenocarcinoma endometrioide	8380/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	tumor maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	carcinoma indiferenciado de células pequeñas-intermedias	8044/34
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	adenocarcinoma endometrioide de patrón villoglandular	8263/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	estromal maligno	8930/3
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	sarcoma del estroma endometrial indiferenciado	8930/34
dev-set1-to-publish/cantemist-norm/cc_onco322.ann	tumoral indiferenciado	8000/34
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	Tumor fibroso solitario	8815/0
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	sarcoma sinovial	9040/3
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	tumor fibroso solitario	8815/0
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	tumor fibroso solitario	8815/0
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco499.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	neurinoma	9560/0
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumor fibroso solitario	8815/0
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumor fibroso solitario maligno	8815/3
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	recaída pleural múltiple	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	tumor fibroso solitario maligno	8815/3
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	progresión pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco452.ann	progresión tumoral a nivel pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	Cáncer de mama metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión a nivel cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco929.ann	progresión a SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	Adenocarcinoma poco diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	Adenocarcinoma poco diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	Nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco309.ann	Nódulo hipermetabólico a nivel de vértice de pulmón	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco261.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	malignidad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	hepatocarcinoma fibrolamelar	8171/3
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	hepatocarcinoma fibrolamelar poco diferenciado	8171/34
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	Hepatocarcinoma fibrolamelar	8171/3
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	T3aN1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	CHC fibrolamelar	8171/3
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	recidiva hepática, peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	implantes perihepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	progresión hepática, intercostal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	lesión intercostal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco717.ann	PE pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	carcinoma ductal	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	adenocarcinoma ductal moderadamente diferenciado	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	nodulares presentes en el pulmón	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	cáncer de páncreas intervenido con extensión abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	Infiltración del peritoneo parietal por adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	Metástasis pulmonares de cáncer	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco101.ann	extensión abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	metástasis de carcinoma microcítico	8041/6
dev-set1-to-publish/cantemist-norm/cc_onco2.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco821.ann	adenocarcinoma invasor de alto grado	8140/34/H
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	Masa retroperitoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	Tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	masa retroperitoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	masa retroperitoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor del seno endodérmico	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor del seno endodérmico de patrón microquístico	9071/3/H
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor germinal no seminomatoso	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor no seminomatoso	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor de células germinales no seminomatoso	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	meduloepitelioma	9501/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	tumor del seno endodérmico de patrón microquístico y variedad hepatoide	9071/3/H
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	variedad hepatoide	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	meduloepitelioma	9501/3
dev-set1-to-publish/cantemist-norm/cc_onco137.ann	afectación retroperitoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco135.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco135.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco135.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco135.ann	neoformativo	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco135.ann	lesiones nodulares pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	afectación hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	afectación hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	carcinomas de la vía biliar	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	tumores de origen desconocido	8000/9
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	tumores de origen desconocido	8000/9
dev-set1-to-publish/cantemist-norm/cc_onco807.ann	tumores de vías biliares	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	Carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	Implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma poco diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	carcinoma seroso de alto grado	8441/34
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco746.ann	lesión sospechosa en hígado	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	Neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	cT1cN0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	carcinoma ductal	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	neoplásicas	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	metástasis de una neoplasia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	carcinoma lobulillar infiltrante G2 cT2N1M1	8520/62
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	metástasis orbitaria por carcinoma lobulillar	8520/6
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	Carcinoma ductal infiltrante G2	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco243.ann	Carcinoma infiltrante ducto-lobulillar	8522/3
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco114.ann	adenocarcinoma de endometrio de tipo endometrioide moderadamente diferenciado	8380/32
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	síndrome mielodisplásico	9989/3
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	carcinoma escamoso infiltrante	8070/3/H
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	carcinoma escamoso infiltrante queratinizante	8071/3/H
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	lesiones líticas en acromion	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco992.ann	carcinoma escamoso de pulmón, T4N2M1b	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	melanoma maligno	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	melanoma maligno	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	nódulos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	metastásico de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	nodulares subcutáneas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	nodulillos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco963.ann	satelitosis	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	Carcinoma coloide	8480/3
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	cT2N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	cT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	carcinoma coloide	8480/3
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	tumoración epitelial infiltrante constituida por muy abundante material coloide	8480/3
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	pT3aN1(1/16)M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco161.ann	carcinoma renal de células claras, grado 1-2 de Fürhman	8310/32
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	carcinoma seroso papilar	8461/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	lesiones blásticas a nivel de L1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Afectación de apófisis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	focos nodulares en D11	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	afectación del cuerpo vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	expansión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Carcinoma Ductal Infiltrante Grado II de Nottingham	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	lesiones de predominio lítico en unión condro-esternal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Carcinoma Ductal Infiltrante de Mama cT4NxM1	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco341.ann	Ca	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor germinal	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	hepatocarcinoma multifocal	8170/3/H
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor de yolk salk de tipo endometroide	9071/3/H
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	tumor de células germinales del seno endodérmico	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	yolk sac tumor	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco93.ann	neoplasia que adopta un patrón de crecimiento papilar y tubular infiltrante	8000/3/H
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco972.ann	carcinoma ductal infiltrante (CDI) grado 3	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	Carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	Nódulo pulmonar contralateral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco8.ann	Carcinoma indiferenciado de pulmón, Estadio IV (T2bN2M1a)	8020/6
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	HCC moderadamenteo diferenciado	8170/32
dev-set1-to-publish/cantemist-norm/cc_onco392.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	infiltración medular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	leucemia aguda	9801/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	masa anexial	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	adenocarcinoma gástrico de tipo difuso	8145/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	adenocarcinoma gástrico de tipo difuso antral, con células en anillo de sello	8490/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	adenocarcinoma gástrico de tipo difuso con células en anillo sello	8490/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	adenocarcinoma gástrico de tipo difuso	8145/3
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	ypT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	ypT4N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	recidiva ovárica bilateral de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	infiltración masiva de médula ósea por adenocarcinoma gástrico con células en anillo de sello	8490/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	progresión ganglionar y ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	infiltración masiva difusa de médula ósea por adenocarcinoma con células en anillo de sello	8490/6
dev-set1-to-publish/cantemist-norm/cc_onco911.ann	infiltración masiva de médula ósea por adenocarcinoma con células en anillo de sello	8490/6
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	carcinoma seroso	8441/3
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	carcinoma seroso de alto grado	8441/34
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	células neoplásicas	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco570.ann	carcinoma seroso de ovario de alto grado	8441/34
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	Metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	adenocarcinoma bien diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco856.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	progresión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	carcinoma ductal infiltrante grado III	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	Carcinoma ductal infiltrante grado III	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	pT4N2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	lesiones milimétricas supratentoriales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco620.ann	enfermedad a nivel sistémico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	carcinoma de células claras de riñón derecho grado 2 (Fuhrman)	8310/32
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	carcinoma de células claras grado 2 (Fuhrman)	8310/32
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	nódulos en el LSI	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco166.ann	nódulo de 8 mm en el LSI	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	tumoración de origen mesenquimal	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	tumoración mesenquimal	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	tumor estromal gastrointestinal (GIST) maligno	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	metastatizado	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco952.ann	nódulo hipodenso de 12 mm en región iliaca	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	CHC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	CHC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	neoplásica	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco438.ann	CHC multicéntrico	8170/3/H
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	Carcinoma Medular de tiroides	8510/3
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	Carcinoma medular de tiroides	8510/3
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	Carcinoma medular de tiroides	8510/3
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	Leucemia mieloide crónica	9863/3
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco256.ann	MEN 2	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	CNMP	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	lesión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	progresión a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	progresión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	adenopatías mediastínicas y supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	lesiones blásticas en columna cervical	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	adenocarcinoma de pulmón ALK positivo avanzado (estadio cT4cN3M1b	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	progresión a nivel del SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco865.ann	lesiones subcentimétricas supra e infratentoriales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	afectación hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	progresión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	lesión hipodensa en el lóbulo hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco73.ann	lesiones ocupantes de espacio hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	metástasis por adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	masa pulmonar maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	LOE de 14 x 17 mm en región parietal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco879.ann	LOE cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	enfermedad a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	lesiones cerebrales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	lesiones cerebrales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	lesiones ocupantes de espacio en hemisferio cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	carcinoma epidermoide de pulmón estadio IV, cT4 cN0 M1c	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco917.ann	lesiones pulmonares y hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	síndrome de Lynch	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	tumor de origen pancreatobiliar	8163/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	síndrome de Lynch	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco875.ann	masas peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	"tumor neuroendocrino (TNE) indiferenciado tipo ""oat cell"""	8002/34
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	tumor neuroendocrino (TNE) indiferenciado	8000/34/H
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	TNE de alto grado	8000/34/H
dev-set1-to-publish/cantemist-norm/cc_onco391.ann	Tumor Neuroendocrino pulmonar de alto grado	8000/34/H
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	T3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión spitzoide	8770/0
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión hiperpigmentada	8720/0
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	M1d(1)	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	metástasis por melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	enfermedad a nivel del sistema nervioso central	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	lesión paracardiaca	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco649.ann	captación nodular peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	Carcinoma urotelial	8120/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	Nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	micronódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	micronódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	neoformación maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	tumoración papilar sólida	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	carcinoma sólido urotelial de alto grado (G3)	8120/33
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	micronódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	lesión intrapélvica renal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	lesión en la pelvis renal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	lesión renal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	Lesión renal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	masa en cara anterior de iris	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	masa a nivel del iris	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	Lesión en iris	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco747.ann	lesión intraocular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	Carcinoma de mama ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma inflamatorio	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	enfermedad ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma ductal infiltrante subtipo no especial (tipo inflamatorio)	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma ductal infiltrante subtipo no especial(tipo inflamatorio)	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	Carcinoma de mama ductal infiltrante (tipo inflamatorio)	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	carcinoma infiltrante de subtipo histológico no especial grado 3	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	captación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	diseminación leptomeníngea de su neoplasia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	captación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	enfermedad a nivel del SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco42.ann	nodulares osteoblásticas en columna vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	carcinomatosa	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	neoformativa	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	lesión intraepitelial tipo CIN-3	8077/2
dev-set1-to-publish/cantemist-norm/cc_onco933.ann	CT2B CN0 CMX	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	coriocarcinoma	9100/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	coriocarcinoma	9100/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumor germinal no seminomatoso	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	recaída tardía de un tumor germinal no seminomatoso	9065/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	metástasis de tumor de células germinales no seminomatoso	9065/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumor testicular germinal no seminomatoso	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	coriocarcinoma y probablemente de carcinoma embrionario	9101/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	coriocarcinoma y probablemente de carcinoma embrionario	9101/3
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	tumor germinal metastásico	9064/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	metástasis de tumor germinal no seminomatoso	9065/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	adenopatía tumoral paratraqueal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	masa paratraqueal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco26.ann	nódulo apical del pulmón	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	progresión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	adenopatía en región supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	Recidiva ganglionar supraclavicular de carcinoma ductal infiltrante	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco753.ann	recaída ganglionar supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	mioma	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	miomas	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	SEE bajo grado	8931/3
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	SEE de bajo grado	8931/3
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	SEE bajo grado	8931/3
dev-set1-to-publish/cantemist-norm/cc_onco806.ann	SEE bajo grado	8931/3
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	METÁSTASIS DE ADENOCARCINOMA	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	meningioma	9530/0
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	meningioma	9530/0
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	infiltración focal ósea por adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	ADK Gleason 4+5	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	lesiones osteogénicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco335.ann	ADK prostático estadío IV, hormonosensible, con diseminación ósea	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco557.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco557.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco557.ann	tumoraciones	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco557.ann	tumoraciones de partes blandas	8800/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	intratumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	suelta de globos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumor germinal	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumor germinal	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	multinodulares pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	neoplásica maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	tumor germinal con enfermedad secundaria	9064/6
dev-set1-to-publish/cantemist-norm/cc_onco501.ann	TxNxM1b	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	neoplasia fusocelular	8004/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	tumoración mesenquimal	8990/1
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	rabdomiosarcoma embrionario	8910/3
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	Rabdomiosarcoma embrionario	8910/3
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	rabdomiosarcoma embrionario	8910/3
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	rabdomiosarcoma de variante fusocelular esclerosante	8912/3
dev-set1-to-publish/cantemist-norm/cc_onco46.ann	rabdomiosarcoma esclerosante	8900/3
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	cáncer folicular de tiroides variante de células claras con metástasis	8310/6
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	cáncer folicular	8330/3
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	CCS de alto grado	8370/34
dev-set1-to-publish/cantemist-norm/cc_onco274.ann	CCS de alto grado	8370/34
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	Teratoma inmaduro	9080/3
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	implante tumoral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	teratoma	9080/1
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	quístico-sólido	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	teratoma inmaduro de ovario grado 3 con implantes en el epiplón	9080/63
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	implantes perihepáticos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	implante en el saco de Douglas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	tejido adiposo metastatizado por tejido teratomatoso maduro	9080/3/H
dev-set1-to-publish/cantemist-norm/cc_onco124.ann	teratoma inmaduro grado 0	9080/3/H
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	carcinoma seroso papilar	8460/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	metástasis de carcinoma pleomórfico de alto grado	8022/64
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	adenopatía supraclavicluar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco257.ann	adenocarcinoma de ovario seroso-papilar de alto grado	8460/34
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	tumor germinal	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco618.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	Melanoma Maligno de extensión superficial	8743/3
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	mixoma	8840/0
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	mixoma	8840/0
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	cáncer metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	T2aN0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco369.ann	Tumor de estroma laxo mucoide	8840/0
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	carcinoma inflamatorio	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	carcinomatosa	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	cistoadenocarcinoma seroso papilar de alto grado	8460/34
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	lesiones cutáneas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	letálides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	tumoraciones	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	carcinoma de alto grado de patrón seroso papilar	8460/34
dev-set1-to-publish/cantemist-norm/cc_onco149.ann	metastásica dérmica de mama bilateral por carcinoma seroso	8441/6
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	CARCINOMA RENAL DE DUCTOS COLECTORES	8319/3
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	carcinoma de ductos colectores pT3b , grado 2 de Fuhrman	8319/32
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	enfermedad a nivel peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco272.ann	carcinoma de túbulos de Bellini	8319/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	afectación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	afectación meníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	infiltración de la medula ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	infiltración de la médula ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	infiltración leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	lesiones líticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metástasica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos subcutáneos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	nódulos subpleurales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	MO infiltrada por SE	9260/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	SE con enfermedad metastásica	9260/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	SE	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	Sarcoma de Ewing metastásico	9260/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	progresión tumoral ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	infiltración de la MO	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	SE	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	SE	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco86.ann	médula ósea infiltrada	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	carcinomas basocelulares	8090/3
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	células neoplásicas	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	lesión lítica en el cuerpo vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	macroadenoma hipofisario	8272/0
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	macroadenoma hipofisario	8272/0
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	mixomas	8840/0
dev-set1-to-publish/cantemist-norm/cc_onco987.ann	tumor papilar intraquístico grado I	8504/31
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	sarcoma epitelioide	8804/3
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco468.ann	progresión a nivel ganglionar, paraespinal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	lesiones de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	carcinoma de células claras Fürhmann 3	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	lesiones en columna vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	metástasis de carcinoma sarcomatoide	8033/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	metástasis de carcinoma de células claras con diferenciación sarcomatoide	8964/6
dev-set1-to-publish/cantemist-norm/cc_onco913.ann	lesiones situadas a nivel lumbosacro	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	Seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	afectación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	coriocarcinoma	9100/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	coriocarcinoma	9100/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	diseminación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	diseminación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinoma	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	infiltración leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	teratoma maduro	9080/0
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	teratoma maduro	9080/0
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores de células germinales	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	GCTs	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores germinales	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	Germ cell tumors	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	GCTs	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinomas	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	non-germinomatous GCTs	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	NGGCTs	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumor seno endodérmio	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	teratoma maduro e inmaduro	9080/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores mixtos	8000/1/H
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	NGGCTs	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	seminomas	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	GCTs	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinomas	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	tumores germinales	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	yolk sac tumor	9071/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinomatosos mixtos	9064/3/H
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germ cell tumors (GCTs) intracraneales non-germinomatous	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	GCTs	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	NGGCTs	9065/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	GCT germinomatous	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinomas multifocales	9064/3/H
dev-set1-to-publish/cantemist-norm/cc_onco258.ann	germinomas multifocales o metastásicos	9064/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	adenocarcinoma de próstata Gleason 6	8140/31
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	adenocarcinoma de próstata Gleason 8	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	adenopatías cervicales, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	mielofibrosis	9931/3
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	adenocarcinoma de próstata estadio IV por afectación ósea	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	progresión exclusivamente a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	progresión a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	fibrosis medular	9931/3
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	progresión a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco757.ann	lesiones blásticas en columna	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	adenoma	8140/0
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	linfangitis carcinomatosa	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	adenocarcinoma de pulmón estadio IV (derrame pericárdico positivo	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	nódulos adrenales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	nódulos suprarrenales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco891.ann	progresión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	formación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	lesiones focales hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	metastasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	lesiones hipoecogénicas hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	adenocarcinoma gástrico moderadamente diferenciado, variante anillo de sello	8490/32
dev-set1-to-publish/cantemist-norm/cc_onco144.ann	focos en el parénquima hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	intratumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	miomas	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	prolactinoma	8271/0
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	macroadenoma hipofisario (2,5x2,0x2,3 cm) secretor de prolactina	8271/0
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	Macroprolactinoma	8271/0
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	adenoma de hipófisis	8272/0
dev-set1-to-publish/cantemist-norm/cc_onco296.ann	adenoma hipofisario	8272/0
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	NSCLC	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	NSCLC	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	cáncer de pulmón no microcítico	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	cáncer de pulmón no microcítico	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	sarcomatoide	8033/3
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	carcinoma adenoescamoso pobremente diferenciado	8560/33
dev-set1-to-publish/cantemist-norm/cc_onco730.ann	progresión torácica y suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	timoma	8580/1
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	timoma de fenotipo e inmunofenotipo tipo B2	8584/1
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	leucemia mielomonocítica crónica (LMMC) tipo mielodisplásica	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	LMMC	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	LMMC-1	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	Timoma tipo B2	8584/1
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	Leucemia mielomonocítica crónica	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	LMMC	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco596.ann	leucemia mielomonocítica crónica	9945/3
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	Adenoma	8140/0
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	Hemangioma	9120/0
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	peritumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	Carcinoma renal de células claras, pT3bN0M1	8310/6
dev-set1-to-publish/cantemist-norm/cc_onco29.ann	carcinoma renal de células claras, Fuhrman 3	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	histiocitosis de células de Langerhans	9751/3
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	histiocitosis de células de Langerhans	9751/3
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	metástasis hepáticas de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	adenocarcinoma de recto localmente avanzado con afectación hepática	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco212.ann	cáncer metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	afectación pulmonar y ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	linfangitis carcinomatosa	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	Adenocarcinoma de pulmón cT4cMxpM1b	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco921.ann	afectación intersticial pulmonar bilateral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	Carcinoma infiltrante	8010/3/H
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	afectación hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	cM1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	carcinoma infiltrante	8010/3/H
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco321.ann	adenopatías sospechosas axilares, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	adenoma	8140/0
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	afectación del sistema nervioso central	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	T1bN1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco182.ann	adenocarcinoma pulmonar de patrón acinar	8550/3
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	mesotelioma	9050/3
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	mesotelioma maligno	9050/3
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco625.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco400.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco400.ann	lesión en pala iliaca izquierda	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco400.ann	carcinoma epidermoide de pulmón estadio IV por afectación suprarrenal	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco400.ann	lesión en pared costal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco752.ann	T1N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco752.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco752.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco752.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco752.ann	nódulos pleurales bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	lesiones a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	metastasis por carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	adenopatías axilares, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	CDI de mama, grado histológico III	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	ganglionar supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco336.ann	CDI de mama oligometastásica	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco954.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco954.ann	enfermedad ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco954.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco954.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	enfermedad a nivel cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	enfermedad pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	implantes pleurales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	lesiones cerebrales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibroma	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibroma	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibromatosis	9540/1
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neurofibromatosis	9540/1
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	sarcoma fusocelular	8801/3
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	sarcoma pleomórfico de alto grado	8802/34
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	suelta de globo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	neoplásica de patrón fusocelular	8004/1
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	sarcoma retroperitoneal pleomórfico de alto grado	8802/34
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	tumor maligno de vaina nerviosa periférica estadio IV por la presencia de metástasis	9540/6
dev-set1-to-publish/cantemist-norm/cc_onco616.ann	implante en pleura	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	adenocarcinoma pobremente diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	neoplasia de origen desconocido	8000/9
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	tumor de Klatskin	8162/3
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	Colangiocarcinoma extrahepático GHIII	8160/33
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	pT2pN1M0-R0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco443.ann	LOE hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	masa pélvica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	miomas	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	miomas	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	miomas	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	progresión peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	recaída pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	miomatosis	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	uM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	ypT3N1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	ypT3N1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	nódulos de 4 y 5 mm en bases pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	adenocarcinoma gástrico rIV (OTHER	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	adenocarcinoma gástrico rIV (PULMONAR	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	progresión a nivel peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	implante rectovesical	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	implantes en cara anterior de recto	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco995.ann	implante en mesocolon	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	CHC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	CHC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	Carcinoma hepatocelular (CHC) moderadamente diferenciado	8170/32
dev-set1-to-publish/cantemist-norm/cc_onco340.ann	implante de hepatocarcinoma	8170/6
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	neoplásicas	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	tumor del estroma gastrointestinal	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	leucemia aguda mielomonocítica	9867/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	sarcoma mieloide	9930/3
dev-set1-to-publish/cantemist-norm/cc_onco932.ann	leucemia aguda mielomonocítica	9867/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	CARCINOMA ESCAMOSO QUERATINIZANTE	8071/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	CELULAS MALIGNAS	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	Carcinoma escamoso	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	Carcinoma metaplásico	8575/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	afectación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	carcinoma metaplásico	8575/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	diferenciación escamosa	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	macrometástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	macrometástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	macrometástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	ypT1cN2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	nódulo en LSD	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	neoformativas	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	metástasis de carcinoma metaplásico	8575/6
dev-set1-to-publish/cantemist-norm/cc_onco378.ann	lesión endobronquial	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	carcinoma no microcítico	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	metástasis de carcinoma ductal infiltrante	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	mioma	8895/0
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	pT1bN0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	pT2N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	carcinoma medular atípico	8513/3
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	carcinoma ductal infiltrante pT1bN0M0, grado III	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco678.ann	Adenocarcinoma de pulmón metastásico	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco146.ann	tumor odontogénico sarcomatoso	9270/1
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	T4N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	células neoplásicas	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	neoplásicas	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	progresión pulmonar bilateral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	adenocarcinoma de pulmón patrón bronquioalveolar bien diferenciado	8250/31
dev-set1-to-publish/cantemist-norm/cc_onco30.ann	afectación pulmonar bilateral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco763.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco763.ann	cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	Carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	carcinoma infiltrante	8010/3/H
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	diferenciación escamosa	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	lesiones a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	cT3cN0cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco813.ann	cT3cN0cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	progresión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	pT4bN+Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	carcinoma ductal infiltrante, grado I de la clasificación de Nottingham	8500/31
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesión osteolítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	ypT1bN0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	lesión osteolítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	enfermedad, esta vez a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco415.ann	enfermedad a nivel de sacro	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco154.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco154.ann	adenocarcinoma de próstata Gleason (4+5)	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco154.ann	Adenocarcinoma de próstata metastásico (metástasis óseas) Gleason 4+5	8140/63
dev-set1-to-publish/cantemist-norm/cc_onco154.ann	ADC de próstata E-IV (metástasis	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco154.ann	PE ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	macrometástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	carcinoma ductal infiltrante G1	8500/31
dev-set1-to-publish/cantemist-norm/cc_onco123.ann	carcinoma ductal infiltrante de 5,5 mm grado histológico 1	8500/31
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	implantes peritoneales con diagnóstico de carcinoma de ovario pobremente diferenciado	8010/63
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	lesión localizada en el ligamento gastrohepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	masa del ligamento gastrohepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco368.ann	carcinoma de ovario pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	Feocromocitoma	8700/3
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	Nódulo hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	feocromocitoma	8700/3
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	masa mediastínica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	nódulo hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	feocromocitoma suprarrenal derecho con metástasis	8700/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	Feocromocitoma maligno metastásico	8700/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	Metástasis de Feocromocitoma	8700/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	metastatizante	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	metástasis de feocromocitoma	8700/6
dev-set1-to-publish/cantemist-norm/cc_onco244.ann	enfermedad a nivel laterocervical y hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	condrosarcoma	9220/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	condrosarcoma	9220/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	progresa a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	proliferación mesenquimal maligna	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma metaplásico heterólogo	8575/3/H
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma ductal infiltrante grado III	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	sarcoma de alto grado con diferenciación de matriz cartilaginosa	8800/34/H
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	fusocelular mesenquimal neoplásico	8801/3
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma de mama metaplásico heterólogo con diferenciación condrosarcomatoide estadio IV con afectación pulmonar	8575/6
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma de mama metaplásico heterólogo	8575/3/H
dev-set1-to-publish/cantemist-norm/cc_onco725.ann	carcinoma de mama metaplásico heterólogo con diferenciación condrosarcomatoide	9220/3
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	captación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	Meduloblastoma grado IV	9470/34
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	meduloblastoma grado IV	9470/34
dev-set1-to-publish/cantemist-norm/cc_onco206.ann	recidiva a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	cT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	fibroadenoma	9010/0
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	lesión lítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumor de Phyllodes	9020/1
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	tumor Phyllodes maligno	9020/3
dev-set1-to-publish/cantemist-norm/cc_onco502.ann	benignidad	8000/0
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	CM	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	enfermedad a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	metástasis de carcinoma lobulillar	8520/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	patrón difuso tipo lobulillar	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	neoplasia gástrica con enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	adenomegalia supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	adenocarcinoma difuso	8145/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	patrón difuso	8145/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	carcinoma de células en anillo de sello	8490/3
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	médula ósea (que aparece masivamente infiltrada	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	CLI metastásico	8520/6
dev-set1-to-publish/cantemist-norm/cc_onco555.ann	lesión gástrica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	Melanoma metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	focos osteoblásticos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	masa suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	metástasis por melanoma maligno	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	lesión en cuerpo vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	masa pararrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	masa pararrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	lesión residual pararrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco965.ann	lesión residual pararrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	Neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	tumoraciones	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	adenocarcinoma de recto-sigma clásico tipo infiltrante	8140/3/H
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	metastáticos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco176.ann	enfermedad secundaria	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	M1c	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	T2aN2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	células epiteliales malignas	8001/3/H
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	Masa supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	neoplasia de pulmón estadio radiológico T2aN3M1a	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	metástasis de carcinoma no célula pequeña	8046/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	carcinoma no célula pequeña metastásico	8046/6
dev-set1-to-publish/cantemist-norm/cc_onco560.ann	afectación supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	afectación secundaria	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	carcinoma de célula no pequeña	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	tumor maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	adenocarcinoma de pulmón poco diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	adenocarcinoma de pulmón poco diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	carcinoma de células gigantes	8031/3
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	adenoma tubular con displasia de bajo grado	8211/0/H
dev-set1-to-publish/cantemist-norm/cc_onco355.ann	metástasis polipoide del carcinoma	8210/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	Progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	Progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	Progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco462.ann	carcinoma ductal infiltrante en mama izquierda con componente in situ grado III	8500/23
dev-set1-to-publish/cantemist-norm/cc_onco836.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco836.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco836.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco836.ann	carcinoma epidermoide no queratinizante	8072/3
dev-set1-to-publish/cantemist-norm/cc_onco836.ann	carcinoma epidermoide de timo	8585/3
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	melanoma de extensión superficial	8743/3
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	melanoma maligno de extensión superficial	8743/3
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	progresión a nivel pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	progresión pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	adenopatías en la región supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	ganglionar supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco145.ann	ganglionar axilo-supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	adenocarcinoma infiltrante	8140/3/H
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco935.ann	neoplasia mucinosa intraductal papilar con displasia de alto grado	8453/2
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	adenopatías laterocervicales,supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	enfermedad tumoral diseminada	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco195.ann	lesión a nivel del seno esfenoidal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	Tumor de células gigantes	8003/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	condrosarcoma	9220/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	intratumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	osteosarcoma	9180/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumor de células gigantes	8003/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumor de células gigantes	8003/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumor de células gigantes	8003/3
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco824.ann	Tumor de células gigantes en cóndilo femoral	9250/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	tumor neuroendocrino	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	Tumor maligno indiferenciado de células redondas inclasificable	8000/34/H
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	recidiva tumoral de sarcoma	8800/6
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	Tumor maligno indiferenciado de células redondas inclasificable	8000/34/H
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	recidiva de sarcoma	8800/6
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	progresión a nivel abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco711.ann	tumor de corteza suprarrenal	8370/1
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	carcinoma infiltrante	8010/3/H
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	carcinoma infiltrante	8010/3/H
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	carcinoma inflamatorio	8530/3
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	enfermedad diseminada	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	letálides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	bultoma supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	progresión local en mama, pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	progresión a nivel de SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	lesión única frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	enfermedad estable a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	RC hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	progresión en SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco598.ann	RC pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	pT2pN1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	tumor de Klatskin	8162/3
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	adenocarcinoma de la vía biliar principal, bien diferenciado	8160/31
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	tumor de Klatskin	8162/3
dev-set1-to-publish/cantemist-norm/cc_onco833.ann	colangiocarcinoma (tumor de Klatskin) pT2pN1M0 bien diferenciado	8160/31
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	T4N2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	carcinoma poco diferenciado de células pequeñas	8041/33
dev-set1-to-publish/cantemist-norm/cc_onco203.ann	oat cell	8002/3
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	adenocarcinoma moderadamente diferenciado, que en su superficie muestra patrón túbulo-velloso	8263/3
dev-set1-to-publish/cantemist-norm/cc_onco472.ann	adenocarcinoma de uretra moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco839.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco839.ann	CNE G3	8246/33
dev-set1-to-publish/cantemist-norm/cc_onco839.ann	afectación multisistémica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	Timoma	8580/1
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	Timoma	8580/1
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	Timoma	8580/1
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	Timoma linfocítico	8583/1
dev-set1-to-publish/cantemist-norm/cc_onco236.ann	Timoma mixto linfocítico y epitelial	8582/1
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	adenocarcinoma de próstata Gleason 6	8140/31
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	enfermedad sistémica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	lesiones cerebrales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	lesión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	oligometastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	progresión sistémica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	benignidad	8000/0
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	benignidad	8000/0
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	tejido cerebral infiltrados por un adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	lesión intraparietal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	Adenocarcinoma de pulmón cT1pN2 pM1	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	nódulo suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	nódulo suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco930.ann	progresión tumoral sistémica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	masa pericárdica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco455.ann	masa pericárdica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	recaída pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	rabdomiosarcoma embrionario	8910/3
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	Rabdomiosarcoma embrionario	8910/3
dev-set1-to-publish/cantemist-norm/cc_onco648.ann	masa parahiliar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	cT4N1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	letálides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	metástasis del carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	carcinoma ductal infiltrante (CDI) de mama derecha, grado 2	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco519.ann	cT1bN0M1b	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco346.ann	Melanoma maligno	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco346.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco346.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco346.ann	Melanoma de células epitelioides y fusiformes	8770/3
dev-set1-to-publish/cantemist-norm/cc_onco346.ann	pT4N3M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco626.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	carcinomatosa	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	seminoma	9061/3
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumor de células germinales	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumor germinal	9064/3
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	Tumor germinal extragonadal mediastínico mixto	9085/3
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	tumor germinal extragonadal mixto	9085/3
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	masa a nivel supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco76.ann	teratoma maligno	9080/3
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	T3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	carcinoma ductal infiltrante de mama derecha grado II	8500/34
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	adenocarcinoma invasor	8140/3/H
dev-set1-to-publish/cantemist-norm/cc_onco393.ann	progresión ganglionar, ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	celularidad tumoral	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes en el peritoneo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	nódulos peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	neuroblastoma anaplásico	9500/34
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	neuroblastoma anaplásico	9500/34
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes en la superficie del bazo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes de tumor neuroectodérmico primitivo	9473/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	implantes en la grasa perihiliar esplénica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	tumor neuroectodérmico periférico	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	recaída precoz esplénica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	enfermedad a nivel abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	neuroblastoma anaplásico	9500/34
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	recidiva precoz peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco117.ann	nódulo pélvico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	letálides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	letálides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	cáncer ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	cT4bN1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	carcinoma ductal infiltrante residual multifocal, grado 2 de Bloom-Richardson Modificada	8500/32/H
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	lesión en oído	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	cáncer de mama avanzado por metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco692.ann	lesión de oído	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	adenoma	8140/0
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	hepatoblastoma	8970/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	lesión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	leucemia linfoblástica aguda	9835/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	masa hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	nefroblastoma	8960/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	hepatoblastoma embrionario con diferenciación colangiolar	8970/3/H
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	blastoma	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	hepatoblastoma mixto: epitelial (embrionario y fetal)	8970/3/H
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	recidiva hepática de hepatoblastoma	8970/6
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	hepatoblastoma embrionario con diferenciación colangiolar	8970/3/H
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	Hepatoblastoma embrionario	8970/3
dev-set1-to-publish/cantemist-norm/cc_onco229.ann	Recidiva hepática tardía de Hepatoblastoma Embrionario	8970/6
dev-set1-to-publish/cantemist-norm/cc_onco207.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco207.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco207.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco207.ann	sarcoma pleomórfico indiferenciado	8802/34
dev-set1-to-publish/cantemist-norm/cc_onco876.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco876.ann	carcinoma pulmonar de células no pequeñas	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco876.ann	carcinoma escamoso de pulmón T3 N3 M1a	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	carcinoma escamoso infiltrante	8070/3/H
dev-set1-to-publish/cantemist-norm/cc_onco653.ann	carcinoma escamoso de pulmón T4N3M1	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco273.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco273.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco273.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco273.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco689.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco689.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco689.ann	adenocarcinoma de patrón micropapilar	8265/3
dev-set1-to-publish/cantemist-norm/cc_onco689.ann	adenocarcinoma de pulmón cT2aN3M1c	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	Carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	CDI GIII (sistema de Nottingham)	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco846.ann	CDI GIII	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	tumor de células redondas	8041/1
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	sarcoma indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	pMX	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	recidiva pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	metástasis pulmonares de sarcoma	8800/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	implante paratraqueal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	masa subcarinal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	progresó a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco552.ann	implante subcarinal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibroma	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibromas	9540/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibromatosis	9540/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	sarcomatosa	8800/9
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumor maligno de la vaina nerviosa	9540/3
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumor maligno de la vaina nerviosa	9540/3
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumor maligno de alto grado de la vaina nerviosa	9540/34
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibroma plexiforme	9550/0
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	tumor maligno de la vaina nerviosa	9540/3
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	recaída frontal de tumor maligno de la vaina nerviosa	9540/6
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	infiltración parenquimatosa cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco116.ann	neurofibroma con degeneración maligna	9540/3
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	TCG	8620/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	afectación hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	tumor de células de la granulosa juvenil	8622/1
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	Implante en fondo uterino	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	Implantes neoplásicos en subserosa de cérvix	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco303.ann	tumor ovárico bilateral de células de la granulosa (TCG) juvenil	8622/1
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	T3N1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco878.ann	adenocarcinoma de recto moderadamente diferenciado	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	carcinoma in situ	8010/2
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	carcinoma neuroendocrino de célula pequeña	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	lesión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	lesión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	lesión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	lesión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	CIN III	8077/2
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	recidiva tumoral suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco780.ann	progresión suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	carcinoma seroso de alto grado	8441/34
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	diseminación peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	implantes peritoneales múltiples	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	progresión peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	implantes sólidos en el peritoneo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	afectación extensa del meso	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	diseminación meníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco733.ann	realces meníngeos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	Carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	Carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	afectación peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	carcinoma pobremente diferenciado	8010/33
dev-set1-to-publish/cantemist-norm/cc_onco126.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	carcinoma sarcomatoide	8033/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesiones de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesión de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	progresión radiológica a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	síndrome linfoproliferativo	9970/1
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	tumor de células fusiformes	8004/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	tumor fusocelular	8032/1
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	síndrome linfoproliferativo crónico T variedad linfocitos granulares grandes	9831/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	adenocarcinoma de pulmón infiltrante tipo papilar	8503/3
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	metástasis de un carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	Carcinoma sarcomatoide de origen pulmonar cTx cNx pM1c	8033/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	afectación múltiple en tejidos blandos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	progresión a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesiones conocidas de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco590.ann	lesiones sospechosas en partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	diseminación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	implantes pleurales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	adenocarcinoma de lóbulo superior izquierdo T2aN2M1a	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	progresión sintomática a nivel del sistema nervioso central	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco866.ann	progresión a nivel del SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	células tumorales malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	lesión esplénica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	melanoma nodular	8721/3
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	pT4bpN1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco523.ann	melanoma BRAF no mutado metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	recidiva a nivel de hilio pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	tumor de estirpe mesenquimal	8800/1
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	PEComa	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	perivascular epithelioid cell neoplasms	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	PEComa	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	PEComa	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	PEComa	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	recidiva a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco412.ann	PEComa	8011/1/H
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	HCC	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco550.ann	hepatocarcinoma	8170/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	fibrosarcoma	8810/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	implantes mesentéricos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma retroperitoneal de bajo grado	8800/31
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma retroperitoneal indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	Sarcoma indiferenciado pleomórfico con fenotipo epitelioide/rabdoide	8901/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas	8806/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	Sarcoma indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	Sarcoma indiferenciado pleomórfico con fenotipo epitelioide	8804/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas con fenotipo rabdoide	8963/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma retroperitoneal indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	fibrosarcoma epitelioide	8804/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas pequeñas	8806/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	fibrosarcoma epitelioide esclerosante	8810/3/H
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma de bajo grado	8800/31
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	progresión radiológica hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma indiferenciado pleomórfico con fenotipo epitelioide/rabdoide	8901/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma indiferenciado pleomórfico con fenotipo epitelioide	8804/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas con fenotipo rabdoide	8963/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas	8806/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	tumor desmoplásico de células redondas	8806/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco170.ann	sarcoma de Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	afectación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	masa de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	adenocarcinoma de próstata Gleason 3+5	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	afectación metastásica a nivel cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco381.ann	lesiones blásticas que afectan a la calota	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	Tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	hemangioendotelioma epitelioide	9133/1
dev-set1-to-publish/cantemist-norm/cc_onco28.ann	HE	9133/1
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	Melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	Melanoma de extensión superficial	8743/3
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	Melanoma de extensión superficial	8743/3
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	afectación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	peritumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco367.ann	pT3bpN1b(2/8)M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	carcinoma cortical adrenal	8370/3
dev-set1-to-publish/cantemist-norm/cc_onco904.ann	Carcinoma cortical adrenal productor de testosterona pT3pN0M1	8370/6
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	cordoma	9370/3
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	linfoma	9590/3
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	plasmocitoma	9731/3
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	tumor de células gigantes de hueso	9250/1
dev-set1-to-publish/cantemist-norm/cc_onco68.ann	Tumor de células gigantes óseo	9250/1
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	Carcinoma epidermoide de pulmón izquierdo cT2N3 M1a	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	nódulo pulmonar contralateral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	carcinoma urotelial de bajo grado no invasivo	8130/21
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	tumoración papilar vesical	8130/1
dev-set1-to-publish/cantemist-norm/cc_onco571.ann	lesión en cabeza de páncreas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	diferenciación neuroendocrina	8574/3
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	diferenciación neuroendocrina	8574/3
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	diferenciación neuroendocrina	8574/3
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	enfermedad ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	adenocarcinoma de próstata Gleason 9	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	CPRC metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	carcinoma sólido pobremente diferenciado	8230/33
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	neoplásica de alto grado pobremente diferenciada	8000/13
dev-set1-to-publish/cantemist-norm/cc_onco884.ann	lesión esternal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	Ewing	9260/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	Melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	carcinoma indiferenciado	8020/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	carcinomas	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	lesiones focales hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	linfoma	9590/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcoma sinovial	9040/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcoma sinovial	9040/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcomas	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumor maligno	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumor maligno indiferenciado	8000/34
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumor maligno indiferenciado, con cierto patrón epiteloide	8011/34
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcoma indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	sarcoma indiferenciado (sinovial	9040/34
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	carcinoma indiferenciado con patrón sarcomatoide	8033/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	linfoma anáplasico	9590/34
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	neoplasias indiferenciadas	8000/34
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	leucemias granulocíticas	9860/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	melanomas	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	tumores melánicos	8720/1
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	enfermedad hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	enfermedad hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco299.ann	Melanoma primario de mucosa esofágica, enfermedad avanzada (metastasis	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	adenocarcinoma infiltrante	8140/3/H
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	diseminación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	peritumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco419.ann	adenocarcinoma moderadamente diferenciado túbulo-papilar	8263/32
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	lipomas	8850/0
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	metástasis de Ca. papilar de tiroides	8260/6
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	gangliocitoma displásico	9493/0
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	gangliocitoma displásico cerebeloso	9493/0
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	enfermedad de Lhermitte-Duclos	9493/0
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	ELD	9493/0
dev-set1-to-publish/cantemist-norm/cc_onco970.ann	tricolemoma	8102/0
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	adenopatías cervicales, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	linfoma anaplásico de células grandes ALK (-)	9702/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	síndrome linfoproliferativo CD 30 (+)	9718/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	linfoma anaplásico de células grandes	9714/3
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	linfoma anaplásico	9590/3/H
dev-set1-to-publish/cantemist-norm/cc_onco293.ann	Linfoma anaplásico ALK (-)	9702/3
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	adenocarcinoma poco diferenciado	8140/33
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	adenocarcinoma de pulmón T4N2M1b	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco797.ann	captaciones patológicas óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	infiltración medular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	linfoma	9590/3
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	linfoma de Hodgkin, esclerosis nodular	9663/3
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	linfoma Hodgkin esclerosis nodular	9663/3
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	progresión supra e infradiafragmática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	afectación esplénica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	afectación esplénica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco829.ann	progresión supra e infradiafragmática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	estesioneuroblastoma	9522/3
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	estesioneuroblastoma	9522/3
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	estesioneuroblastoma de alto grado	9522/34
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	neoplasia maligna de célula pequeña	8002/3
dev-set1-to-publish/cantemist-norm/cc_onco210.ann	neuroblastoma olfatorio de alto grado	9500/34
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	captación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	captaciones radiológicas a nivel meníngeo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	infiltración meníngea por carcinoma escamoso	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	neoplasia cerebral diseminada a nivel leptomeníngeo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	malignización	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco990.ann	carcinoma escamoso y diseminación leptomeníngea	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	Carcinoma lobulillar infiltrante	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	Carcinoma lobulillar infiltrante	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	Metástasis por carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	enfermedad a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	adenopatías axilares, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	Carcinoma lobulillar infiltrante de mama izquierda, Grado Histológico (GH) II	8520/32
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	Carcinoma infiltrante mixto (lobulillar y sin tipo especial)	8524/3
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	en pala ilíaca derecha un área blástica y lítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco342.ann	lesión en pala ilíaca	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	carcinoma lobulillar infiltrante	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco121.ann	Carcinoma lobullilar infiltrante	8520/3
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	Leiomiosarcoma	8890/3
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	Metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	leiomiosarcoma de alto grado	8890/34
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	lesiones focales hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	recidiva única pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	nódulos subcentimétricos en cavidad peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco253.ann	mucosa bronquial infiltrada por un leiomiosarcoma	8890/6
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	adenocarcinoma de tipo intestinal	8144/3
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	adenocarcinoma intestinal	8144/3
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	carcinoma embrionario	9070/3
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	masa mediastínica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	seminoma anaplásico	9062/3
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	T2N2M0S1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	metástasis mediastínica por teratoma maduro	9080/6
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	lesión hipodensa en mediastino	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	teratoma histológicamente maduro con un foco de carcinoma embrionario	9081/3
dev-set1-to-publish/cantemist-norm/cc_onco697.ann	teratoma maduro, y un foco de carcinoma embrionario	9081/3
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	afectación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	melanoma de tipo nodular	8721/3
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	metástasis por melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	T4bN0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco510.ann	satelitosis	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	nódulos pulmonares bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	Carcinoma de pulmón no Célula pequeña	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco325.ann	cT3N3Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco254.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco254.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco254.ann	lesión nodular frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco254.ann	neoplásico hiliar con metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco254.ann	neoplasia pulmonar y metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	TNE	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor neuroendocrino	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumor neuroendocrino	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco602.ann	TNE de páncreas grado 2 estadio IV por múltiples metástasis	8249/6
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	tumoración sólido-quística	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	tumoración sólido-quística	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	carcinoma seromucinoso bien diferenciado	8441/31/H
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	neoplasia mucinosa apendicular de bajo grado	8480/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	tumor primario apendicular mucinoso	8480/1
dev-set1-to-publish/cantemist-norm/cc_onco458.ann	neoplasia mucinosa apendicular	8480/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	adenocarcinoma de células en anillo de sello	8490/3
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	implante tumoral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	lesiones esplénicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	neoproliferativo	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	progresión peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	pólipo en recto distal de aspecto adenomatoso	8210/0
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	extensión a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	adenocarcinoma de células en anillo de sello y mucinoso	8480/3
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	T4aN2bMx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	tumoración pobremente diferenciada	8000/13
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	recidiva peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	implantes subfrénicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	implantes pararrenales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco401.ann	lesiones focales esplénicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	PNET	9364/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumor neuroectodérmico primitivo	9473/3
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco776.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	carcinomatosis	8010/9
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	melanoma maligno	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	melanoma metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	neoplasia ileal pigmentada maligna	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	lesión frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco545.ann	TxNxM1d	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	diseminación leptomeníngea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	cáncer micropapilar	8265/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	blastoma pleuropulmonar tipo II (sólido-quístico)	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	blastoma pleuropulmonar	8973/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	blastoma pleuropulmonar	8973/3
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	blastoma pleuropulmonar tipo II	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	metástasis de PPB	8973/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	masa en región parietal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	recaída intracraneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco787.ann	recaída a nivel del sistema nervioso central	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco699.ann	carcinoma ductal infiltrante de 1,3 cm, moderadamente diferenciado	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	Angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	lesiones esplénicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco348.ann	enfermedad a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	Diseminación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	Tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	carcinoma renal de células claras grado 3 de Furman	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	Carcinoma renal de células claras grado 3	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	pT2bN0M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco483.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	Melanoma metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	células neoplásicas	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	melanoma maligno	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	melanoma en el antebrazo derecho de tipo epitelioide	8771/3
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	nódulos en el pulmón	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	lesión ocupante de espacio hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	T2N2M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco205.ann	satelitosis	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	Carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	carcinoma epidermoide pobremente diferenciado	8070/33
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco177.ann	T3N1-2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	múltiples implantes en omento	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	neoplasias	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	mesotelioma maligno epitelioide papilar	9052/3
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	MP epitelioide papilar	9052/3
dev-set1-to-publish/cantemist-norm/cc_onco773.ann	mesotelioma peritoneal maligno	9050/3
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	diseminación peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	hemangioma	9120/0
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	hemangioma cavernoso	9121/0
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	implantes de aspecto gelatinoso - mucoide cubriendo asas intestino	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	adenocarcinoma apendicular mucinoso invasivo bien diferenciado	8480/31
dev-set1-to-publish/cantemist-norm/cc_onco334.ann	quístico-sólida	8452/1
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	lesiones cutáneas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	lesiones osteoblásticas en la calota	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	lesión cutánea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	metástasis por carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	carcinoma de células transicionales de vejiga E-IV (pulmonares	8120/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	Progresión cutánea y ósea múltiple de carcinoma de células transicionales	8120/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	progresión a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco100.ann	cutánides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	progresiones a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	sarcoma de partes blandas	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	leiomiosarcoma indiferenciado	8890/34
dev-set1-to-publish/cantemist-norm/cc_onco131.ann	nódulos milimétricos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	Carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	T2N1M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	células malignas	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco18.ann	carcinoma ducal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	CCR	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	adenocarcinoma mucinoso	8480/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	intratumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	linfoma	9590/3
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	peritumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	adenocarcinoma infiltrante moderadamente diferenciado con áreas coloides	8480/32/H
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	adenocarcinoma mucinoso moderadamente diferenciado	8480/32
dev-set1-to-publish/cantemist-norm/cc_onco354.ann	tumor budding	8001/3
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	carcinoma papilar	8260/3
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	implantes en peritoneo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	adenocarcinoma de ovario seroso papilar	8460/3
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	progresión abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco857.ann	progresión abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	adenocarcinoma de páncreas metastásico	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	afectación pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	diseminación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	enfermedad pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	micronódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	micronódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco786.ann	adenocarcinoma de páncreas bien diferenciado	8140/31
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	afectación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	proceso linfoproliferativo	9970/1
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	adenopatías múltiples a nivel supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	ganglionar supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	linfoma de Hodgkin clásico subtipo esclerosis nodular	9663/3
dev-set1-to-publish/cantemist-norm/cc_onco642.ann	afectación del cuerpo vertebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	carcinoide	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	carcinoide	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	carcinoide	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	enfermedad a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	TNE bien diferenciado G2	8249/32
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	TNE de origen en intestino delgado G2 metastásico	8249/62
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	TNE G2	8249/32
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	implantes en intestino	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	TNE G2	8249/32
dev-set1-to-publish/cantemist-norm/cc_onco433.ann	TNE y origen no pancreático G1/2	8249/32
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	oligometastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	recidiva hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	recidiva hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	ypT0N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	metástasis de adenocarcinoma grado II	8140/62
dev-set1-to-publish/cantemist-norm/cc_onco198.ann	lesión a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	progresión a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	tumor mesenquimal	8800/1
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	sarcoma sinovial monofásico grado 3	9040/33/H
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	recidiva peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	lesiones en ambos riñones	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	metástasis de sarcoma sinovial	9040/6
dev-set1-to-publish/cantemist-norm/cc_onco684.ann	afectación de partes blandas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	adenocarcinoma moderadamente diferenciado invasor	8140/32/H
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	implante peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	metástasis de adenocarcinoma moderadamente diferenciado	8140/62
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	adenocarcinoma de colon estadio IV (metástasis	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	lesión vegetante rugosa en aritenoides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco372.ann	lesión vegetante, sésil e irregular sobre aritenoides	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	carcinoma ductal infiltrante pobremente diferenciado	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	CMOH	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	CPRH	8050/3
dev-set1-to-publish/cantemist-norm/cc_onco263.ann	CPRH	8050/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	Carcinoma de célula pequeña	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	adenocarcinoma metastásico	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	carcinoma microcítico	8041/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	carcinoma no célula pequeña	8046/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	lesión lítica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	mieloma	9732/3
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	nódulos pulmonares subcentimétricos bilaterales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	metástasis pleurales izquierdas de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	adenocarcinoma pulmonar (TXNXM1a)	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	Progresión tras 10 meses a nivel pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	Masa de nueva aparición en ángulo cardiofrénico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	enfermedad a nivel del SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	enfermedad pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	enfermedad a nivel pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	progresión a nivel de SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco580.ann	enfermedad pleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	neoproliferativo	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	rabdomiosarcoma indiferenciado	8900/34
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	Rabdomiosarcoma indiferenciado	8900/34
dev-set1-to-publish/cantemist-norm/cc_onco214.ann	lesiones satélites en la musculatura paraespinal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	adenocarcinoma ductal	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	adenocarcinoma ductal de páncreas grado 2	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	pT3pN0pMx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	Adenocarcinoma ductal de páncreas grado 2	8500/32
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	pT3pN0cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco991.ann	lesiones ocupantes de espacio hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	lesión frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	lesión frontal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	leucemia	9800/3
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	progresión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	progresión cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	adenocarcinoma de pulmón, estadio IV (cT2N2M1)	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	PE pulmonar y hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	lesiones focales corticosubcorticales supratentoriales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	metástasis cerebrales de su neoplasia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	adenocarcinoma de pulmón estadio IV (cT2N2M1)	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	PE en el sistema nervioso central (SNC) de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco934.ann	PE en SNC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	neoformación	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco252.ann	pT3N2a (4-6/20)M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	progresión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	carcinoma adenoide quístico de patrón cilindromatoso	8200/3
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	Carcinoma adenoide quístico parotídeo derecho de alto grado de patrón cilindromatoso con adenopatías locorregionales y extensión ósea	8200/64
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	carcinoma papilar tiroideo	8260/3
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	lesión temporal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco297.ann	progresar a nivel pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco727.ann	melanoma metastásico	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco727.ann	infiltración de MO por melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco609.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco609.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco609.ann	CIN III de cérvix	8077/2
dev-set1-to-publish/cantemist-norm/cc_onco609.ann	linfoma anaplásico de células grandes (ALK)	9714/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	GIST	8936/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	Sarcoma de alto grado	8800/34
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	Tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	adenopatías cervicales, supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	celularidad tumoral	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	hipernefroma	8312/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	hipernefroma	8312/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	rabdomiosarcoma pleomórfico	8901/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	rabdomiosarcoma pleomórfico	8901/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	rabdomiosarcoma pleomórfico	8901/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	sarcoma de alto grado	8800/34
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	tumoración de partes blandas	8800/1
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	Adenocarcinoma renal de célula clara, grado nuclear de Fuhrman 3	8310/33
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	Tumor del estroma gastrointestinal (GIST) de células fusiformes de bajo grado	8936/31
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	Tumor del estroma gastrointestinal (GIST) de células fusiformes	8004/3
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	GIST de células fusiformes de bajo grado	8936/31
dev-set1-to-publish/cantemist-norm/cc_onco343.ann	GIST de células fusiformes	8004/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	cT1N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	carcinoma de mama ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	lesión cerebelosa	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	pT1N1micM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	carcinoma ductal de mama infiltrante grado 3	8500/33
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	lesión ocupante de espacio a nivel de vermis cerebeloso	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	pT1N1micM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco477.ann	lesión ocupante de espacio vermiano y cerebeloso	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	Melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	enfermedad hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	enfermedad secundaria	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	melanoma	8720/3
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	lesiones en lóbulo hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco764.ann	infiltración difusa por melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	carcinoma epidermoide	8070/3
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	carcinoma epidermoide pobremente diferenciado	8070/33
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	diseminación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	metástasis de carcinoma de células escamosas	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	recaída mediastínica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	cT4N2M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	metástasis de carcinoma epidermoide	8070/6
dev-set1-to-publish/cantemist-norm/cc_onco551.ann	enfermedad mediastínica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	diseminación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	melanoma en regresión	8723/3
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	melanoma nodular	8721/3
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	melanoma nodular	8721/3
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metastásicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metástasis cutánea de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metástasis de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	nevus	8720/0
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	pT3bpN2bM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	adenopático en la fosa supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	enfermedad a nivel cutáneo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	adenopático en FSC	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco215.ann	metástasis múltiples de melanoma	8720/6
dev-set1-to-publish/cantemist-norm/cc_onco403.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set1-to-publish/cantemist-norm/cc_onco403.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco403.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco403.ann	LOE intracraneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	colangiocarcinoma	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	adenocarcinoma moderadamente diferenciado de patrón tubular	8211/32
dev-set1-to-publish/cantemist-norm/cc_onco186.ann	colangiocarcinoma intrahepático multifocal	8160/3/H
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	adenopatía supraclavicular	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	carcinoma de células renales	8312/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	carcinoma renal de células claras	8310/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	carcinoma renal de células claras	8310/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	carcinoma renal de células claras	8310/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	feocromocitoma	8700/0
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	feocromocitoma	8700/0
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	hemangioblastomas	9161/1
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	lesiones pancreáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	masa suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	masa suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	tumores neuroendocrinos	8240/3
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco830.ann	nódulos pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	adenopatías supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	hemangiomas	9120/0
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	linfangitis carcinomatosa	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	linfangitis carcinomatosa	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	metastático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	nódulo subpleural	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	adenocarcinoma con células en anillo de sello	8490/3
dev-set1-to-publish/cantemist-norm/cc_onco981.ann	T3N3Mx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	células tumorales	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	malignas	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	lesión occipital	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	lesión de la cadera	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco685.ann	progresión ganglionar y suprarrenal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	adenocarcinoma compatible con metástasis	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	adenocarcinoma de tipo intestinal moderadamente diferenciado	8144/32
dev-set1-to-publish/cantemist-norm/cc_onco479.ann	pT3N1Mo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	neoplásica	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco184.ann	Adenopatías en el nivel IIA y supraclaviculares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	Adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	Recaída pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	masa pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	masa pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	masa pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	metástasis de adenocarcinoma	8140/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	nódulo pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	leucemia linfoide crónica B	9823/3
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	adenocarcinoma de colon derecho grado 1	8140/31
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	recidiva pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco669.ann	nódulo milimétrico pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	adenocarcinoma	8140/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	carcinoma urotelial	8120/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	carcinoma urotelial	8120/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	carcinoma urotelial de alto grado	8120/34
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	carcinoma urotelial de alto grado	8120/34
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	neoplásico	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	pT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	pT3N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	síndrome de Lynch	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	Carcinoma urotelial de vía urinaria (uréter izquierdo) de alto grado	8120/34
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	síndrome de Lynch	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco424.ann	síndrome de Lynch	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	enfermedad a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	lesión parietal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	lesión parietal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	metástasis de carcinoma mal diferenciado	8010/63
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	carcinoma ductal infiltrante mal diferenciado, multifocal	8500/33/H
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	Recaída cerebral única de cáncer	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco565.ann	recaída cerebral	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	células neoplásicas	8001/1
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	implantes peritoneales	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	omental cake	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	sarcomas	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	tumores	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	angiosarcoma cardíaco grado 3	9120/33
dev-set1-to-publish/cantemist-norm/cc_onco156.ann	progresión a nivel abdominal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	implantes pericárdicos	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	lesión pulmonar	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	progresión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	sarcoma	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	sarcoma de alto grado	8800/34
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	neoplasia cardiaca primaria maligna y metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	sarcoma de alto grado indiferenciado	8805/3
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	recidiva pericárdica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco688.ann	progresión de las óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	leucemia	9800/3
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	(LOEs) a nivel de parénquima hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	(LOEs) hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	LOEs del lóbulo hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	neoplasia epitelial maligna con diferenciación neuroendocrina	8574/3
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	carcinoma neuroendocrino de probable origen pancreático con metástasis hepáticas y óseas, G1	8246/61
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	TNE no funcionante pancreático	8150/3
dev-set1-to-publish/cantemist-norm/cc_onco357.ann	insulinoma maligno metastásico	8151/3
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	carcinoma neuroendocrino bien diferenciado	8246/31
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	carcinoma neuroendocrino bien diferenciado	8246/31
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	enfermedad hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	lesiones hepáticas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	metastásico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	nódulo mesentérico	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	progresión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	Carcinoma Neuroendocrino de bajo grado de ileon con metástasis	8246/61
dev-set1-to-publish/cantemist-norm/cc_onco249.ann	tumor neuroendocrino de bajo grado de ileon con metástasis	8240/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	CDIS	8500/2
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	CDIS	8500/2
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma	8010/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma ductal in situ	8500/2
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	metástasica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	metástasica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	metástasis de carcinoma	8010/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoraciones	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma basocelular superficial	8090/3/H
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	Carcinoma de mama izquierda ductal in situ	8500/2
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	cT2pN0(sn)cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	carcinoma ductal infiltrante grado I	8500/31
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	ypT2pN0(sn)cM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	lesión a nivel de L1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	proliferación linfoide	9970/1
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	linfoma no Hodgkin de alto grado	9591/34
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	proceso linfoproliferativo B de células grandes	9680/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	Linfoma B difuso de células grandes	9680/3
dev-set1-to-publish/cantemist-norm/cc_onco384.ann	lesiones hipermetabolicas a nivel óseo	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	afectación a distancia	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	neoplasia	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tumorales	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tecoma luteinizado	8601/0
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tecoma luteinizado	8601/3
dev-set1-to-publish/cantemist-norm/cc_onco854.ann	tecoma luteinizado	8601/3
dev-set1-to-publish/cantemist-norm/cc_onco388.ann	carcinoma seroso papilar de ovario de alto grado	8461/34
dev-set1-to-publish/cantemist-norm/cc_onco388.ann	progresión hepática	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco388.ann	carcinoma seroso papilar de alto grado	8461/34
dev-set1-to-publish/cantemist-norm/cc_onco388.ann	infiltración uterina, peritoneal	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco388.ann	recidiva radiológica a nivel hepático	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	cáncer	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	tumor estromal fusocelular de grado histológico intermedio/bajo	8935/12
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	tumor estromal fusocelular	8004/1
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	tumor Phyllodes de alto grado	9020/34
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	Metástasis orbitaria de tumor Phyllodes	9020/6
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	metástasis de tumor Phyllodes de alto grado	9020/64
dev-set1-to-publish/cantemist-norm/cc_onco522.ann	tumoración en región inferolateral de la órbita	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	CDI	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	carcinoma ductal infiltrante	8500/3
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	malignidad	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	cT3NxMx	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	angiomixoma agresivo	8841/1
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	angiomixoma	8841/1
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	cT3NxM0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco976.ann	Angiomixoma vulvar agresivo	8841/1
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	angiosarcoma	9120/3
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	lesión ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	maligna	8000/3
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	sarcoma de alto grado	8800/34
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	neoplasia maligna mesenquimal	8800/3
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	lesión lítica en ala sacra	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	T4N0M1	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco686.ann	lesión en ala sacra	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	afectación ósea	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	tumor	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	tumoral	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	adenocarcinoma de vía biliar con afectación pancreática	8160/6
dev-set1-to-publish/cantemist-norm/cc_onco507.ann	cáncer avanzado de vía biliar	8160/3
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	T1N0M0	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	lesiones pulmonares	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	lesiones óseas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metastásica	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metastásicas	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metástasis	8000/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metástasis de carcinoma ductal	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	metástasis de carcinoma ductal	8500/6
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	tumoración	8000/1
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	carcinoma de tipo ductal infiltrante, de alto grado	8500/34
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	Carcinoma ductal infiltrante de parótida derecha de alto grado	8500/34
dev-set1-to-publish/cantemist-norm/cc_onco910.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	carcinoma urotelial	8120/3
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	lesiones intraparenquimatosas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	suelta de globo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	tumores germinales	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	tumores germinales	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	carcinoma urotelial de alto grado con diferenciación trofoblástica	8120/34/H
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	lesiones nodulares en ambos hemitórax	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco751.ann	Carcinoma urotelial de alto grado con diferenciación trofoblástica	8120/34/H
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	carcinoma escamoso moderadamente diferenciado	8070/32
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	carcinoma in situ	8010/2
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	carcinoma escamoso de pene bien diferenciado	8070/31
dev-set2-to-publish/cantemist-norm/cc_onco1262.ann	enfermedad de Bowen	8081/2
dev-set2-to-publish/cantemist-norm/cc_onco1328.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1328.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1328.ann	tumoración de células epiteliales con empalizada periférica basaloide	8083/3
dev-set2-to-publish/cantemist-norm/cc_onco1328.ann	Carcinoma basaloide	8123/3
dev-set2-to-publish/cantemist-norm/cc_onco1137.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1137.ann	Craneofaringioma Adantinomatoso	9351/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	adenocarcinoma mucinoso	8480/3
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	carcinoma mucinoso	8480/3
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	células en anillo de sello	8490/3
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1329.ann	adenocarcinoma tipo intestinal mixto	8144/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	enfermedad secundaria	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	enfermedad secundaria	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	carcinoma escamoso no queratinizante	8072/3
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	carcinoma escamoso no queratinizante	8072/3
dev-set2-to-publish/cantemist-norm/cc_onco1237.ann	Carcinoma escamoso de orofaringe (cT3cN2cM1)	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	Rabdomiosarcoma tipo embrionario	8910/3
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	lesiones cervicales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	lesión única hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	metástasis por rabdomiosarcoma	8900/6
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	neoplasia maligna de células redondas azules	8000/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	neoplasia maligna de células redondas azules	8000/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	rabdomiosarcoma embrionario	8910/3
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	retinoblastoma	9510/3
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	retinoblastoma	9510/3
dev-set2-to-publish/cantemist-norm/cc_onco1253.ann	nódulos cervicales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	adenocarcinoma infiltrante	8140/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	lesión frontal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	lesión única frontal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	pT3N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	progresión a nivel cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	progresión a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	progresión a nivel de calota	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	lesión de calota	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1429.ann	progresión a nivel temporobasal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	M1a	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	Melanoma metastásico	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	Nódulos subcutáneos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	masa paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	masa paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	masa paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma metastásico	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	melanoma nodular	8721/3
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulo subcutáneo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulo subcutáneo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulo subcutáneo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulos subcutáneos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulos subcutáneos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	nódulos subcutáneos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1164.ann	tumoración a nivel paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	Cáncer infiltrante	8000/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	carcinoma ductal Infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	fibroadenomas	9010/0
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	mioma	8895/0
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	pT3N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	carcinoma infiltrante con componente mixto (ductal y lobulillar)	8522/3
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	leucemia aguda promielocítica M3	9866/3
dev-set2-to-publish/cantemist-norm/cc_onco1350.ann	Leucemia aguda no linfoblástica M3	9866/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	cM1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor del estroma gastrointestinal	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor fusocelular de alto grado	8004/14
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	Neoplasia de sigma T4-N2-M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	metástasis hepática por tumor fusocelular de alto grado	8004/64
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor fusocelular maligno de alto grado	8004/34
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	tumor fusocelular maligno de alto grado, de probable estirpe mesenquimal	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	Carcinosarcoma de alto grado	8980/34
dev-set2-to-publish/cantemist-norm/cc_onco1494.ann	implantes tumorales de carcinosarcoma	8980/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	adenocarcinoma infiltrante	8140/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	progresión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	Adenocarcinoma de la unión gastroesofágica, estadio IV (M1	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1203.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	carcinoma epidermoide moderadamente diferenciado	8070/32
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	carcinoma seroso papilar bien diferenciado	8461/31
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	Carcinoma seroso papilar bien diferenciado	8461/31
dev-set2-to-publish/cantemist-norm/cc_onco1267.ann	pT2N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	adenocarcinoma de tipo intestinal	8144/3
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	pT3N1(2/12)Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	Nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	nódulos infracentimétricos en ambos pulmones	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	metástasis (de su carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	lesión tiroidea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1257.ann	lesión tiroidea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	Lesiones líticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	carcinoma basocelular	8090/3
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	carcinoma basocelular	8090/3
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	malignas	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	Metástasis de carcinoma basocelular	8090/6
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	CBC	8090/3
dev-set2-to-publish/cantemist-norm/cc_onco1339.ann	lesiones líticas de 6.º y 8.º arcos costales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	carcinoma acinar pancreático mixto, con áreas de diferenciación neuroendocrina	8154/3
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	carcinoma mixto acinar-neuroendocrino	8154/3
dev-set2-to-publish/cantemist-norm/cc_onco1337.ann	carcinoma pancreático acinar mixto con áreas de diferenciación neuroendocrina	8154/3
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	lesión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	lesión frontal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	tejido cerebral infiltrados por adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1194.ann	adenocarcinoma acinar Gleason 8	8550/33
dev-set2-to-publish/cantemist-norm/cc_onco1340.ann	seminoma	9061/3
dev-set2-to-publish/cantemist-norm/cc_onco1340.ann	tumor del saco vitelino	9071/3
dev-set2-to-publish/cantemist-norm/cc_onco1340.ann	tumor germinal mixto	9064/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1340.ann	tumor germinal mixto	9085/3
dev-set2-to-publish/cantemist-norm/cc_onco1420.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1420.ann	adenocarcinoma unión gastroesofágica uT3uN2 cM1	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1420.ann	lesión costal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1228.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1228.ann	T3N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1228.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1228.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	adenocarcinoma mucosecretor	8481/3
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	adenocarcinoma de colon mucosecretor	8481/3
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	adenocarcinoma sincrónico (colon ascendente y ciego) G3	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	pT3N2Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1427.ann	adenocarcinoma de colon estadio IV por metástasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1286.ann	CARCINOMA EPIDERMOIDE	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1286.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1286.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1286.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	carcinoma mioepitelial	8982/3
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	liposarcoma de células redondas	8853/3
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	tumor maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	carcinoma mioepitelial de partes blandas	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	tumor maligno indiferenciado de predominio epitelioide	8000/34/H
dev-set2-to-publish/cantemist-norm/cc_onco1025.ann	tumor primario de origen desconocido	8000/9
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	Micrometástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	carcinoma ductal infiltrante de mama grado II	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	Adenocarcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1382.ann	carcinoma endocrino de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	Melanoma lentiginoso acral	8744/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	afectación a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	lesiones subcutáneas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	lesiones subcutáneas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	melanoma lentiginoso acral	8744/3
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	metástasis de melanoma	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1183.ann	progresión inguinal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	signos proliferativos foliculares a células de Hürthle	8290/0
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	linfoma de la zona marginal tipo MALT con prominente diferenciación plasmocítica	9671/3
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	Linfoma de la zona marginal tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1475.ann	linfoma de la zona marginal tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	carcinoma escamoso	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	lesión escamosa intraepitelial de alto grado	8077/2
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	lesión intraepitelial escamosa de alto grado	8077/2
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	HSIL, CIN III	8077/2
dev-set2-to-publish/cantemist-norm/cc_onco1215.ann	carcinoma escamoso microinvasor	8076/3
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	adenocarcinoma de tipo intestinal	8144/3
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	masa anexial	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	progresiones a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	progresión a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	adenocarcinoma de recto superior con metástasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1428.ann	pT3pN2M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1172.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1172.ann	lesiones cutáneas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1172.ann	adenocarcinoma de próstata Gleason 4 + 5	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1172.ann	metástasis cutánea de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1172.ann	Metástasis cutáneas de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	Tumor germinal	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	hemangioma	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	tumor del seno endodérmico	9071/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	tumor del seno endodérmico	9071/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	metástasis de adenocarcinoma bien diferenciado	8140/61
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	adenomas tubulares	8211/0
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	neoplasia de tipo germinal	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1255.ann	afectación adenopática peritoneal múltiple	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	adenocarcinoma endometrioide	8380/3
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	adenocarcinoma infiltrante	8140/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	lesión lítica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1076.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma B tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	Linfoma tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma B de bajo grado	9591/31
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1091.ann	linfoma tipo MALT	9699/3
dev-set2-to-publish/cantemist-norm/cc_onco1234.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1234.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1234.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1234.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1234.ann	recidiva a nivel óseo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	adenocarcinoma de recto moderadamente diferenciado e infiltrante	8140/32/H
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	pT3pN+ (4/8)M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1151.ann	Mioma	8895/0
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	Carcinoma urotelial	8120/3
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	carcinoma urotelial	8120/3
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1356.ann	tumor de pelvis renal metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumor de células gigantes del hueso	9250/3
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumor de células gigantes del hueso	9250/3
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1490.ann	tumor de células gigantes de húmero derecho con metástasis	8003/6
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	TxN3M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco645.ann	carcinoma de células no pequeñas	8046/3
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	LNH	9591/3
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	carcinoma indiferenciado	8020/3
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	carcinoma pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	carcinoma poco diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	metástasis de carcinoma mal diferenciado	8010/63
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	tumoraciones	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1010.ann	meduloblastoma	9470/3
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	enfermedad sistémica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	carcinoma urotelial de patrón sólido, grado 3	8120/33
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	carcinoma urotelial de patrón sólido	8230/3
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	afectación sistémica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	carcinoma urotelial in situ	8120/2
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	pTisN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	Metástasis muscular de carcinoma urotelial	8120/6
dev-set2-to-publish/cantemist-norm/cc_onco1055.ann	metástasis de carcinoma urotelial de alto grado	8120/64
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	captación leptomeníngea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	lesiones cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	recaída cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	pT3bN1aM0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	lesiones expansivas intraparenquimatosas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	captaciones leptomeníngeas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1028.ann	progresión leptomeníngea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	Lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	carcinoma pulmonar derecho tipo oat-cell	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	CPCP	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	lesiones focales subependimarias	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1073.ann	lesiones localizada a nivel subependimario	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	tumor mesenquimal	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	tumor mesenquimal	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	fibromatosis invasiva	8821/1
dev-set2-to-publish/cantemist-norm/cc_onco1295.ann	Fibromatosis invasiva de la raíz del mesenterio	8822/1
dev-set2-to-publish/cantemist-norm/cc_onco1412.ann	carcinoma pulmonar de células pequeñas	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1412.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1412.ann	metástasis de carcinoma pulmonar de células pequeñas	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1412.ann	lesión de la vértebra	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	hígado con múltiples lesiones	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	Adenocarcinoma de colon transverso estenosante con metátasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	cT4N1M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1256.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	adenoma	8140/0
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	carcinoma endometroide	8380/3
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	síndrome de Lynch	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1405.ann	adenocarcinoma endometroide G3	8380/33
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	Angiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	neoformativo	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	Angiosarcoma vesical de alto grado	9120/34
dev-set2-to-publish/cantemist-norm/cc_onco1444.ann	afectación linfática locorregional y pleuropulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	Histiocitoma fibroso maligno	8830/3
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	enfermedad secundaria	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	histiocitoma fibroso maligno	8830/3
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	histiocitoma fibroso maligno	8830/3
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	progresión a nivel pleural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	histiocitoma fibroso pleomórfico maligno	8830/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	recidiva a nivel abdominal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	recidiva a nivel retrocecal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1323.ann	histiocitoma fibroso maligno pleomórfico	8830/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	adenocarcinoma compatible con metástasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	adenocarcinoma de bajo grado	8140/31
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	enfermedad hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1449.ann	adenocarcinoma de ciego con diseminación hepática	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	Carcinoma adrenocortical	8370/3
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1276.ann	Lesión lítica mínima en L1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	adenocarcinoma colorrectal moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	adenocarcinoma de próstata (Gleason 4+3)	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1448.ann	MO	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1418.ann	sarcoma de Kaposi	9140/3
dev-set2-to-publish/cantemist-norm/cc_onco1418.ann	sarcoma de Kaposi	9140/3
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	tumor maligno de células redondas	8000/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	neuroblastoma olfatorio grado 2 de Hymans	9522/32
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	Neuroblastoma olfatorio	9522/3
dev-set2-to-publish/cantemist-norm/cc_onco1147.ann	neuroblastoma olfatorio	9522/3
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	T1aN2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	adenocarcinoma de endometrio endometrioide	8380/3
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	adenocarcinoma de LSD, de patrón sólido predominante y tubular, moderadamente diferenciado, infiltrante	8140/32/H
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	adenocarcinoma de LSD, de patrón sólido	8230/3
dev-set2-to-publish/cantemist-norm/cc_onco1201.ann	adenocarcinoma de LSD, de patrón sólido predominante y tubular	8211/3
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	carcinoma ductal in situ	8500/2
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	carcinoma ductal infiltrante (CDI), grado III/III	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	CDI de 7 mm, con comedonecrosis, grado II/III	8501/33
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	recidiva a distancia del primer tumor	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1141.ann	carcinoma infiltrante grado III	8010/33/H
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	Cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	Fibromas	8810/0
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	carcinoma pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	lipoma	8850/0
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	malignas	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis de carcinoma neuroendocrino	8246/6
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	tumoral muy proliferativa o de alto grado	8000/14
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	metástasis del cáncer indiferenciado	8000/64
dev-set2-to-publish/cantemist-norm/cc_onco1121.ann	tumor neuroendocrino cutáneo	8247/3
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	neoplasia urotelial de bajo grado	8000/11
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	metástasis de carcinoma, sugerente de epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1333.ann	tumor urotelial de bajo grado	8000/11
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	Sarcoma del estroma endometrial indiferenciado	8930/34
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	lesión en cuerpo vertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metástasico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	sarcoma del estroma endometrial indiferenciado	8930/34
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	tumor maligno indiferenciado	8000/34
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1236.ann	sarcoma endometrial indiferenciado	8930/34
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	angiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	carcinoma ductal	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	implante tumoral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1047.ann	Angiosarcoma pobremente diferenciado	9120/33
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	Carcinoma microcítico pulmonar, en estadio IV, por diseminación pulmonar y en sistema nervioso central	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1326.ann	metástasis de un carcinoma microcítico	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	carcinoma medular de tiroides	8510/3
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	pT1N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	carcinoma decélulas basales	8090/3
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	Tumor carcinoide atípico neuroendocrino (variante de células grandes)	8013/3
dev-set2-to-publish/cantemist-norm/cc_onco1166.ann	Tumor carcinoide atípico neuroendocrino	8249/3
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	adenocarcinoma tipo intestinal	8144/3
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	lesión cerebelosa	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	lesión cerebelosa	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	progresión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	progresión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	Adenocarcinoma de unión gastroesofagica EIV ( M1	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco282.ann	metástasis de adenocarcinoma intestinal	8144/6
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	Carcinoma neuroendocrino de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	adenopatías cervicales, supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	tumor maligno de célula pequeña	8002/3
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	cT2-3N3M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1093.ann	recidiva a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	Carcinoma escamoso	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	T4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1402.ann	carcinoma con diferenciación escamosa	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	lesión osteolítica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	Nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1239.ann	Carcinoma folicular de tiroides estadio IV (metástasis	8330/6
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	Sarcoma de bajo grado	8800/31
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	lesiones ocupantes de espacio hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	neoplasia del estroma fibromixoide	8811/0
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	sarcoma de bajo grado	8800/31
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	proliferación fusocelular con patrón de crecimiento infiltrante sobre estroma mixoide	8811/0
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	hemangioendotelioma epiteloide maligno	9133/3
dev-set2-to-publish/cantemist-norm/cc_onco1497.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1462.ann	granuloma eosinófilo	9751/3
dev-set2-to-publish/cantemist-norm/cc_onco1462.ann	histiocitosis X	9751/3
dev-set2-to-publish/cantemist-norm/cc_onco1462.ann	histiocitosis X	9751/3
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	Adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	Implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	lesión mesentérica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	lesión suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	metástasis por carcinoma neuroendocrino bien diferenciado	8240/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	LOE hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	Tumor neuroendocrino de probable origen gastroenteropancreático bien diferenciado con metástasis	8240/6
dev-set2-to-publish/cantemist-norm/cc_onco1229.ann	tumor neruroendocrino bien diferenciado metastásico	8240/6
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	lesión pleural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	masa subpleural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1021.ann	Adenocarcinoma de pulmón estadio IV (T4N0M1a)	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	carcinoma de células renales tipo células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	pT2aNxM1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1331.ann	carcinoma de células renales tipo células claras con áreas desdiferenciadas y sarcomatoides, con metástasis	8318/64
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	carcinoma de células de Merkel	8247/3
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	carcinoma de células de Merkel	8247/3
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	implantes pleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	lesión subcutánea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	letálides	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis de carcinoma de Merkel	8247/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	nódulo mamario	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metástasis de carcinoma de células de Merkel	8247/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	lesión en la espalda	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	lesión en espalda	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1478.ann	metastásica visceral del carcinoma de células de Merkel	8247/6
dev-set2-to-publish/cantemist-norm/cc_onco1293.ann	Timoma	8580/1
dev-set2-to-publish/cantemist-norm/cc_onco1293.ann	timoma	8580/1
dev-set2-to-publish/cantemist-norm/cc_onco1293.ann	timoma tipo AB	8582/1
dev-set2-to-publish/cantemist-norm/cc_onco1293.ann	timoma tipo AB	8582/1
dev-set2-to-publish/cantemist-norm/cc_onco1293.ann	síndrome de Good	8580/1
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	carcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	carcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1016.ann	adenocarcinoma mesonéfrico	9110/3
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	Angiomiolipoma epitelioide	8860/0/H
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	angiomiolipoma epitelioide	8860/0/H
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	metástasis de melanoma	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	angiomiolipoma epitelioide maligno con metástasis	8860/6/H
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	LOE hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	masas pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1094.ann	Progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1353.ann	Germinoma	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1353.ann	germinoma	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1353.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1353.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	Melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1315.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	afectación ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	meningioma	9530/0
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	meningioma con afectación ósea	9530/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	lesiones hiperatenuadas en la columna	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	metástasis de meningioma tipo fibroso	9532/6
dev-set2-to-publish/cantemist-norm/cc_onco1150.ann	meningioma tipo fibroso con metástasis	9532/6
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	enfermedad hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	tumor de células de la granulosa	8620/1
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	carcinoma de células de la granulosa	8620/3
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	carcinoma de células de la granulosa de ovario E.IIA G1	8620/31
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	metástasis por tumor de células de la granulosa pobremente diferenciado	8620/63
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	metástasis por carcinoma de células de la granulosa pobremente diferenciado	8620/63
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	(LOE) hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1171.ann	recaída tumoral abdominal por tumor de células de la granulosa	8620/63
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	carcinoma urotelial	8120/3
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	carcinoma urotelial sólido con diferenciación escamosa	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	pT4N2M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1222.ann	carcinoma urotelial sólido	8230/3
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	tumor de origen gliomatoso	9380/1
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	glioblastoma multiforme (grado IV de la WHO)	9440/34
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	carcinoma ductal infiltrante multicéntrico	8500/3/H
dev-set2-to-publish/cantemist-norm/cc_onco691.ann	glioblastoma multiforme	9440/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	Carcinoma lobulillar	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	metastatizado	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	carcinoma lobular	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	carcinoma de mama infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	carcinoma lobular infiltrante	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	LOE óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	carcinoma lobular tipo pleomórfico	8022/3
dev-set2-to-publish/cantemist-norm/cc_onco1123.ann	carcinoma lobular	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	Carcinoma de mama ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	Lesiones focales hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	Neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	cT1N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	hepatocarcinoma	8170/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	hepatocarcinoma	8170/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	malignas	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	carcinoma ductal infiltrante G1	8500/31
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	Adenocarcinoma estenosante de sigma cT3cN2M1	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	carcinoma ductal infiltrante de 1,2 cm G1	8500/31
dev-set2-to-publish/cantemist-norm/cc_onco1145.ann	hepatocarcinoma multicéntrico, moderadamente diferenciado	8170/32/H
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	adenopatías axilares, supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	enfermedad linfoproliferativa	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	linfoma folicular	9690/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	linfoma folicular grado 1	9695/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	linfoma no Hodgkin de células B centrofolicular grado 1	9695/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	proceso linfoproliferativo de células pequeñas B	9670/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	linfoma B centrofolicular grado 3a	9698/3
dev-set2-to-publish/cantemist-norm/cc_onco1035.ann	síndrome linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	Adenocarcinoma gástrico difuso IV (pT3 pN2 M1	8145/6
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	adenocarcinoma difuso e infiltrante en anillo de sello con metástasis	8145/6
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	adenocarcinoma difuso e infiltrante en anillo de sello	8490/3
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	metástasi,s	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1188.ann	lesiones pumonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1034.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1034.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	Hemangioma	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	carcinoma lobulillar	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	carcinoma de mama lobulillar infiltrante	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	ypT0N1Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1032.ann	Infiltración meníngea por carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1131.ann	tumor dermoide	9084/0
dev-set2-to-publish/cantemist-norm/cc_onco1152.ann	adenocarcinoma de células en anillo de sello	8490/3
dev-set2-to-publish/cantemist-norm/cc_onco1152.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1152.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1152.ann	T4aN2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1152.ann	metastásica de su neoplasia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	Lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	lipoma	8850/0
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	metástásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	micrometástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1391.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	hepatocarcinoma fibrolamelar	8171/3
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	hepatocarcinoma fibrolamelar	8171/3
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	satelitosis	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	satelitosis	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	FLC	8171/3
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	FLC	8171/3
dev-set2-to-publish/cantemist-norm/cc_onco1330.ann	Recidiva pulmonar y retroperitoneal irresecable de hepatocarcinoma fibrolamelar	8171/6
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	macroadenoma	8140/0
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	melanoma coroideo derecho estadio IV por diseminación hepática	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco994.ann	macroadenoma de la hipófisis	8272/0
dev-set2-to-publish/cantemist-norm/cc_onco1142.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1142.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	coriocarcinoma	9100/3
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	hemangiomas	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	hemangiomas	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	lesión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	lesión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	neoformativo	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	Coriocarcinoma extragonadal de probable origen duodenal con metástasis	9100/6
dev-set2-to-publish/cantemist-norm/cc_onco1072.ann	tumor de estirpe germinal	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1318.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1318.ann	carcinoma embrionario	9070/3
dev-set2-to-publish/cantemist-norm/cc_onco1318.ann	carcinoma embrionario	9070/3
dev-set2-to-publish/cantemist-norm/cc_onco1318.ann	tumor embrionario	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1007.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1007.ann	sarcoma de Kaposi	9140/3
dev-set2-to-publish/cantemist-norm/cc_onco1007.ann	sarcoma de Kaposi	9140/3
dev-set2-to-publish/cantemist-norm/cc_onco1007.ann	sarcoma de Kaposi	9140/3
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	Metástasis de adenocarcinoma de células claras	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	carcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	adenocarcinoma de ovario derecho tipo células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1008.ann	Adenocarcinoma de ovario de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1088.ann	carcinoma papilar	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco1088.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1088.ann	lesión dorsal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1088.ann	pT3N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	adenocarcinoma mal diferenciado	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	diseminación hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	lesiones hipervasculares hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1492.ann	Tumor neuroendocrino de páncreas diseminado hepático	8150/6
dev-set2-to-publish/cantemist-norm/cc_onco1138.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	adenocarcinoma pobremente diferenciado	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	lesiones focales hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1014.ann	cT2N2M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	implante peritoneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	adenocarcinoma de células caliciformes con componente mucinoso	8480/3
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	Adenocarcinoide apendicular estadio IV por afectación peritoneal	8245/6
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	adenocarcinoide apendicular estadio IV por afectación peritoneal	8245/6
dev-set2-to-publish/cantemist-norm/cc_onco1226.ann	implantes peritoneales múltiples por adenocarcinoma mucosecretor	8481/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	T4N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	afectación suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	lesión suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	metástasis por adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	progresión a nivel suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	adenocarcinoma de pulmon E-IVb, por metástasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	progresión única a nivel suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1221.ann	lesiones a nivel suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	carcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	hipernefroma	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	carcinoma de células claras renales	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	masa intramiocárdica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	Neoformación cardíaca	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	tumoración intracardíaca	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1368.ann	tumoración intraventricular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	lesión cutánea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	lesión cutánea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	neoformación maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	progresión a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	carcinoma de los túbulos colectores de Bellini de 7,2 cm de diámetro mayor, grado 4 de Furhman	8319/34
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	pT3bNxM1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	carcinoma de túbulos colectores	8319/3
dev-set2-to-publish/cantemist-norm/cc_onco1484.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	neoplásicas	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	linfoma no Hodgkin B de células grandes	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	linfoma B	9591/3
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	Linfoma no Hodgkin B de células grandes	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1111.ann	linfoma difuso de células grandes B	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	lesiones pleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	sarcoma de células claras	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	SCC	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	adenopatías a nivel cervical, supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	sarcoma de células claras	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	sarcoma de células claras	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	sarcoma de células claras	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	recidiva de sarcoma de células claras a nivel pleural	9044/6
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	sarcomas de partes blandas	9044/3
dev-set2-to-publish/cantemist-norm/cc_onco1058.ann	nódulos pleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumoración sólida de la región pineal	9360/1
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumor de la región pineal	9360/1
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumor pineal tipo pleomórfico grado II-III	9360/13/H
dev-set2-to-publish/cantemist-norm/cc_onco1198.ann	tumor pineal parenquimatoso de diferenciación intermedia grado II-III	9360/13
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	Estesioneuroblastoma	9522/3
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	T4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	estesioneuroblastoma	9522/3
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1355.ann	estesioneuroblastoma GI-II de Hyams	9522/32
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	tumor de partes blandas	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	hemangioendotelioma	9130/1
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	hemangiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1018.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1042.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	feocromocitoma	8700/3
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	feocromocitoma	8700/3
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	feocromocitoma	8700/3
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1308.ann	feocromocitoma maligno con metástasis	8700/6
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	adenocarcinoma metastásico	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	adenocarcinoma moderadamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	pT2bpN2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1045.ann	diseminación intracraneal de su adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1104.ann	Carcinoma indiferenciado de célula pequeña	8041/34
dev-set2-to-publish/cantemist-norm/cc_onco1104.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1104.ann	pT2N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1104.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1118.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1118.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1118.ann	carcinoma microcítico de pulmón diseminado	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1118.ann	progresión adenopática locorregional y ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	ADC	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	Metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1036.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	T2N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	carcinoma intraductal	8500/2
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	carcinoma seroso	8441/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	cistoadenocarcinoma seroso papilar	8460/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	pT2pN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	carcinoma ductal infiltrante de mama derecha multicéntrico	8500/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1067.ann	quístico y sólido	8452/1
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	benignidad	8000/0
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	carcinoma ductal infiltrante grado 2	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	carcinoma ductal infiltrante grado 3	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	carcinoma infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	lesión occipital	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	fibroadenoma gigante	9016/0
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	cistosarcoma phyloides	9020/1
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	Carcinoma ductal infiltrante de mama derecha grado 3, pT2N1(2/16)M1	8500/63
dev-set2-to-publish/cantemist-norm/cc_onco1181.ann	lesión descrita previamente occipital	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	Carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	carcinoma medular	8510/3
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	diseminación ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	LOE hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	metástasis de carcinoma medular de tiroides	8510/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	afectación ganglionar cervical y supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	Carcinoma medular de tiroides estadio IV (metástasis	8510/6
dev-set2-to-publish/cantemist-norm/cc_onco1424.ann	carcinoma medular de tiroides con diseminación hepática	8510/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	Carcinoma microcítico de pulmón, enfermedad extendida	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1186.ann	cáncer microcítico de pulmón con evidencia de metástasis	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	carcinoma epidermoide G1	8070/31
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	pT2bN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	adenocarcinoma sobre adenoma velloso	8261/3
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	adenocarcinoma G3	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1189.ann	pT4pN1Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	Carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	TGNS	9065/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	TGNS	9065/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	tumor del seno endodérmico	9071/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	tumor germinal no seminomatoso	9065/3
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1011.ann	TGNS subtipo seno endodérmico	9071/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	carcinoma infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	carcinoma lobulillar infiltrante	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	metástasis de carcinoma lobulillar	8520/6
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	Carcinoma mamario infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	carcinoma lobulillar infiltrante de tipo pleomórfico	8022/3
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	lesión proliferativa estenosante en colon	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	recidiva única cecal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1258.ann	metástasis de carcinoma lobulillar infiltrante	8520/6
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	Condrosarcoma	9220/3
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	adenoma tubular	8211/0
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	condrosarcoma	9220/3
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	lipoma	8850/0
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	tumor de estirpe cartilaginosa	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	condrosarcoma de bajo grado	9220/31
dev-set2-to-publish/cantemist-norm/cc_onco1097.ann	condrosarcoma de bajo grado	9220/31
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	Astrocitoma de alto grado	9400/34
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	astrocitoma de bajo grado	9400/31
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	tumoración glial	9380/1
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	astrocitoma grado IV	9400/34
dev-set2-to-publish/cantemist-norm/cc_onco1319.ann	astrocitoma que ha virado a alto grado	9400/34
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	hipernefroma	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	metástasis de carcinoma de células claras	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	pT3N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	Carcinoma renal izquierdo de células claras convencional con zonas cromófobas G2	8270/32
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	pT2N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	Carcinoma renal izquierdo de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	Adenocarcinoma de próstata, Gleason 3 + 4	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	carcinoma renal izquierdo de células claras convencional con zonas cromófobas	8270/3
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	carcinoma renal izquierdo de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1254.ann	adenocarcinoma de próstata Gleason 3 + 4	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1304.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1304.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1304.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1304.ann	linfoma no Hodgkin B difuso de célula grande	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1304.ann	Linfoma no Hodgkin B difuso de célula grande	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1054.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	Adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	adenopático supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	afectación visceral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	carcinoma sólido	8230/3
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	masa en la región supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	tumoración supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	ganglio supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	adenocarcinoma de patrón indiferenciado	8140/34
dev-set2-to-publish/cantemist-norm/cc_onco1184.ann	Adenocarcinoma de origen desconocido, probablemente de origen biliopancreático	8163/3
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	seminoma	9061/3
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	metástasis por carcinoma embrionario	9070/6
dev-set2-to-publish/cantemist-norm/cc_onco1264.ann	Tumor germinal mixto S2pT2N2M1a	9085/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	CCR	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	CCR	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	CCR	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	carcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	carcinoma de células renales	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	hipernefroma	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	metastatiza	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	CCR metastásico	8312/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	CCR metastásico	8312/6
dev-set2-to-publish/cantemist-norm/cc_onco1260.ann	metástasis nasal del hipernefroma	8312/6
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	neoplásicas	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	rabdoide	8963/3
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	rabdoide	8963/3
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	carcinoma ductal infiltrante de mama izquierda GIII	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	Adenocarcinoma muy escasamente diferenciado	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1419.ann	Carcinoma rabdoide	8963/3
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	carcinoma renal papilar	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	progresión a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1376.ann	carcinoma papilar de células renales tipo 2, de 55 x 50 x 45 mm, de grado 3 de Führman	8260/33
dev-set2-to-publish/cantemist-norm/cc_onco1314.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	tumores del estroma gastrointestinal	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	tumoración sólida, estirpe mesenquimal	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1488.ann	Leiomiosarcoma yeyunal de alto grado	8890/34
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	PAF	8220/0
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	PAF	8220/0
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	fibromatosis	8000/0
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	fibromatosis	8000/0
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	poliposis adenomatosa familiar	8220/0
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	tumor desmoide	8821/1
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1115.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	Carcinoma de pulmón no microcítico	8046/3
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	carcinoma epidermoide moderadamente diferenciado	8070/32
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	linfoma B difuso de célula grande	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	Linfoma no Hodgkin B difuso de célula grande	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	Carcinoma de pulmón no microcítico subtipo epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1311.ann	cT3cN1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	Carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	Carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	T3N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	T3N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1312.ann	afectación masiva meníngea por carcinoma de células pequeñas	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	progresión a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	progresión a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1404.ann	carcinoma neuroendocrino (sinaptofisina +, cromogranina -), estadio diseminado	8246/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	PNET	9364/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	PNET	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	nódulos subpleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	Sarcoma Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	enfermedad de Paget	9184/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	enfermedad de Paget	9184/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	enfermedad de Paget	9184/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	neoplásica infiltrante de células pequeñas	8002/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1022.ann	tumor neuroectodérmico primitivo	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	carcinoma suprarrenal derecho, funcionante, estadio IV, con metástasis	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1482.ann	nódulos nuevos en cúpula hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	Macrometástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	afectación a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	lesión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	micrometástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	carcinoma infiltrante de subtipo no especial	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	Carcinoma infiltrante (SNE)	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	lesión ocupante de espacio intraaxial	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	metástasis de carcinoma infiltrante SNE	8010/6/H
dev-set2-to-publish/cantemist-norm/cc_onco1049.ann	carcinoma infiltrante SNE	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	Melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	micrometástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	melanoma maligno tipo histológico de extensión superficial	8743/3
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	nevus pigmentado	8720/0
dev-set2-to-publish/cantemist-norm/cc_onco1451.ann	nevus de unión	8740/0
dev-set2-to-publish/cantemist-norm/cc_onco1415.ann	adenocarcinoma papilar	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco1415.ann	diseminación ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1415.ann	linfangitis carcinomatosa	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1415.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1415.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	astrocitoma grado II	9400/32
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	oligodendroglioma grado II	9450/32
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	astrocitoma grado II	9400/32
dev-set2-to-publish/cantemist-norm/cc_onco735.ann	astrocitoma cerebral grado II	9400/32
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	Carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	T2N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1043.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	LNH	9591/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	lesiones a nivel cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	lesión focal hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis de melanoma	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	metástasis de melanoma	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	progresión a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	pT4aN1aM0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	enfermedad a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1241.ann	Progresión cerebral de melanoma	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	angiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	enfermedad ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	masa pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	nodulares pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1474.ann	Angiosarcoma mediastínico estadio IV por metástasis	9120/6
dev-set2-to-publish/cantemist-norm/cc_onco1061.ann	carcinoma infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1061.ann	malignas	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1061.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1061.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1061.ann	metástasis de cáncer	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	TNEP	8150/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	TNEP	8150/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	adenocarcinoma de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	angiomiolipomas	8860/0
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	angiomiolipomas	8860/0
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	hemangioblastomas	9161/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	hemangioblastomas	9161/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	hemangioblastomas	9161/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	tumor neuroendocrino de páncreas no funcionante	8150/3
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	adenomas	8140/0
dev-set2-to-publish/cantemist-norm/cc_onco1296.ann	tumor neuroendocrino de páncreas (TNEP) bien diferenciado G1 (Ki67 2 %) no funcionante	8150/31
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	PNET	9364/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	intratumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	mioepitelioma	8982/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumor neuroectodérmico primitivo	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	sarcoma de Ewing (SE) atípico, variante de células grandes	9260/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	SE	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	SE atípico, variante células grandes	9260/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	SE	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	SE atípico	9260/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	SE	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	osteosarcoma de células pequeñas	9185/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	osteoide maligno	9191/0
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	sarcoma epitelial	8804/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	condrosarcoma mesenquimal	9240/3
dev-set2-to-publish/cantemist-norm/cc_onco1077.ann	sarcoma sinovial atípico	9040/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	linfangitis carcinomatosa	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	proceso linfoproliferativo	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	LNH linfoblástico T	9837/3
dev-set2-to-publish/cantemist-norm/cc_onco1373.ann	Linfoma no Hodgkin linfoblástico T	9837/3
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	Carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	T4N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	lesión cerebelosa	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	lesiones focales intraaxiales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	lesiones en la calota craneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	Carcinoma pulmonar microcítico estadio diseminado	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1062.ann	carcinoma microcítico pulmonar (estadio diseminado)	8041/6
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	tumor de células fusiformes	8004/3
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	tumor del estroma gastrointestinal	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	tumor del estroma gastrointestinal	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1390.ann	Tumor del estroma gastrointestinal avanzado (metástasis	8936/6
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	carcinoma infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	progresión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1359.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	extensión a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	neoformativa	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	neoformativo	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	sarcoma sinovial	9040/3
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	sarcoma sinovial	9040/3
dev-set2-to-publish/cantemist-norm/cc_onco1245.ann	sarcoma sinovial monofáscio fusocelular	9041/3
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	carcinoma renal de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	lesión única frontal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	pT3aNxMx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	carcinoma de células claras de alto grado	8310/34
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	metástasis de carcinoma renal convencional (célula clara)	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1227.ann	Carcinoma renal izquierdo de células claras, estadio IV (M1	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	enfermedad hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1001.ann	adenocarcinoma T4N3M1b	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	carcinoma de células transicionales	8120/3
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	carcinoma poco diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	tumor neuroendocrino	8240/3
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1154.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	tumor multicéntrico	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	tumor multicéntrico	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1199.ann	carcinoma ductal infiltrante de 15 mm grado II	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	carcinoma compatible con metástasis	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	carcinoma renal de células claras grado I de Fuhrmann	8310/31
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	carcinoma renal de células claras estadio IV (metástasis	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1275.ann	lesión endotraqueal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco734.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco734.ann	infiltración meníngea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	neoplasia maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1170.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	Melanoma nodular	8721/3
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	intratumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	linfangitis carcinomatosa	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	masa suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	melanoma nodular	8721/3
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	metástasis por melanoma maligno	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	pT2 pN0[0/2]M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1235.ann	nodulares milimétricas en ambos pulmones	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1393.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1393.ann	tumor miofibroblastico inflamatorio	8825/1
dev-set2-to-publish/cantemist-norm/cc_onco1393.ann	TMI	8825/1
dev-set2-to-publish/cantemist-norm/cc_onco1393.ann	TMI	8825/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	Neurofibromas múltiples	9540/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	neurofibromatosis	9540/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	neurofibromatosis	9540/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	neurofibromatosis	9540/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	tumores del estroma gastrointestinal	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	NF-1	9540/1
dev-set2-to-publish/cantemist-norm/cc_onco1435.ann	paraganglioma extraadrenal	8693/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1069.ann	Cistoadenocarcinoma papilar seroso	8460/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	cT4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	cT4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	carcinoma de células pequeñas	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	carcinoma neuroendocrino de alto grado	8240/34
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	cáncer microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	carcinoma de rasgos neuroendocrinos de alto grado	8574/34
dev-set2-to-publish/cantemist-norm/cc_onco1175.ann	tumoral metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1225.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1225.ann	linfoma B difuso de células grandes	9680/3
dev-set2-to-publish/cantemist-norm/cc_onco1225.ann	Linfoma no Hodking B difuso de células grandes CD 20 + de alto grado	9680/34
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	carcinoma papilar de tiroides variante esclerosante difusa con metástasis	8350/6
dev-set2-to-publish/cantemist-norm/cc_onco1090.ann	Carcinoma papilar de tiroides, variante esclerosante difusa	8350/3
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	Neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	Neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	carcinoma de células acinares	8550/3
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	cavernoma	9121/0
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	cistoadenocarcinoma	8440/3
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	ganglionar supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	hemangioma	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	neoplásico	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	neoplásico	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1101.ann	carcinoma de células acinares de patrón sólido	8230/3
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	afectación cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	metástasis de neoplasia poco diferenciada de tumor de la capa granulosa	8620/63
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	masas pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	tumor de la granulosa	8620/1
dev-set2-to-publish/cantemist-norm/cc_onco1351.ann	Progresión pulmonar y adenopática de un tumor testicular de la capa de la granulosa	8620/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	T4N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	lesión hipodensa en cuerpo de páncreas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	masa pancreática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	masa pancreática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	masa pancreática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	metástasis de carcinoma escamoso moderadamente diferenciado	8070/62
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	neoplasia mucinosa	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	neoplasia sólido-quística	8452/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	neoplásico	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1438.ann	Carcinoma epidermoide de pulmón derecho T4N2M1	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	lesiones cutáneas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	neoplásicos	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	tumoraciones	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	ypT3N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	cT3N+M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1063.ann	metástasis cutánea de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	Tumor germinal no seminomatoso	9065/3
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	coriocarcinoma	9100/3
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1392.ann	nódulo pararrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	carcinoma epidermoide no queratinizante	8072/3
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	carcinoma papilar de tiroides	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	leucemia	9800/3
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1033.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	lesiones cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	metástasis cerebelosas en paciente con cáncer	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	lesiones cerebelosas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1437.ann	LOES cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	carcinoide	8240/3
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	enfermedad a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	recidiva a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	tumor neuroendocrino pancreático	8150/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	TNE-P	8150/1
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	Tumor carcinoide pancreatico E-IV (pT2N0M1) no funcionante de bajo grado	8240/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	Tumor carcinoide pancreatico E-IV (pT2N0M1) no funcionante	8150/6
dev-set2-to-publish/cantemist-norm/cc_onco1354.ann	lesiones nodulares a nivel segmentos hepáticos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	Angiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	angiosarcoma de alto grado	9120/34
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	hemangiomas	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	tumor filodes	9020/1
dev-set2-to-publish/cantemist-norm/cc_onco1271.ann	pT2bN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	adenocarcinoma de pulmón, estadio IV (pulmón, pleura	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1187.ann	blastoma pulmonar con diferenciación rabdomiosarcomatosa	8972/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1388.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1388.ann	linfoma no Hodgkin	9591/3
dev-set2-to-publish/cantemist-norm/cc_onco1388.ann	linfoma no Hodgkin B folicular de grado 3a	9698/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	Rabdomiosarcoma sólido alveolar	8920/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	infiltración de médula ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	infiltración de médula ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	infiltración de médula ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	rabdomiosarcoma	8900/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	rabdomiosarcoma alveolar de muy alto riesgo (patrón sólido	8920/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	rabdomiosarcoma sólido alveolar	8920/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	rabdomiosarcomas	8900/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	sarcoma desmoplásico de células redondas	8806/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	tumor de células pequeñas redondas	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	tumor indiferenciado formado por células redondas	8000/34/H
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	tumor maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	tumoraciones	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	sarcoma	8800/3
dev-set2-to-publish/cantemist-norm/cc_onco1179.ann	afectación ganglionar a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1371.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1371.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1371.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	carcinoma intraductal de alto grado	8500/24
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	progresión a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	sarcoma en el glúteo izquierdo pleomorfo	8802/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	fibrohistiocitoma maligno pleomórfico	8830/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	Sarcoma en el glúteo izquierdo pleomorfo	8802/3
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	fibrohistiocitoma maligno pleomórfico	8830/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	fibrohistiocitoma maligno pleomórfico	8830/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	metástasis de fibrohistiocitoma	8830/6
dev-set2-to-publish/cantemist-norm/cc_onco1338.ann	CDI G2	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	Lesión suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	Metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	Metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	adenopatías laterocervicales, supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	LOES hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	Tumoración en relación con glándula suprarrenal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco657.ann	LOE hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco898.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco898.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco898.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco898.ann	adenocarcinoma de próstata T3b Gleason 5+4	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco898.ann	nódulos pulmonares paramediastínicos apicales bilaterales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1143.ann	linfoma	9590/3
dev-set2-to-publish/cantemist-norm/cc_onco1143.ann	astrocitoma anaplásico	9401/3
dev-set2-to-publish/cantemist-norm/cc_onco1143.ann	astrocitoma anaplásico GIII	9401/33
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	Diseminación neoplásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	afectación meníngea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	metástasis de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	pT1pN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	carcinoma de mama oculto con diseminación a distancia	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	lesiones a nivel dural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	afectación orbitaria	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	infiltración de la duramadre	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1280.ann	masa intraobitaria	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	carcinoma renal de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	lesión osteolítica en la cara interna del clivus	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	pT1aN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	seminoma anaplásico pT2pN3M1b	9062/6
dev-set2-to-publish/cantemist-norm/cc_onco1384.ann	lesión en clivus	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	melanoma maligno	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	nevus	8720/0
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	nevus de Spitz	8770/0
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	adenopatías laterocervicales infra y supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	bulto supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	ganglio supraclavicular izquierdo con afectación de melanoma maligno	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	melanoma maligno estadio IV (por afectación ganglionar, TxNxM1a	8720/6
dev-set2-to-publish/cantemist-norm/cc_onco1159.ann	adenopatías supra e infraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	Carcinoma pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	carcinoma pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	metástasis de carcinoma pobremente diferenciado	8010/63
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	múltiples pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	progresión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	cTxN2aM0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	carcinoma nasofaríngeo indiferenciado no queratinizante	8072/34
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	linfoepitelioma	8082/3
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	T2N2bM0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	lesión blástica dolorosa en el húmero	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1432.ann	metástasis (M1) de carcinoma	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	Carcinoma escamoso	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	metástasis de carcinoma escamoso	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	carcinoma escamoso bien diferenciado	8070/31
dev-set2-to-publish/cantemist-norm/cc_onco1397.ann	T3bN1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1459.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1459.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1459.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1459.ann	carcinoma renal de células claras, grado 4 Fuhrman	8310/34
dev-set2-to-publish/cantemist-norm/cc_onco1459.ann	T2bN1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	Leiomiosarcoma	8890/3
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	Lesión lítica en el cuerpo vertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	leiomiosarcoma	8890/3
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	lesión osteolítica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	miomas	8895/0
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	miomas	8895/0
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	neoplasia maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	leiomiosarcoma grado 2 (sistema de grado FNCLCC)	8890/32
dev-set2-to-publish/cantemist-norm/cc_onco1098.ann	leiomiosarcoma grado 2	8890/32
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	tumor maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	Carcinoma poco diferenciado de tipo neuroendocrino/oat cell de alto grado	8041/34
dev-set2-to-publish/cantemist-norm/cc_onco874.ann	carcinoma supraglótico tipo microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	Adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	Adenocarcinoma de tipo intestinal	8144/3
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1102.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	carcinoma papilar de tiroides	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	carcinoma papilar de tiroides	8260/3
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	enfermedad a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	implantes pleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	carcinoma papilar clásico moderadamente diferenciado	8260/32
dev-set2-to-publish/cantemist-norm/cc_onco945.ann	pT2N1bM1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	dermatofibrosarcoma protuberans	8832/3
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	dermatofibrosarcoma protuberans	8832/3
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	metástasis de dermatofibrosarcoma protuberans	8832/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	implante neoplásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	nódulo en el mediastino	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	nódulo en el mediastino	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	nódulo en el mediastino	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1463.ann	nódulo mediastínico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	Carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	adenocarcinoma bien diferenciado	8140/31
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	afectación pleural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	afectación pleural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	cT1N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	carcinoma ductal infiltrante grado 2	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	enfermedad a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1307.ann	adenocarcinoma pulmonar cT3N2M1	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	adenocarcinoma metastásico	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	adenocarcinoma seroso de ovario de alto grado	8441/34
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	implante tumoral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	implantes peritoneales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	lesión categoría BI-RADS 4A en mama	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	metástasis de adenocarcinoma seroso	8441/6
dev-set2-to-publish/cantemist-norm/cc_onco1336.ann	Adenocarcinoma seroso de ovario estadio IV con metástasis	8441/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	afectación cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	lesiones cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	lesiones supratentoriales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	adenocarcinoma de próstata (pT2bN0M0), Gleason 7	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	pT2bN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	Metástasis cerebrales múltiples de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1283.ann	lesiones dispersas por el parénquima cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	Metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	carcinoma epidermoide bien diferenciado	8070/31
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	extensión a distancia	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	metastásicos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	metástasis de carcinoma escamoso	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	neoplásico	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	Carcinoma epidermoide de vulva estadio IV (metástasis	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	recidiva tumoral a nivel del periné, bronquial	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	lesión lítica en el tercio interno de la clavícula	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1124.ann	lesiones de carácter infiltrante en la clavícula	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1377.ann	T2N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1377.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1377.ann	carcinoma ductal infiltrante clásico con GN II y GH II-III	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1377.ann	Adenoarcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	carcinoma ductal	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	lesión retroperitoneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	lesión retroperitoneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	masa paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	masa retroperitoneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	masa retroperitoneal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	neoplásico	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	cN1cM0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	carcinoma escasamente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	Carcinoma ductal de mama triple negativo con recaída retroperitoneal	8500/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	recaída retroperitoneal de carcinoma ductal	8500/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	masa retrocrural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1168.ann	masa retrocrural	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	celularidad maligna	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	metastásis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	metástasis de un carcinoma lobulillar infiltrante	8520/6
dev-set2-to-publish/cantemist-norm/cc_onco1324.ann	Carcinoma lobulillar infiltrante de mama cT2N1M1	8520/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	enfermedad pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	infiltración hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metastásico	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	sarcoma sinovial	9040/3
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	tumoración blanda	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	sarcoma sinovial bifásico	9043/3
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	sarcoma sinovial de patrón bifásico	9043/3
dev-set2-to-publish/cantemist-norm/cc_onco1070.ann	masas pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	carcinoma indiferenciado de célula pequeña	8041/34
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	diseminación ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	lesiones óseas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metastásicas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metastático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metastático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	carcinoma indiferenciado de célula pequeña de mucosa yugal T4aN2bM1	8041/64
dev-set2-to-publish/cantemist-norm/cc_onco1467.ann	lesiones a nivel hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1361.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1361.ann	metástasis de adenocarcinoma	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1361.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1361.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1361.ann	Adenocarcinoma de origen intestinal estadio IV (pulmonar	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	M1	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	síndromes linfoproliferativos	9970/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	neoplasia de células renales con metástasis	8312/6
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	carcinoma renal de células claras Fuhrman 4	8310/34
dev-set2-to-publish/cantemist-norm/cc_onco1130.ann	Carcinoma renal de células claras Fuhrman 4 (estadio T4 N2 M1	8310/64
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1383.ann	carcinoma epidermoide de pulmón diseminado	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	carcinoma neuroendocrino de célula intermedia	8044/3
dev-set2-to-publish/cantemist-norm/cc_onco1173.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1074.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1074.ann	carcinoma renal de células claras con diseminación hepática	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	GIST	8936/3
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	Carcinoma transicional de vejiga pTaG2	8130/2
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	tumoración sólida, de estirpe mesenquimal	8800/1
dev-set2-to-publish/cantemist-norm/cc_onco1487.ann	Leiomiosarcoma yeyunal distal de alto grado	8890/34
dev-set2-to-publish/cantemist-norm/cc_onco1208.ann	T3N2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1208.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1208.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	adenocarcinoma de tipo intestinal	8144/3
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	adenoma	8140/0
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	lesión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	lesión única a nivel cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulo hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulo pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	progresión cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	progresión pleuropulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	adenocarcinoma grado 1	8140/31
dev-set2-to-publish/cantemist-norm/cc_onco1041.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	carcinoma neuroendocrino	8246/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesiones hepáticas	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesión hepática	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	neuroendocrino	8240/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	neoplasia neuroendocrina	8240/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	metástasis de carcinoma neuroendocrino grado II	8249/6
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	carcinoma neuroendocrino moderadamente diferenciado	8249/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	carcinoma neuroendocrino moderadamente diferenciado	8249/3
dev-set2-to-publish/cantemist-norm/cc_onco1230.ann	lesiones en el parénquima hepático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1272.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1272.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1272.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1272.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumoraciones	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumor estromal	8935/1
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	sarcoma del estroma gastrointestinal de alto grado	8936/34
dev-set2-to-publish/cantemist-norm/cc_onco1079.ann	tumor estromal de alto grado	8935/14
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	carcinosarcoma	8980/3
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	tumor maligno indiferenciado	8000/34
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	tumor mulleriano mixto maligno	8950/3
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	adenocarcinoma moderamente diferenciado	8140/32
dev-set2-to-publish/cantemist-norm/cc_onco1387.ann	tumor mesodérmico mixto maligno	8951/3
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	Linfoma no Hodgkin	9591/3
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	células tumorales malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	proliferación tumoral linfoide con un patrón predominantemente angiocéntrico	9766/1
dev-set2-to-publish/cantemist-norm/cc_onco1132.ann	Linfoma no Hodgkin NT/K extranodal de tipo nasal	9719/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	Carcinoma de células grandes	8012/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	T1bN0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	T4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	carcinoma de células grandes	8012/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	neoplasias	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1068.ann	adenocarcinoma, variante mixta, moderadamente diferenciado	8140/32/H
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	diseminación tumoral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1052.ann	adenocarcinoma de colon derecho G3	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1317.ann	maligna	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1317.ann	timoma linfocítico	8583/1
dev-set2-to-publish/cantemist-norm/cc_onco1317.ann	timoma de predominio linfocítico (compatible con B1)	8583/3
dev-set2-to-publish/cantemist-norm/cc_onco1317.ann	timoma linfocítico (B1)	8583/3
dev-set2-to-publish/cantemist-norm/cc_onco1277.ann	carcinoma de células renales	8312/3
dev-set2-to-publish/cantemist-norm/cc_onco1277.ann	carcinoma renal de células claras	8310/3
dev-set2-to-publish/cantemist-norm/cc_onco1277.ann	metastático	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1277.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	LMA	9861/3
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	LMA	9861/3
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	T2N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	sarcoma mieloide	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	carcinoma intraductal de grado I	8500/21
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	células mieloides neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	Sarcomas mieloides	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1358.ann	leucemia mieloide aguda (LMA) relacionada con la terapéutica	9920/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	CLI	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	T2N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	carcinoma lobulillar	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	carcinoma lobulillar infiltrante	8520/3
dev-set2-to-publish/cantemist-norm/cc_onco65.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	Adenocarcinoma poco diferenciado	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	Adenoma tubular	8211/0
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	pT3N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	peritumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	poliposis	8210/0
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	poliposis	8210/0
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	síndrome de Lynch	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	síndrome de Lynch	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	síndrome de Lynch	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1117.ann	intratumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	carcinoma de célula pequeña	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	células tumorales	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	carcinoma vesicular con invasión hepática	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	carcinoma de vesícula T3 N1 M1	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	tumoral maligna indiferenciada de célula pequeña	8002/34
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	neoplasia de célula pequeña	8002/1
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	metástasis hepática por tumor PNET	9473/6
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1089.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	Mx	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	T2N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	T4N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma de células escamosas	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma escamoso	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma escamoso moderadamente diferenciado	8070/32
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma no microcítico	8046/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	pT3N0M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	carcinoma de células escamosas (epidermoide) bien diferenciado	8070/31
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	adenocarcinoma escasamente diferenciado	8140/33
dev-set2-to-publish/cantemist-norm/cc_onco1177.ann	MX	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	Carcinoma indiferenciado	8020/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	adenomatosa	8140/0
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	cTxN3M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	carcinoma indiferenciado	8020/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	carcinoma indiferenciado	8020/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	carcinoma indiferenciado	8020/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	mieloma	9732/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	mieloma múltiple	9732/3
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	adenopatía a nivel supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco437.ann	carcinoma mal diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	Neoplasia indiferenciada	8000/14
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	sarcoma granulocítico	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	sarcoma granulocítico	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	sarcoma granulocítico	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	sarcoma granulocítico	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	sarcoma granulocítico	9930/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	células con caracteres citológicos de malignidad	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1495.ann	tumor neuroectodérmico	9364/3
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	angiosarcoma	9120/3
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	angiosarcoma de alto grado	9120/34
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1500.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	adenocarcinoma	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	carcinoma neuroendocrino de alto grado	8246/34
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	lesiones ocupantes de espacio supratentoriales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	tumor neuroendocrino de alto grado	8240/34
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	neoformación epitelial moderada/pobremente diferenciada, de hábito glandular	8010/13/H
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	carcinoma pobremente diferenciado no microcítico	8046/33
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	adenocarcinoma de pulmón estadio IV por afectación pleural	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1020.ann	implante en la pleura	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1320.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1320.ann	meduloblastoma	9470/3
dev-set2-to-publish/cantemist-norm/cc_onco1320.ann	foco satélite	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1320.ann	Meduloblastoma	9470/3
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	masa paravertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	neuroblastoma	9500/3
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	progresión a nivel óseo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	neuroblastoma bien diferenciado	9500/31
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	lesiones vertebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1363.ann	lesión infiltrativa intertrocantérea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1273.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1273.ann	enfermedad a nivel óseo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1273.ann	lesiones cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1273.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	hemangiomas	9120/0
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	metástasis de carcinoma de células claras	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	metástasis de carcinoma de células renales	8312/6
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	neoplásicos	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	tumor de células claras	8005/1
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	cáncer renal de células claras grado III de Furhman	8005/33
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	neoplasia de células claras con áreas de alto y bajo grado	8005/34
dev-set2-to-publish/cantemist-norm/cc_onco1071.ann	metástasis resecada en el yeyuno de carcinoma renal de células claras	8310/6
dev-set2-to-publish/cantemist-norm/cc_onco1217.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1217.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1217.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1217.ann	mesotelioma maligno de tipo epitelial	9052/3
dev-set2-to-publish/cantemist-norm/cc_onco1217.ann	Mesotelioma pleural maligno de tipo epitelial	9052/3
dev-set2-to-publish/cantemist-norm/cc_onco1211.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1211.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1211.ann	carcinoma in situ	8010/2
dev-set2-to-publish/cantemist-norm/cc_onco1211.ann	metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	Masa mediastínica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	Tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	lesiones pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	masa mediastínica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	masa mediastínica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	masa pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	progresión pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	seminoma	9061/3
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	Seminoma testicular derecho cT3-4N3M1a	9061/6
dev-set2-to-publish/cantemist-norm/cc_onco1127.ann	Nódulos pulmonares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	CDI	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	carcinoma ductal in situ	8500/2
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	lesiones cerebrales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	carcinoma ductal infiltrante tipo común (CDI) grado 3	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	CDI grado 1	8500/31
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	CDI grado 3	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	carcinoma pulmonar pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1012.ann	CDI en la mama contralateral, grado 3	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	cT2N1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma	8010/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante	8500/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma inflamatorio	8530/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma inflamatorio	8530/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante grado II	8500/32
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	carcinoma ductal infiltrante (GII-GIII)	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco639.ann	afectación axilar contralateral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	Adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	adenopatía supraclavicular	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	adenopatías supraclaviculares	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	carcinoma pobremente diferenciado	8010/33
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	miomatoso	8895/0
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	neoplasia	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1009.ann	carcinoma de ovario enfermedad diseminada	8010/6
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	PNET	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	neoplasia primitiva	8000/1/H
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	seminoma	9061/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	teratoma	9080/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumor germinal	9064/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumorales	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumor neuroendocrino primitivo	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	neoplasia germinal mixta (seminoma y teratoma)	9085/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	pT2NxM1a	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumores neuroendocrinos primitivos	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1461.ann	tumor neuroendocrino primitivo	9473/3
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	Tumor de células gigantes	8003/3
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	suelta de globos	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	tumor de células gigantes	8003/3
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1163.ann	tumor de células gigantes grado tres de Sanerkin	8003/33
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	Carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	carcinoma epidermoide	8070/3
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	lesión ósea	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	metástasis de carcinoma epidermoide	8070/6
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1048.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	Carcinoma de células pequeñas	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	neoplásica	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	Tumor vesical (PTA G2)	8130/2
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	Carcinoma microcítico	8041/3
dev-set2-to-publish/cantemist-norm/cc_onco1031.ann	TxN2M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	enfermedad a nivel cerebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	enfermedad a nivel pulmonar	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	implantes pleurales	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	tumoral	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	timoma maligno	8580/3
dev-set2-to-publish/cantemist-norm/cc_onco1232.ann	lesiones a nivel vertebral	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	Sarcoma indiferenciado	8805/3
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	sarcoma de células redondas grandes de alto grado	8800/34/H
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	sarcoma Ewing-like	8800/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	sarcoma de Ewing	9260/3
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	Sarcoma indiferenciado de células redondas grandes de alto grado tipo Ewing-like	8800/34/H
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	metástasis por sarcoma indiferenciado	8805/6
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	Ewing-like	8800/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1325.ann	T2aN1M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	M0	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma infiltrante	8010/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	células neoplásicas	8001/1
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	malignidad	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	tumoración	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma intraductal grupo 3 de Van Nuys con cancerización lobulillar	8522/33
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar y sólido de alto grado citológico con necrosis) con cancerización lobulillar	8522/33
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar	8265/23
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar y sólido	8230/23
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	Carcinoma ductal infiltrante de 1 cm G1	8500/31
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	Carcinoma ductal infiltrante de 2,5 mm G3	8500/33
dev-set2-to-publish/cantemist-norm/cc_onco1218.ann	carcinoma de mama ductal infiltrante (multifocal)	8500/3/H
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	Carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	NEOPLASIA	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	adenocarcinomas	8140/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	carcinomatosis	8010/9
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	cáncer	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	células malignas	8001/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	maligno	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	melanoma	8720/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	metastásica	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	neoformación	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	neoformativo	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	tumores	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	enfermedad de Paget	8000/3
dev-set2-to-publish/cantemist-norm/cc_onco1133.ann	Carcinoma escamoso poco diferenciado	8070/33
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	macroprolactinoma	8271/0
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	meningioma	9530/0
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	meningioma	9530/0
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	nódulo subcutáneo	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	tumor	8000/1
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	metástasis de adenocarcinoma de origen pulmonar, moderadamente diferenciado	8140/62
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	neoplasia pleuropulmonar en lóbulo superior derecho con metástasis	8973/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	Adenocarcinoma de pulmón estadio IV (metástasis	8140/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	enfermedad abdominal	8000/6
dev-set2-to-publish/cantemist-norm/cc_onco1019.ann	enfermedad peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco819.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco819.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco819.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco819.ann	adenocarcinoma de colon en fragmentos de tumor velloso	8262/3
train-set-to-publish/cantemist-norm/cc_onco819.ann	pT2N0(0/12)M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco819.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco819.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco819.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco819.ann	enfermedad a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco217.ann	Carcinoma Escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco217.ann	carcinoma de células escamosas	8070/3
train-set-to-publish/cantemist-norm/cc_onco217.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco217.ann	progresión mediastínica y ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco316.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco316.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco316.ann	tumor de células germinales	9064/3
train-set-to-publish/cantemist-norm/cc_onco316.ann	neoplasia germinal no seminomatosa	9065/3
train-set-to-publish/cantemist-norm/cc_onco316.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco316.ann	implantes en la superficie hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco3.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	adenocarcinoma pulmonar metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco3.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco592.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco592.ann	sinovitis villonodular pigmentada	8000/0
train-set-to-publish/cantemist-norm/cc_onco592.ann	sinovitis villonodular pigmentada	8000/0
train-set-to-publish/cantemist-norm/cc_onco592.ann	sinovitis villonodular pigmentada	8000/0
train-set-to-publish/cantemist-norm/cc_onco592.ann	sinovitis villonodular pigmentada	8000/0
train-set-to-publish/cantemist-norm/cc_onco767.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco767.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	tumor neuroendocrino bien diferenciado	8240/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	carcinoide atípico	8249/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	tumor carcinoide atípico pulmonar bien diferenciado con metástasis	8249/61
train-set-to-publish/cantemist-norm/cc_onco767.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	metástasis de tumor neuroendocrino bien diferenciado	8240/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco767.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco767.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	carcinoma de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco848.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	neuroblastoma	9500/3
train-set-to-publish/cantemist-norm/cc_onco848.ann	adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco848.ann	adenocarcinoma de pulmón cT3N2M1b	8140/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	enfermedad pulmonar, hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	progresión sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco848.ann	lesiones hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco405.ann	Carcinoma anaplásico	8021/3
train-set-to-publish/cantemist-norm/cc_onco405.ann	carcinoma anaplásico	8021/3
train-set-to-publish/cantemist-norm/cc_onco405.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco405.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco405.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco405.ann	pT3NxM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco405.ann	diseminación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco107.ann	implante tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	T2bN2M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	malignas	8000/3
train-set-to-publish/cantemist-norm/cc_onco107.ann	carcinoma de células grandes	8012/3
train-set-to-publish/cantemist-norm/cc_onco107.ann	Carcinoma de pulmón de células grandes estadio IV (T2B N3 M1B)	8012/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco107.ann	progresión ganglionar, ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco475.ann	tumor carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco475.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco475.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco475.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco475.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	metástasis de TNE bien diferenciado grado 1 (OMS	8240/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	Tumor neuroendocrino ileoyeyunal bien diferenciado grado 1 (Ki-67 1-2 %) con afectación metastásica	8240/6
train-set-to-publish/cantemist-norm/cc_onco475.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco882.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco882.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco882.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco882.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco882.ann	angiomiolipoma epitelioide	8860/0/H
train-set-to-publish/cantemist-norm/cc_onco882.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco882.ann	AML	8860/0
train-set-to-publish/cantemist-norm/cc_onco882.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco141.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco141.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco141.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco141.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco141.ann	cT2aN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco141.ann	T1N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco141.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco709.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	carcinoma embrionario	9070/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco979.ann	teratoma quístico	9080/0
train-set-to-publish/cantemist-norm/cc_onco979.ann	tumor del seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco979.ann	suelta de globos	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco979.ann	tumor mixto de células germinales no seminomatoso	9065/3/H
train-set-to-publish/cantemist-norm/cc_onco979.ann	Tumor germinal no seminomatoso	9065/3
train-set-to-publish/cantemist-norm/cc_onco979.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco892.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco892.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco892.ann	carcinoma seroso papilar de ovario de alto grado	8461/34
train-set-to-publish/cantemist-norm/cc_onco942.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco942.ann	leiomiomas	8890/0
train-set-to-publish/cantemist-norm/cc_onco942.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco942.ann	metástasis ovárica de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	adenocarcinoma intestinal medianamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco942.ann	citología maligna	8001/3
train-set-to-publish/cantemist-norm/cc_onco942.ann	metástasis en ovario derecho de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	adenocarcinoma de colon sigmoide estadio IV (metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	recaída ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco942.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco36.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco36.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco36.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco36.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco36.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco36.ann	carcinoma escamoso moderadamente diferenciado	8070/32
train-set-to-publish/cantemist-norm/cc_onco36.ann	cT4N2M	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco796.ann	carcinoma ductal infiltrante grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco796.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco796.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco796.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco796.ann	adenocarcinoma ovárico tipo endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco796.ann	implante de 1,2 cm en el fondo de saco de Douglas	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	adenocarcinoma tipo endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco796.ann	recaída pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	implante subcapsular hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	metástasis de carcinoma indiferenciado	8020/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	implantes de carcinoma pobremente diferenciado	8020/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	nódulo peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco796.ann	enfermedad a nivel peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	adenocarcinoma mal diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco802.ann	adenocarcinoma mal diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco802.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	carcinoma de célula no pequeña	8046/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	carcinoma escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco802.ann	tumor carcinoide típico	8240/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	lesiones supra e infratentoriales	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	carcinoide atípico	8249/3
train-set-to-publish/cantemist-norm/cc_onco802.ann	diseminación mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco802.ann	tumor carcinoide atípico	8249/3
train-set-to-publish/cantemist-norm/cc_onco955.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco955.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco955.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco955.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco955.ann	carcinoma basocelular	8090/3
train-set-to-publish/cantemist-norm/cc_onco955.ann	linfoma no Hodgkin B difuso de células grandes	9680/3
train-set-to-publish/cantemist-norm/cc_onco955.ann	Linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco955.ann	linfoma no Hodgkin B difuso de células grandes	9680/3
train-set-to-publish/cantemist-norm/cc_onco319.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco319.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco319.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco319.ann	carcinoma intraductal de alto grado	8500/24
train-set-to-publish/cantemist-norm/cc_onco319.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	lesión parietal	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco319.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco319.ann	intraductal de alto grado	8500/24
train-set-to-publish/cantemist-norm/cc_onco319.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	metástasis cerebrales múltiples de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	lesión cerebelosa	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	lesiones intratentoriales	8000/6
train-set-to-publish/cantemist-norm/cc_onco319.ann	metástasis cerebrales de carcinoma ductal infiltrante	8500/6
train-set-to-publish/cantemist-norm/cc_onco643.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco643.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco643.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco643.ann	linfoma folicular grado 2	9691/3
train-set-to-publish/cantemist-norm/cc_onco643.ann	carcinoma de células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco643.ann	carcinoma anaplásico neuroendocrino	8246/34
train-set-to-publish/cantemist-norm/cc_onco643.ann	Carcinoma de células de Merkel estadio IV por afectación hepática	8247/6
train-set-to-publish/cantemist-norm/cc_onco643.ann	linfoma folicular	9690/3
train-set-to-publish/cantemist-norm/cc_onco643.ann	CMM	8000/6
train-set-to-publish/cantemist-norm/cc_onco427.ann	afectación ganglionar, ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco427.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco427.ann	infiltración de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco427.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco427.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco427.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco427.ann	síndrome leucoeritroblástico	8000/6
train-set-to-publish/cantemist-norm/cc_onco23.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco23.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco23.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco23.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco23.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco23.ann	carcinoma ductal infiltrante, de grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco23.ann	carcinoma ductal infiltrante de mama, de grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco23.ann	cT2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco23.ann	carcinoma ductal infiltrante de grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco673.ann	Carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco673.ann	neurofibroma	9540/0
train-set-to-publish/cantemist-norm/cc_onco673.ann	carcinoma renal de células claras izquierdo, estadio IV, con afectación pulmonar	8310/6
train-set-to-publish/cantemist-norm/cc_onco673.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco673.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco673.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco765.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco765.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco765.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco765.ann	Lesión ocupante de espacio en segmento VIII hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	Adenocarcinoma de colon pT3pN1aM1	8140/6
train-set-to-publish/cantemist-norm/cc_onco765.ann	adenocarcinoma de colon sincrónico G2 y áreas focales G3	8140/33
train-set-to-publish/cantemist-norm/cc_onco765.ann	progresión mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco6.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco6.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco6.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco6.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco6.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco6.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco6.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco6.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco6.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	carcinoma de próstata metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	carcinoma de próstata metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	progresión radiológica a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	carcinoma de próstata metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	progresión radiológica (ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	enfermedad prostática a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	lesiones blásticas óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	lesión a nivel suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	nódulo suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco6.ann	nódulo suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco98.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco98.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco98.ann	neoplásica metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco98.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco98.ann	carcinoma epidermoide cutáneo estadio IV (metástasis	8070/6
train-set-to-publish/cantemist-norm/cc_onco98.ann	enfermedad extendida	8000/6
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinoma no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco62.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco62.ann	tumoral maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	leucemia aguda mieloblástica	9872/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	metástasis de carcinoma epidermoide pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco62.ann	leucemia aguda mieloblástica	9872/3
train-set-to-publish/cantemist-norm/cc_onco62.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco62.ann	carcinoma epidermoide estadio IV al diagnóstico por nódulos subcutáneos	8070/6
train-set-to-publish/cantemist-norm/cc_onco62.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco62.ann	nódulo en la región axilar	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco873.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco873.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco873.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco873.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco873.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco873.ann	GANT	8936/3
train-set-to-publish/cantemist-norm/cc_onco873.ann	metástasis de GIST	8936/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	recaída a nivel perihepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	lesiones pélvicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	recaída a nivel sacro	8000/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	metástasis de GIST	8936/6
train-set-to-publish/cantemist-norm/cc_onco873.ann	masa en fosa iliaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco337.ann	MELANOMA	8720/3
train-set-to-publish/cantemist-norm/cc_onco337.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco337.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco337.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco337.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco337.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco337.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco337.ann	tumor maligno muy indiferenciado	8000/34
train-set-to-publish/cantemist-norm/cc_onco337.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco337.ann	masa pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco337.ann	masa pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco406.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco406.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	carcinoma renal de células claras (CRCC) grado 3 de Fuhrman	8310/33
train-set-to-publish/cantemist-norm/cc_onco406.ann	CRCC	8310/3
train-set-to-publish/cantemist-norm/cc_onco406.ann	extensión extrarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	pT1bN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	metástasis de CRCC	8310/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	oligometastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	metastásicas para CRCC	8310/6
train-set-to-publish/cantemist-norm/cc_onco406.ann	CRCC	8310/3
train-set-to-publish/cantemist-norm/cc_onco406.ann	CRCC	8310/3
train-set-to-publish/cantemist-norm/cc_onco406.ann	Carcinoma renal de células claras pT1bN1M1	8310/6
train-set-to-publish/cantemist-norm/cc_onco630.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco630.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco630.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco630.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco227.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco227.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco227.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco227.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco227.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco227.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco227.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco227.ann	implante omental	8000/6
train-set-to-publish/cantemist-norm/cc_onco227.ann	afectación tumoral peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco227.ann	omental cake	8000/6
train-set-to-publish/cantemist-norm/cc_onco492.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco492.ann	carcinoide de células caliciformes	8243/3
train-set-to-publish/cantemist-norm/cc_onco492.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco492.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco492.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco80.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco80.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco80.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco80.ann	nevus azul	8780/0
train-set-to-publish/cantemist-norm/cc_onco80.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco80.ann	melanoma de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco80.ann	melanoma de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco80.ann	metástasis cutánea de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco80.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco460.ann	Carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco460.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco460.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco460.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco460.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco460.ann	adenoma pleomorfo	8940/0
train-set-to-publish/cantemist-norm/cc_onco460.ann	adenoma pleomorfo	8940/0
train-set-to-publish/cantemist-norm/cc_onco460.ann	T4bN2bM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco460.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco480.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco480.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco480.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco480.ann	adenocarcinoma de pulmón estadio IV (TxNxM1a)	8140/6
train-set-to-publish/cantemist-norm/cc_onco480.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco480.ann	nódulo subpleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco480.ann	lesión pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco97.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco97.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco97.ann	neoformativa	8000/1
train-set-to-publish/cantemist-norm/cc_onco97.ann	carcinoma poco diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco97.ann	Carcinoma poco diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco97.ann	cT1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco204.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco204.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco204.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	pT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco204.ann	progresión locorregional y a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	micronódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco204.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco771.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	melanoma infiltrante	8720/3/H
train-set-to-publish/cantemist-norm/cc_onco771.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	realce ependimario	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	invasión leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco771.ann	recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central	8720/6
train-set-to-publish/cantemist-norm/cc_onco731.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco731.ann	higroma	9173/0
train-set-to-publish/cantemist-norm/cc_onco731.ann	neoplásica diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco731.ann	metástasis de neoplasia	8000/6
train-set-to-publish/cantemist-norm/cc_onco731.ann	infiltración de la MO	8000/6
train-set-to-publish/cantemist-norm/cc_onco731.ann	anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco731.ann	invasión de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco731.ann	neoplasia gástrica diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	angioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco155.ann	angioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco155.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco155.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco155.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenocarcinoma ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenocarcinoma ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco155.ann	Adenocarcinoma ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco155.ann	Carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco155.ann	adenopatías cervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco231.ann	Oncocitoma	8290/0
train-set-to-publish/cantemist-norm/cc_onco231.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco231.ann	Nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco231.ann	enfermedad a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	progresión tras 3 ciclos a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	Afectación adenopática mediastínica y supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco231.ann	nódulos pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco790.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumor de células germinales	9064/3
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumor germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumor del saco vitelino (Yolk sac tumor) tipo glandular	9071/3/H
train-set-to-publish/cantemist-norm/cc_onco790.ann	sarcomatosa	8800/9
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumor germinal no seminoma	9065/3
train-set-to-publish/cantemist-norm/cc_onco790.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco790.ann	Yolk sac tumor	9071/3
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumor del saco vitelino (seno endodérmico), variante glandular	9071/3/H
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco790.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco790.ann	neoproliferativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco159.ann	Recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco159.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco159.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco159.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco159.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco159.ann	Progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco432.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco432.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco432.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco432.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco432.ann	CDI de mama, grado histológico 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco432.ann	T3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco432.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco45.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco45.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco45.ann	adenocarcinoma gástrico con células en anillo de sello, grado 3	8490/33
train-set-to-publish/cantemist-norm/cc_onco45.ann	Adenocarcinoma gástrico reintervenido estadio IV (metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	pT2bN0/15M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	linitis plástica	8142/3
train-set-to-publish/cantemist-norm/cc_onco45.ann	afectación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco45.ann	malignos	8000/3
train-set-to-publish/cantemist-norm/cc_onco338.ann	Meningioma	9530/0
train-set-to-publish/cantemist-norm/cc_onco338.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco338.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco338.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco338.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco338.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco338.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco338.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco338.ann	carcinoma de células escamosas pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco338.ann	mestastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco338.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco338.ann	cT4cN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco338.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco390.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco390.ann	adenocarcinoma de próstata grado combinado de Gleason 7 (3+4) estadio IV (OSS	8140/62
train-set-to-publish/cantemist-norm/cc_onco390.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco390.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco390.ann	adenocarcinoma de próstata grado histológico combinado de Gleason 7 (3+4)	8140/62
train-set-to-publish/cantemist-norm/cc_onco390.ann	adenopatías cervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco390.ann	ADENOCARCINOMA DE PÓSTATA GRADO HISTOLÓGICO COMBINADO DE GLEASON 7 (3+4) ESTADIO IV (OSS	8140/62
train-set-to-publish/cantemist-norm/cc_onco896.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco896.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco896.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco896.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco896.ann	TNEp	8240/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	TNEp bien diferenciado	8240/3
train-set-to-publish/cantemist-norm/cc_onco896.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco896.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	estesioneuroblastoma	9522/3
train-set-to-publish/cantemist-norm/cc_onco360.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	intratumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco360.ann	tumor mal diferenciado	8000/13
train-set-to-publish/cantemist-norm/cc_onco360.ann	estesioneuroblastoma de alto grado	9522/34
train-set-to-publish/cantemist-norm/cc_onco360.ann	Estesioneuroblastoma	9522/3
train-set-to-publish/cantemist-norm/cc_onco360.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	Adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco360.ann	afectación de glándula hipofisaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	adenocarcinoma de tipo intestinal	8144/3
train-set-to-publish/cantemist-norm/cc_onco951.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco951.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco951.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco951.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco951.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco951.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	recidiva hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco951.ann	lesión en pene	8000/6
train-set-to-publish/cantemist-norm/cc_onco115.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco115.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	neoplasia de células dendríticas plasmocitoides blásticas	9727/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	linfoma de células dendríticas	9727/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	leucemia	9800/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	Neoplasia de células dendríticas plasmocitoides blásticas	9727/3
train-set-to-publish/cantemist-norm/cc_onco115.ann	NCDPB	9727/3
train-set-to-publish/cantemist-norm/cc_onco789.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco789.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco789.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco789.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco789.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco789.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco789.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco789.ann	ADC endometrioide moderadamente diferenciado	8380/32
train-set-to-publish/cantemist-norm/cc_onco789.ann	pT1b1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco789.ann	implante en pared abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco789.ann	adenocarcinoma endometrioide en implantes tumorales intestinales	8380/6
train-set-to-publish/cantemist-norm/cc_onco789.ann	adenocarcinoma túbulo-papilar	8263/3
train-set-to-publish/cantemist-norm/cc_onco789.ann	adenocarcinoma túbulo-papilar con metaplasia escamosa	8570/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco152.ann	Adenocarcinoma de endometrio tipo endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco152.ann	adenocarcinoma bien diferenciado de endometrio, tipo endometrioide	8380/31
train-set-to-publish/cantemist-norm/cc_onco264.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco264.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco264.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco264.ann	tumoral maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco264.ann	LBDCG	9680/3
train-set-to-publish/cantemist-norm/cc_onco264.ann	LB	9687/3
train-set-to-publish/cantemist-norm/cc_onco937.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco937.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco937.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco937.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco937.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco937.ann	carcinoma de células renales tipo células claras grado 3 de Fürhman	8312/33
train-set-to-publish/cantemist-norm/cc_onco937.ann	T3N0M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco937.ann	CCR	8312/3
train-set-to-publish/cantemist-norm/cc_onco937.ann	lesión cutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco937.ann	cáncer de células claras	8005/3
train-set-to-publish/cantemist-norm/cc_onco937.ann	carcinoma de células renales tipo células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco937.ann	lesión supraciliar	8000/6
train-set-to-publish/cantemist-norm/cc_onco267.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumor Phyllodes de bajo grado	9020/11
train-set-to-publish/cantemist-norm/cc_onco267.ann	carcinoma infiltrante grado II	8010/32/H
train-set-to-publish/cantemist-norm/cc_onco267.ann	carcinoma metaplásico	8575/3
train-set-to-publish/cantemist-norm/cc_onco267.ann	carcinoma metaplásico	8575/3
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumor Phyllodes de bajo grado	9020/11
train-set-to-publish/cantemist-norm/cc_onco267.ann	tumor Phyllodes de bajo grado	9020/11
train-set-to-publish/cantemist-norm/cc_onco267.ann	carcinoma ecriescamoide ductal	8070/3/H
train-set-to-publish/cantemist-norm/cc_onco267.ann	carcinoma secretor	8502/3
train-set-to-publish/cantemist-norm/cc_onco267.ann	cT4N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco267.ann	cT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco267.ann	celularidad tumoral	8001/1
train-set-to-publish/cantemist-norm/cc_onco267.ann	Adenopatía axilar y en fosa supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco180.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco180.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco180.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco180.ann	linfoma tipo B de la zona marginal extraganglionar (MALT) con afectación gástrica	9699/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	MALT	9699/3
train-set-to-publish/cantemist-norm/cc_onco180.ann	adenocarcinoma de endometrio tipo endometroide bien diferenciado	8380/31
train-set-to-publish/cantemist-norm/cc_onco180.ann	epitelioma sebáceo	8410/0
train-set-to-publish/cantemist-norm/cc_onco180.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	lesiones intraparenquimatosas	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	lesiones de parénquima cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	Xantroastrocitoma pleomórfico grado II de la OMS	9424/32
train-set-to-publish/cantemist-norm/cc_onco180.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco180.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco739.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	tumor fibroso solitario	8815/0
train-set-to-publish/cantemist-norm/cc_onco739.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco739.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco739.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco739.ann	metástasis de tumor fibroso solitario	8815/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	recidiva hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	Recidiva hepática y pulmonar de tumor fibroso solitario	8815/6
train-set-to-publish/cantemist-norm/cc_onco739.ann	Nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco311.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	metástasis de carcinoma indiferenciado de alto grado de estirpe epitelial	8070/64
train-set-to-publish/cantemist-norm/cc_onco311.ann	CARCINOMA INDIFERENCIADO DE ALTO GRADO	8020/34
train-set-to-publish/cantemist-norm/cc_onco311.ann	sarcomatoide	8033/3
train-set-to-publish/cantemist-norm/cc_onco311.ann	Tumoración de características malignas	8000/3
train-set-to-publish/cantemist-norm/cc_onco311.ann	TUMOR RABDOIDE	8963/3
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	enfermedad residual y a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco311.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco108.ann	adenocarcinoma seroso papilar	8460/3
train-set-to-publish/cantemist-norm/cc_onco108.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco108.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco108.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco108.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco108.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco108.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco108.ann	adenocarcinoma de ovario seroso papilar G2	8460/32
train-set-to-publish/cantemist-norm/cc_onco108.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco108.ann	Metástasis cerebral única de adenocarcinoma seroso papilar de ovario de alto grado	8460/64
train-set-to-publish/cantemist-norm/cc_onco108.ann	lesión ocupante de espacio nodular en el lóbulo frontal	8000/6
train-set-to-publish/cantemist-norm/cc_onco108.ann	LOE cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco108.ann	adenocarcinoma seroso papilar de alto grado	8460/34
train-set-to-publish/cantemist-norm/cc_onco56.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco56.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco56.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco56.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco56.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco56.ann	Angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	enfermedad linfoproliferativa	9970/1
train-set-to-publish/cantemist-norm/cc_onco774.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	sarcomatosa	8800/9
train-set-to-publish/cantemist-norm/cc_onco774.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco774.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco774.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco774.ann	tumoración de partes blandas	8800/1
train-set-to-publish/cantemist-norm/cc_onco774.ann	proceso linfoproliferativo de diferenciación plasmablástica	9970/1/H
train-set-to-publish/cantemist-norm/cc_onco774.ann	linfoma plasmablástico	9735/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	mieloma plasmablástico	9732/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	linfoma B difuso	9591/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	linfoma B difuso ALK+	9591/3/H
train-set-to-publish/cantemist-norm/cc_onco774.ann	linfoma plasmablástico	9735/3
train-set-to-publish/cantemist-norm/cc_onco774.ann	linfoma plasmablástico estadio IV por afectación hepática	9735/6
train-set-to-publish/cantemist-norm/cc_onco774.ann	neoplásica	8000/3
train-set-to-publish/cantemist-norm/cc_onco852.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco852.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco852.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco852.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco852.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco852.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco852.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco92.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco92.ann	adenopatías cervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco92.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	hepatocarcinoma	8170/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	pM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco844.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	leiomiosarcoma	8890/3
train-set-to-publish/cantemist-norm/cc_onco48.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco48.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco48.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco48.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco48.ann	CDI de mama derecha grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco48.ann	CDI de mama izquierda grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco48.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco48.ann	CDI de mama derecha grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco48.ann	CDI de mama izquierda grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco48.ann	cistoadenocarcinoma seroso papilar de alto grado	8460/34
train-set-to-publish/cantemist-norm/cc_onco48.ann	adenocarcinoma mixto	8323/3
train-set-to-publish/cantemist-norm/cc_onco567.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	metástasis de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	metástasis de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco567.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	carcinoma de células claras grado 2 de Fuhrman	8310/32
train-set-to-publish/cantemist-norm/cc_onco567.ann	nódulos subpleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	masa abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	masa infradiafragmática	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	masa infradiafragmática	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	lesiones subpleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	masa pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco567.ann	masa pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco912.ann	carcinoma de células renales	8312/3
train-set-to-publish/cantemist-norm/cc_onco912.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco912.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco912.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco912.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco912.ann	tumor renal, variante histológica, células claras	8005/0
train-set-to-publish/cantemist-norm/cc_onco912.ann	pT3aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco847.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco847.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco847.ann	carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco847.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco847.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco847.ann	metástasis de carcinoma lobulillar	8520/6
train-set-to-publish/cantemist-norm/cc_onco847.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco847.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco847.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco847.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco847.ann	carcinoma pobremente diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco847.ann	cáncer de mama lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco847.ann	metástasis pilórica-duodenal de carcinoma lobulillar	8520/6
train-set-to-publish/cantemist-norm/cc_onco847.ann	carcinomas	8010/3
train-set-to-publish/cantemist-norm/cc_onco331.ann	carcinoma ductal in situ	8500/2
train-set-to-publish/cantemist-norm/cc_onco331.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco331.ann	carcinoma in situ	8010/2
train-set-to-publish/cantemist-norm/cc_onco331.ann	carcinoma ductal infiltrante, grado histológico (GH) II	8500/32
train-set-to-publish/cantemist-norm/cc_onco331.ann	metástasis por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco331.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco331.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	Carcinoma in situ	8010/2
train-set-to-publish/cantemist-norm/cc_onco614.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco614.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco614.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	adenocarcinoma de pulmón con afectación cerebral	8140/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	Adenocarcinoma de pulmón estadio IVB (cT2 CN2 M1c)	8140/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	adenocarcinoma de patrón papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco614.ann	progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	lesión ocupante de espacio (LOE) en hemisferio cerebeloso	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	afectación cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	progresión radiológica (pulmonar y cerebral)	8000/6
train-set-to-publish/cantemist-norm/cc_onco614.ann	afectación cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco894.ann	Carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco894.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	adenocarcinoma de próstata Gleason 8	8140/33
train-set-to-publish/cantemist-norm/cc_onco894.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco894.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco894.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco894.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco894.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco894.ann	T2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	adenopatías laterocervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco894.ann	carcinoma invasor	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco894.ann	carcinoma ductal infiltrante de 1,5 cm, grado histológico 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco894.ann	adenocarcinoma acinar Gleason 9 con infiltración bilateral, con extensión extraprostática	8550/63
train-set-to-publish/cantemist-norm/cc_onco894.ann	letálides	8000/6
train-set-to-publish/cantemist-norm/cc_onco931.ann	carcinoma de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco931.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco931.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco931.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco931.ann	carcinoma microcítico de pulmón estadio IV (T4, N3, M1b)	8041/6
train-set-to-publish/cantemist-norm/cc_onco931.ann	focos hipermetabólicos en distintos territorios ganglionares (supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco841.ann	poliposis adenomatosa familiar	8220/0
train-set-to-publish/cantemist-norm/cc_onco841.ann	fibromatosis desmoide	8821/1
train-set-to-publish/cantemist-norm/cc_onco841.ann	neoplásica mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco841.ann	tumor desmoide	8821/1
train-set-to-publish/cantemist-norm/cc_onco841.ann	poliposis adenomatosa familiar	8220/0
train-set-to-publish/cantemist-norm/cc_onco841.ann	síndrome de Gardner	8220/0
train-set-to-publish/cantemist-norm/cc_onco277.ann	diseminación tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco277.ann	Sarcoma osteogénico	9180/3
train-set-to-publish/cantemist-norm/cc_onco277.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	progresión pleuropulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	metástasis de Sarcoma osteogénico	9180/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	progresión peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	implantes calcificados en ángulo cardiofrénico	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	progresión peritoneal extensa de sarcoma osteogénico	9180/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	afectación hiliar hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	nódulos peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco277.ann	afectación calcificante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco871.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco871.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco871.ann	cT1cN2aM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	metástasis por carcinoma infiltrante	8010/6/H
train-set-to-publish/cantemist-norm/cc_onco871.ann	recaída cutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	afectación pleuropulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	enfermedad a nivel cutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	afectación pleuropulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	metástasis por carcinoma ductal infiltrante	8500/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	metástasis por carcinoma ductal infiltrante	8500/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	Metástasis en colon por carcinoma ductal infiltrante	8500/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	enfermedad a nivel cutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	enfermedad cutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco871.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco521.ann	Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática	8806/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	(LOE) hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	masa pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	masa pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco521.ann	masa pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco320.ann	diseminación tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco320.ann	ependimoma	9391/3
train-set-to-publish/cantemist-norm/cc_onco320.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco320.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco320.ann	germinoma	9064/3
train-set-to-publish/cantemist-norm/cc_onco320.ann	pinealoblastoma	8000/3
train-set-to-publish/cantemist-norm/cc_onco320.ann	GERMINOMA	9064/3
train-set-to-publish/cantemist-norm/cc_onco320.ann	tumoral pineal	9360/1
train-set-to-publish/cantemist-norm/cc_onco295.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco295.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco295.ann	masa hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco295.ann	lesión pseudonodular heterogénea en región frontal	8000/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco385.ann	carcinoma urotelial de vejiga superficial de alto grado	8120/34
train-set-to-publish/cantemist-norm/cc_onco385.ann	carcinoma transicional de alto grado	8120/34
train-set-to-publish/cantemist-norm/cc_onco385.ann	adenocarcinoma de próstata multifocal gleason 6	8140/31
train-set-to-publish/cantemist-norm/cc_onco385.ann	carcinoma transicional de vejiga, G3	8120/33
train-set-to-publish/cantemist-norm/cc_onco385.ann	metástasis de carcinoma urotelial	8120/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco385.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco486.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco486.ann	neoplasia testicular germinal mixta	9085/3
train-set-to-publish/cantemist-norm/cc_onco486.ann	seminoma testicular derecho estadio IIIC (metástasis	9061/6
train-set-to-publish/cantemist-norm/cc_onco486.ann	lesiones líticas desde primera vértebra	8000/6
train-set-to-publish/cantemist-norm/cc_onco13.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco13.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco13.ann	hepatoblastoma metastásico	8970/6
train-set-to-publish/cantemist-norm/cc_onco13.ann	tumor de células pequeñas	8002/1
train-set-to-publish/cantemist-norm/cc_onco13.ann	hepatoblastoma	8970/3
train-set-to-publish/cantemist-norm/cc_onco13.ann	hepatoblastoma	8970/3
train-set-to-publish/cantemist-norm/cc_onco13.ann	afectación extrahepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco13.ann	afectación pancreática	8000/6
train-set-to-publish/cantemist-norm/cc_onco237.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco237.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco237.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco237.ann	Tumor fusiforme	8004/3
train-set-to-publish/cantemist-norm/cc_onco237.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	peritumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco237.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco237.ann	implantes presacros	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco449.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma epidermoide pobremente diferenciado, metastásico	8070/63
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma de células escamosas basaloide pobremente diferenciado	8083/33
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma escamoso pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco449.ann	pT2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	carcinoma epidermoide de cabeza y cuello metastásico	8070/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco449.ann	lesiones nodulares a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco754.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco754.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco754.ann	tumor desmoplásico de células pequeñas y redondas	8806/3
train-set-to-publish/cantemist-norm/cc_onco754.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco754.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco754.ann	diseminación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco754.ann	sarcoma de Ewing	9260/3
train-set-to-publish/cantemist-norm/cc_onco754.ann	Sarcoma de Ewing	9260/3
train-set-to-publish/cantemist-norm/cc_onco754.ann	T3bN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco754.ann	sarcomas de Ewing	9260/3
train-set-to-publish/cantemist-norm/cc_onco529.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco529.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco529.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	adenocarcinoma pulmonar categoría cT2bN3M1c	8140/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	diseminación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	adenocarcinoma mal diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco529.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco529.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	lesiones líticas a nivel de axis	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco529.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	lesiones en la región costal	8000/6
train-set-to-publish/cantemist-norm/cc_onco529.ann	afectación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco906.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco906.ann	carcinoma epidermoide de pulmón cT4N2M1a	8070/6
train-set-to-publish/cantemist-norm/cc_onco906.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco197.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco197.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco197.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco197.ann	T1N2M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco162.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco162.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco162.ann	adenoma tubular	8211/0
train-set-to-publish/cantemist-norm/cc_onco162.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco162.ann	neoplásicas	8000/1
train-set-to-publish/cantemist-norm/cc_onco162.ann	adenocarcinoma de vesícula biliar E IV (pT2N1M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco162.ann	adenopatías a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco313.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco313.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco313.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco313.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco313.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco313.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco851.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco851.ann	infiltración por adenocarcinoma moderadamente diferenciado	8140/62
train-set-to-publish/cantemist-norm/cc_onco851.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco851.ann	adenopatías hiliares, mediastínicas, supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco851.ann	TxN3M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco407.ann	Adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco407.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco407.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco407.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco407.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco407.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco407.ann	metástasis de carcinoma seroso de ovario de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	cistoadenocarcinoma	8440/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	cistoadenocarcinoma	8440/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco439.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco439.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	neoplásicas	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco439.ann	Adenocarcinoma endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	Adenocarcinoma endometrioide de endometrio G2	8380/32
train-set-to-publish/cantemist-norm/cc_onco439.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma endometrioide moderadamente diferenciado	8380/32
train-set-to-publish/cantemist-norm/cc_onco439.ann	implantes a nivel de colon	8000/6
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma endometrioide	8380/3
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma endometrioide de endometrio G2	8380/32
train-set-to-publish/cantemist-norm/cc_onco439.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	tumor de células de la granulosa	8620/1
train-set-to-publish/cantemist-norm/cc_onco306.ann	tumoral maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	tumor de células de Sertoli, estroma gonadal pobremente diferenciado	8631/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	tumor de cordones sexuales / estroma gonadal maligno	8590/1
train-set-to-publish/cantemist-norm/cc_onco306.ann	Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a	8590/6
train-set-to-publish/cantemist-norm/cc_onco306.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco306.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco306.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco306.ann	lesión osteolítica en L5	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	Neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco444.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco444.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco444.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco444.ann	tumoración cerebral benigna	8000/0
train-set-to-publish/cantemist-norm/cc_onco444.ann	carcinoma ductal infiltrante grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco444.ann	pT1bN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	carcinoma ductal infiltrante grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco444.ann	pT1bN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	Carcinoma ductal infiltrante poco diferenciado	8500/33
train-set-to-publish/cantemist-norm/cc_onco444.ann	macrometástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	infiltración de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	infiltración de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco444.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco667.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco667.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco667.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco667.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco667.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco667.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco667.ann	leucemia	9800/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	adenocarcinoma (ADK) metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco667.ann	ADK	8140/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	ADK	8140/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	adenocarcinoma de origen desconocido con metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco667.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco667.ann	ADK	8140/3
train-set-to-publish/cantemist-norm/cc_onco667.ann	infiltración tumoral de medula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco19.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	enfermedad ganglionar retrocrural	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	gammagrafía ósea positiva	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	progresión ganglionar, ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	afectación difusa de la calota craneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco19.ann	Adenocarcinoma de próstata estadio IV por metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco78.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco78.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco78.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco78.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco78.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco78.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco78.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco78.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco78.ann	metástasis de carcinoma indiferenciado de célula pequeña	8041/64
train-set-to-publish/cantemist-norm/cc_onco78.ann	metástasis de carcinoma indiferenciado de célula pequeña	8041/64
train-set-to-publish/cantemist-norm/cc_onco78.ann	neoplásica	8000/3
train-set-to-publish/cantemist-norm/cc_onco78.ann	cáncer microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco78.ann	Carcinoma indiferenciado de célula pequeña	8041/34
train-set-to-publish/cantemist-norm/cc_onco78.ann	Carcinoma indiferenciado de célula pequeña de pulmón (carcinoma microcítico) estadio IV (metástasis	8041/64
train-set-to-publish/cantemist-norm/cc_onco78.ann	lesiones focales en lóbulo derecho	8000/6
train-set-to-publish/cantemist-norm/cc_onco78.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco832.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco832.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco832.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco832.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco832.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco832.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco832.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco832.ann	progresión locorregional y hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma bien diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenopatías hipermetabólicas supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco832.ann	adenocarcinoma de pulmón, con presencia de células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco999.ann	Paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco999.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco999.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	paraganglioma	8680/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco999.ann	infiltración ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco310.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco310.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco310.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco310.ann	tumor mixto maligno de células germinales (coriocarcinoma 60% + teratoma maduro 40%)	9101/3
train-set-to-publish/cantemist-norm/cc_onco310.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco310.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco310.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco310.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco310.ann	pT2cN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco310.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco504.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	cT2aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesión de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	metástasis por melanoma maligno	8720/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	lesión retroesternal	8000/6
train-set-to-publish/cantemist-norm/cc_onco504.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco710.ann	histiocitosis de células de Langerhans	9751/3
train-set-to-publish/cantemist-norm/cc_onco710.ann	tumor de células germinales mixto	9085/3
train-set-to-publish/cantemist-norm/cc_onco710.ann	pT2cN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco710.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco862.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco862.ann	células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco862.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco862.ann	cT3dN2M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	carcinoma con células con citoplasma vacuolado en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco862.ann	células epiteliales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco862.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco862.ann	afectación secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	Metástasis cutánea de adenocarcinoma de origen intestinal con células en anillo de sello	8490/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	Nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	Nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	implante en mesosigma	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	progresión exclusivamente ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	nódulos cutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	progresión tumoral a nivel cutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco862.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco77.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco77.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco77.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco77.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco77.ann	osteosarcoma convencional de alto grado	9180/34
train-set-to-publish/cantemist-norm/cc_onco77.ann	osteosarcoma convencional de alto grado	9180/34
train-set-to-publish/cantemist-norm/cc_onco77.ann	pT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco77.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco77.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco77.ann	enfermedad a nivel mediastínico	8000/6
train-set-to-publish/cantemist-norm/cc_onco77.ann	enfermedad mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco289.ann	carcinoma escamocelular	8070/3
train-set-to-publish/cantemist-norm/cc_onco289.ann	carcinoma pulmonar no microcítico (CPNM) de tipo escamoso Estadio IV (T4N3M1)	8046/6
train-set-to-publish/cantemist-norm/cc_onco289.ann	CPNM	8046/3
train-set-to-publish/cantemist-norm/cc_onco289.ann	carcinoma pulmonar no microcítico (CPNM) de tipo escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco289.ann	nódulos pulmonares múltiples bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco289.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco315.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco315.ann	cáncer de sigma estadio IV cT3N1bM1	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	adenocarcinoma de sigma pT3N2b (7/20) M1 (enfermedad hepática bilobar) de bajo grado	8140/61
train-set-to-publish/cantemist-norm/cc_onco315.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	carcinoma colorrectal metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	adenocarcinoma colorrectal metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	Progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco315.ann	lesión en pala ilíaca izquierda	8000/6
train-set-to-publish/cantemist-norm/cc_onco628.ann	Carcinoma urotelial	8120/3
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma in situ	8010/2
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma in situ	8010/2
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma urotelial	8120/3
train-set-to-publish/cantemist-norm/cc_onco628.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco628.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco628.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco628.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma papilar urotelial (CUP) de alto grado	8130/34
train-set-to-publish/cantemist-norm/cc_onco628.ann	CUP	8130/3
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma urotelial de alto grado	8120/34
train-set-to-publish/cantemist-norm/cc_onco628.ann	pT1cN0cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco628.ann	pT1cN0cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco628.ann	CUP de alto grado	8120/34
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma urotelial papilar no invasivo de alto grado	8130/24
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma papilar urotelial de alto grado	8130/34
train-set-to-publish/cantemist-norm/cc_onco628.ann	carcinoma urotelial infiltrante	8120/3/H
train-set-to-publish/cantemist-norm/cc_onco628.ann	adenocarcinoma prostático acinar	8550/3
train-set-to-publish/cantemist-norm/cc_onco628.ann	oligometastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco628.ann	progresión hepática única y pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco628.ann	pTis	8010/2
train-set-to-publish/cantemist-norm/cc_onco628.ann	pTis	8010/2
train-set-to-publish/cantemist-norm/cc_onco353.ann	Carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	Neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco353.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco353.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco353.ann	T2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco353.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco353.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	Carcinoma epidermoide pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco353.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco353.ann	Carcinoma epidermoide pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco353.ann	T2N1Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco353.ann	T2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco724.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco724.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco724.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco724.ann	adenocarcinoma de ciego moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco724.ann	afectación pélvica ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	masa en psoas	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	masa en el psoas	8000/6
train-set-to-publish/cantemist-norm/cc_onco724.ann	síndrome de Lynch	8010/3
train-set-to-publish/cantemist-norm/cc_onco724.ann	masa del psoas	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco138.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco138.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco138.ann	adenocarcinoma de tipo intestinal	8144/3
train-set-to-publish/cantemist-norm/cc_onco138.ann	metastasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco138.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco138.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	lesión frontoparietal	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	lesión frontoparietal	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	metástasis de adenocarcinoma de tipo intestinal	8144/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	LOE cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	lesión parietal	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	metástasis por adenocarcinoma moderadamente diferenciado de tipo intestinal	8144/62
train-set-to-publish/cantemist-norm/cc_onco138.ann	T3N0M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco138.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	Cistoadenocarcinoma	8440/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco183.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco183.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco183.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco183.ann	cistoadenocarcinoma seroso papilar	8460/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	carcinoma infiltrante pobremente diferenciado	8010/33/H
train-set-to-publish/cantemist-norm/cc_onco183.ann	cistoadenocarcinoma	8440/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	metástasis cutánea de carcinoma neuroendocrino moderadamente diferenciado	8246/62
train-set-to-publish/cantemist-norm/cc_onco183.ann	Carcinoma medular de tiroides metastásico	8510/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	tumor tiene rasgos neuroendocrinos	8240/3
train-set-to-publish/cantemist-norm/cc_onco183.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	mestástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	carcinoma medular de tiroides metastásico	8510/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	afectación suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	progresion a nivel del SNC	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	afectación suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa a nivel del ovario	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa anexial	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masas suprarrenales	8000/6
train-set-to-publish/cantemist-norm/cc_onco183.ann	masa anexial	8000/6
train-set-to-publish/cantemist-norm/cc_onco638.ann	Carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco638.ann	carcinoma pobremente diferenciado compatible con estirpe epidermoide	8070/33
train-set-to-publish/cantemist-norm/cc_onco638.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco638.ann	T2aT4N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco201.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco201.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco201.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco201.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco201.ann	pT3N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco201.ann	afectación hiliar izquierda, ganglionar torácica, supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco375.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	carcinoma mal diferenciado de célula grande	8012/33
train-set-to-publish/cantemist-norm/cc_onco375.ann	carcinoma de pulmón de célula no pequeña (CPCNP) extendido a pleura	8046/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	CPCNP	8046/3
train-set-to-publish/cantemist-norm/cc_onco375.ann	carcinoma de célula grande LSD pulmón G3 cT1bN1M1a	8012/63
train-set-to-publish/cantemist-norm/cc_onco375.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	afectación del sistema nervioso central	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	progresión pulmonar (basal derecha) y meníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	progresión meníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco375.ann	adenocarcinoma acinar G2	8550/32
train-set-to-publish/cantemist-norm/cc_onco375.ann	Adenocarcinoma LSD pulmón Estadio IV por afectación meníngea	8140/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma epidermoide moderadamente diferenciado	8070/32
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma epidermoide moderadamente diferenciado	8070/32
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma pobremente diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco650.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco650.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco650.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	pT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco650.ann	pT4N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma epidermoide pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco650.ann	carcinoma epidermoide pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco903.ann	cavernoma	9121/0
train-set-to-publish/cantemist-norm/cc_onco903.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco903.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco903.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco903.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco903.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco903.ann	nevus	8720/0
train-set-to-publish/cantemist-norm/cc_onco903.ann	tumoración benigna	8000/0
train-set-to-publish/cantemist-norm/cc_onco903.ann	Neoplasia de melanocitos epitelioides con pleomorfismo	8771/3/H
train-set-to-publish/cantemist-norm/cc_onco903.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco903.ann	Melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco903.ann	melanoma metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco903.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco903.ann	afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco603.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco603.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco603.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco603.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco603.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco603.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco603.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco603.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco603.ann	CPNCP	8046/3
train-set-to-publish/cantemist-norm/cc_onco603.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco603.ann	carcinoma indiferenciado de células pequeñas	8041/34
train-set-to-publish/cantemist-norm/cc_onco220.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco220.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado	8249/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	metástasis de tumor neuroendocrino	8240/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	pT3N1Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	tumor heterogéneo	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco220.ann	carcinoma mixto (adeno-neuroendocrino)	8244/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco220.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco220.ann	infiltración medular	8000/6
train-set-to-publish/cantemist-norm/cc_onco784.ann	adenocarcinoma de pulmón izquierdo cT4 N2 M1c	8140/6
train-set-to-publish/cantemist-norm/cc_onco784.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco784.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco760.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco760.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco760.ann	linfoma difuso de células grandes B	9680/3
train-set-to-publish/cantemist-norm/cc_onco760.ann	Linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco760.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco760.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco760.ann	LOP	9590/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco88.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco88.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco88.ann	carcinoma renal papilar de células claras y eosinofílicas grado 3-4 de Furhman	8310/34
train-set-to-publish/cantemist-norm/cc_onco88.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco88.ann	carcinoma renal papilar de células claras y eosinofílicas	8280/3
train-set-to-publish/cantemist-norm/cc_onco88.ann	carcinoma renal papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	Carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco825.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco825.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco825.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminoma clásico	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco825.ann	tumores germinales	9064/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	seminomas	9061/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	metástasis del seminoma	9061/6
train-set-to-publish/cantemist-norm/cc_onco825.ann	Ca. epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco825.ann	Ca.	8000/3
train-set-to-publish/cantemist-norm/cc_onco266.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco266.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco266.ann	adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco266.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco266.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco266.ann	hepatocarcinoma	8170/3
train-set-to-publish/cantemist-norm/cc_onco266.ann	Ca epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco640.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco640.ann	metástasis de neoplasia	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	adenocarcinoma pobremente diferenciado con células en anillo de sello	8490/33
train-set-to-publish/cantemist-norm/cc_onco640.ann	metástasis por un carcinoma pobremente diferenciado con presencia de abundantes células en anillo de sello	8490/63
train-set-to-publish/cantemist-norm/cc_onco640.ann	neoplásica con células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco640.ann	adenocarcinoma de colon pobremente diferenciado con células en anillo de sello	8490/33
train-set-to-publish/cantemist-norm/cc_onco640.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	lesiones intraparenquimatosas	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	adenomegalias laterocervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	infiltración medular	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	afectación meníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco640.ann	infiltración de la médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco959.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco959.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco959.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco959.ann	adenocarcinoma infiltrante, moderadamente diferenciado	8140/32/H
train-set-to-publish/cantemist-norm/cc_onco959.ann	adenocarcinoma de colon sub-estenosante moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco959.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	afectación la hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	adenocarcinoma de bajo grado	8140/31
train-set-to-publish/cantemist-norm/cc_onco959.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco959.ann	(LOES) hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco635.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco635.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco635.ann	metástasis en tránsito en pierna derecha de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco635.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco868.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco868.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco868.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco868.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco868.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco868.ann	mioma	8895/0
train-set-to-publish/cantemist-norm/cc_onco868.ann	carcinoma lobulillar in situ	8520/2
train-set-to-publish/cantemist-norm/cc_onco868.ann	CLIS	8520/2
train-set-to-publish/cantemist-norm/cc_onco868.ann	CLIS	8520/2
train-set-to-publish/cantemist-norm/cc_onco868.ann	cT1bN0Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco868.ann	carcinoma ductal infiltrante grado dos	8500/32
train-set-to-publish/cantemist-norm/cc_onco234.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco234.ann	carcinoma de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco234.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco234.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco234.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco927.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco927.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco927.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco927.ann	mioma	8895/0
train-set-to-publish/cantemist-norm/cc_onco927.ann	carcinoma renal de células claras grado nuclear 3 de Furhman	8310/33
train-set-to-publish/cantemist-norm/cc_onco927.ann	tumor como estadio IV, pT3aN0M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco927.ann	masa vertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco996.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco996.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco996.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco996.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco356.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco356.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco356.ann	Tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco356.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco356.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco356.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco356.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco356.ann	Neoplasia predominantemente fusocelular	8004/1
train-set-to-publish/cantemist-norm/cc_onco356.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco140.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	melanoma metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco140.ann	melanoma lentiginoso acral	8744/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	Melanoma acral	8744/3
train-set-to-publish/cantemist-norm/cc_onco140.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	progresión a nivel de la cápsula esplénica	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	nódulo de 35,4 mm en el hipocondrio	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	lesión periesplénica	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	nódulo en el hipocondrio	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	progresión a nivel del hipocondrio	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	afectación muscular	8000/6
train-set-to-publish/cantemist-norm/cc_onco140.ann	enfermedad a nivel de la cápsula esplénica	8000/6
train-set-to-publish/cantemist-norm/cc_onco464.ann	MALT	9699/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	astrocitoma	9400/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	gammapatía monoclonal	9765/1
train-set-to-publish/cantemist-norm/cc_onco464.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	linfoma plasmablástico	9735/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco464.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco464.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco464.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco464.ann	linfoma de la zona marginal extranodal	9699/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	LPB	9735/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	astrocitoma difuso	9400/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	neoplasia glial	9380/3
train-set-to-publish/cantemist-norm/cc_onco464.ann	glioma de alto grado	9380/34
train-set-to-publish/cantemist-norm/cc_onco798.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco798.ann	tumor mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco798.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco279.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco279.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco279.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco279.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco279.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco279.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco279.ann	cT3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco279.ann	ypT0N0(0/5)M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco279.ann	Recidiva local, ganglionar y pulmonar de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco886.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco886.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco886.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco886.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco886.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco886.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco915.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco915.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco915.ann	carcinoma ductal infiltrante de mama derecha (cuadrante supero-externo) grado 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco915.ann	progresión múltiple a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	lesiones de cavidad glenoide	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	lesión de L1	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	lesión en región sacroiliaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco915.ann	Metástasis intracardiaca en neoplasia	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	Angioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco889.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco889.ann	nevus melanocítico	8720/0
train-set-to-publish/cantemist-norm/cc_onco889.ann	Melanoma estadio IV TxN2bM1c	8720/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión sacroiliaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	conglomerado supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión sacroiliaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	letálides	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	letálides	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	Lesión lítica	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	masa de partes blandas en arco posterior de 9ª costilla	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión lítica ya conocida en hueso iliaco	8000/6
train-set-to-publish/cantemist-norm/cc_onco889.ann	lesión probable en el cuerpo vertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco347.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	metástasis por carcinoma ductal	8500/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	proliferacion epitelial neoplásica	8010/1
train-set-to-publish/cantemist-norm/cc_onco347.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco347.ann	ypM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	Progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	Progresión de enfermedad ganglionar y hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco347.ann	enfermedad cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco702.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco702.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco702.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco702.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco702.ann	Adenocarcinoma de pulmón E-IV (cT3cN2cM1)	8140/6
train-set-to-publish/cantemist-norm/cc_onco702.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco702.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco702.ann	Diseminación micronodular pulmonar bilateral	8000/6
train-set-to-publish/cantemist-norm/cc_onco702.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco702.ann	lesión a nivel de la calota	8000/6
train-set-to-publish/cantemist-norm/cc_onco718.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco718.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco718.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco718.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco718.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco718.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco818.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	melanoma en regresión	8723/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco818.ann	melanoma retroauricular izquierdo pT2bNxM1a	8720/6
train-set-to-publish/cantemist-norm/cc_onco818.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco818.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco818.ann	Melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	melanoma de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco818.ann	Recaída única cutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco619.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco619.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco619.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco619.ann	Adenocarcinoma de pulmón estadio IVA por metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco619.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco619.ann	lesión cerebelosa	8000/6
train-set-to-publish/cantemist-norm/cc_onco619.ann	lesión cerebelosa	8000/6
train-set-to-publish/cantemist-norm/cc_onco619.ann	progresión se había dado exclusivamente a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	Implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	enfermedad sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco803.ann	progresión peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco803.ann	tumor maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	tumor mülleriano mixto maligno	8950/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	tumor mülleriano mixto maligno	8950/3
train-set-to-publish/cantemist-norm/cc_onco803.ann	nódulos omentales	8000/6
train-set-to-publish/cantemist-norm/cc_onco803.ann	tumor mülleriano mixto	8950/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	Melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	meningioma	9530/0
train-set-to-publish/cantemist-norm/cc_onco308.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco308.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco308.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco308.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco308.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco308.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	adenocarcinoma de pulmón de tipo papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	carcinoma de patrón papilar	8050/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	carcinoma ductal in situ de bajo grado	8500/21
train-set-to-publish/cantemist-norm/cc_onco308.ann	adenocarcinoma de pulmón papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	pT2aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	Carcinoma ductal infiltrante grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco308.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	carcinoma de patrón papilar sólido	8230/3
train-set-to-publish/cantemist-norm/cc_onco308.ann	nódulo peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco308.ann	nódulo mesentérico	8000/6
train-set-to-publish/cantemist-norm/cc_onco125.ann	síndrome de Gorlin	8090/3
train-set-to-publish/cantemist-norm/cc_onco125.ann	tumores basocelulares	8090/1
train-set-to-publish/cantemist-norm/cc_onco125.ann	carcinomas basocelulares	8090/3
train-set-to-publish/cantemist-norm/cc_onco125.ann	Síndrome de Gorlin-Goltz	8090/3
train-set-to-publish/cantemist-norm/cc_onco125.ann	quistes odontogénicos	9301/0
train-set-to-publish/cantemist-norm/cc_onco125.ann	quistes odontogénicos	9301/0
train-set-to-publish/cantemist-norm/cc_onco259.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco259.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco259.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco259.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco259.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco259.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco259.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco259.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco259.ann	adenocarcinoma de probable origen pancreato-biliar	8163/3
train-set-to-publish/cantemist-norm/cc_onco690.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	recidiva hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco690.ann	adenocarcinoma de colon mixto mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco690.ann	adenocarcinoma de colon mixto	8323/3
train-set-to-publish/cantemist-norm/cc_onco949.ann	carcinoma medular de tiroides	8510/3
train-set-to-publish/cantemist-norm/cc_onco949.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco949.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco949.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco949.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco949.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco949.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco949.ann	metástasis de CMT	8510/6
train-set-to-publish/cantemist-norm/cc_onco949.ann	metástasis de CMT	8510/6
train-set-to-publish/cantemist-norm/cc_onco949.ann	CMT (pT3), con afectación metastásica	8510/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco858.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco858.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco858.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco858.ann	carcinoma ductal infiltrante micropapilar grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco858.ann	carcinoma ductal infiltrante micropapilar	8265/3
train-set-to-publish/cantemist-norm/cc_onco858.ann	enfermedad a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	lesiones blásticas óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco858.ann	hígado con múltiples lesiones	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	Cáncer de mama metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco147.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco147.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco147.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco147.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco147.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco147.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	cáncer infiltrante	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco147.ann	PE a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	afectación linfática axilar, mamaria interna, supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	enfermedad a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco147.ann	enfermedad torácica	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	T1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco171.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco171.ann	lesiones del intestino delgado	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	tumoración melanocítica atípica, fundamentalmente fusiforme	8772/3
train-set-to-publish/cantemist-norm/cc_onco171.ann	Recidiva peritoneal de un melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	recidiva intestinal	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	peritumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco171.ann	recidiva en fosa nasal	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	progresión tumoral pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco171.ann	nódulo mesentérico	8000/6
train-set-to-publish/cantemist-norm/cc_onco150.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco150.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco150.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco150.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante (CDI) con diferenciación neuroendocrina	8574/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante (CDI), grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante, pT2 (23 mm), con diferenciación neuroendocrina, grado 2	8574/32
train-set-to-publish/cantemist-norm/cc_onco150.ann	carcinoma ductal infiltrante con diferenciación neuroendocrina	8574/3
train-set-to-publish/cantemist-norm/cc_onco150.ann	proceso infiltrativo a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco153.ann	Carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco153.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco153.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco153.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco920.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco920.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco920.ann	implantes nodulares	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	nódulos epiploicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	lesiones esplénicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	lesión esplénica	8000/6
train-set-to-publish/cantemist-norm/cc_onco920.ann	lesiones esplénicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco118.ann	metástasis de tumor neuroendocrino	8240/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	metastásico por tumor	8000/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	carcinoma neuroendocrino bien diferenciado	8246/31
train-set-to-publish/cantemist-norm/cc_onco118.ann	Insulinoma maligno estadio IV (metástasis	8151/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	insulinoma pancreático maligno con metástasis	8151/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco118.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco883.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco883.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco883.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco883.ann	tumor germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco883.ann	TCG	9064/3
train-set-to-publish/cantemist-norm/cc_onco883.ann	TCG mixto de testículo izquierdo Estadio IIIA (pT3N2M1aS0)	9085/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	TCG mixto pT3 N2 M1a	9085/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	TCG mixto (90 % seminoma y 10 % teratoma con diferenciación escamosa)	9085/3/H
train-set-to-publish/cantemist-norm/cc_onco883.ann	PE pulmonar, hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco883.ann	PE a nivel retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanocitoma	8726/0
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanocitoma	8726/0
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco966.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco966.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanocitoma de grado intermedio	8728/32
train-set-to-publish/cantemist-norm/cc_onco966.ann	tumor de bajo grado	8000/11
train-set-to-publish/cantemist-norm/cc_onco966.ann	diseminación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanocitoma cerebral de grado intermedio	8728/32
train-set-to-publish/cantemist-norm/cc_onco966.ann	meningioma pigmentado	9530/0/H
train-set-to-publish/cantemist-norm/cc_onco966.ann	neoplasias pigmentadas	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco966.ann	melanoma cerebral maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	metástasis de melanoma maligno	8720/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco966.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	lesiones múltiples a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco966.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	Adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco380.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco380.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco380.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco380.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco380.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco380.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco380.ann	carcinoma in situ	8010/2
train-set-to-publish/cantemist-norm/cc_onco380.ann	displasia severa	8077/2
train-set-to-publish/cantemist-norm/cc_onco380.ann	Adenocarcinoma moderadamente diferenciado de patrón intestinal compatible con metástasis	8144/62
train-set-to-publish/cantemist-norm/cc_onco380.ann	neoplasia de hipofaringe en estadio cT3N2 con una metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	metástasis hepática resecable de un adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	adenocarcinoma de patrón intestinal, metastásico	8144/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	Masa hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco380.ann	Neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco85.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco85.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco85.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco85.ann	infiltración médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco85.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco85.ann	Carcinoma de mama cT4b N2a M1	8010/6
train-set-to-publish/cantemist-norm/cc_onco85.ann	infiltración de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco997.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco997.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco997.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco997.ann	sarcoma de Kaposi	9140/3
train-set-to-publish/cantemist-norm/cc_onco997.ann	Sarcoma de Kaposi	9140/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco835.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco835.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco835.ann	células de Meckel	8247/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	adenocarcinoma gástrico difuso con células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	adenocarcinoma gástrico difuso	8145/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco835.ann	Adenocarcinoma gástrico difuso con células en anillo de sello estadio IV (metástasis	8490/6
train-set-to-publish/cantemist-norm/cc_onco835.ann	Adenocarcinoma gástrico difuso	8145/3
train-set-to-publish/cantemist-norm/cc_onco835.ann	lesiones en la cavidad oral	8000/6
train-set-to-publish/cantemist-norm/cc_onco835.ann	lesión en la cavidad oral	8000/6
train-set-to-publish/cantemist-norm/cc_onco41.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco41.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco41.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco41.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco41.ann	carcinoma ductal infiltrante G2	8500/32
train-set-to-publish/cantemist-norm/cc_onco41.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco969.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco969.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco969.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco969.ann	carcinoma de células claras, Führman I	8310/31
train-set-to-publish/cantemist-norm/cc_onco969.ann	carcinoma de células claras, Führman 3	8310/33
train-set-to-publish/cantemist-norm/cc_onco969.ann	tumor renal de células claras pT3a pN1 M1	8005/6
train-set-to-publish/cantemist-norm/cc_onco969.ann	progresión neoplásica tanto a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco591.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco591.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco591.ann	tumor vascular de bajo grado	8000/11
train-set-to-publish/cantemist-norm/cc_onco591.ann	angiosarcoma de bajo grado	9120/31
train-set-to-publish/cantemist-norm/cc_onco591.ann	hemangioma multicéntrico	9120/0/H
train-set-to-publish/cantemist-norm/cc_onco591.ann	Angiosarcoma óseo multicéntrico	9120/3/H
train-set-to-publish/cantemist-norm/cc_onco591.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	carcinoma de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco239.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco239.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco239.ann	CCP	8041/3
train-set-to-publish/cantemist-norm/cc_onco239.ann	CARCINOMA PULMONAR DE CÉLULA PEQUEÑA	8041/3
train-set-to-publish/cantemist-norm/cc_onco239.ann	neoplasia de pulmón en LSI T4 N2 M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	metastásica hepática de tumor	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	enfermedad secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	enfermedad secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco239.ann	metastásica hepática de tumor primario desconocido	8000/9
train-set-to-publish/cantemist-norm/cc_onco670.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco670.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco670.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco670.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco670.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco670.ann	tumor desmoplásico de células pequeñas y redondas	8806/3
train-set-to-publish/cantemist-norm/cc_onco670.ann	TDCPR	8806/3
train-set-to-publish/cantemist-norm/cc_onco670.ann	TDCPR intraabdominal estadio IV por afectación pleural	8806/6
train-set-to-publish/cantemist-norm/cc_onco670.ann	síndrome linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco105.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco105.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco105.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco105.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco105.ann	neoplasia de células germinales intratubulares	9064/2
train-set-to-publish/cantemist-norm/cc_onco105.ann	tumor testicular germinal regresado burned-out	9064/3/H
train-set-to-publish/cantemist-norm/cc_onco105.ann	Tumor testicular burned-out	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco105.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco105.ann	afectación visceral únicamente a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco376.ann	leucemia aguda	9801/3
train-set-to-publish/cantemist-norm/cc_onco376.ann	leucemia aguda	9801/3
train-set-to-publish/cantemist-norm/cc_onco376.ann	rabdomiosarcoma subtipo alveolar en estadio IV, con infiltración medular	8920/6
train-set-to-publish/cantemist-norm/cc_onco376.ann	neoplasia sólida con infiltración masiva de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco617.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco617.ann	Glioma difuso	9380/3/H
train-set-to-publish/cantemist-norm/cc_onco617.ann	glioma difuso	9380/3/H
train-set-to-publish/cantemist-norm/cc_onco17.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco17.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco17.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco17.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco17.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco17.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco17.ann	CDI de mama izquierda estadio IIIA Grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco556.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco556.ann	diseminación	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	enfermedad secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco556.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco556.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco556.ann	carcinoma urotelial no infiltrante	8120/3/H
train-set-to-publish/cantemist-norm/cc_onco556.ann	carcinoma no microcítico poco diferenciado de célula grande	8012/33
train-set-to-publish/cantemist-norm/cc_onco556.ann	adenocarcinoma poco diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco556.ann	carcinoma no microcítico poco diferenciado	8046/33
train-set-to-publish/cantemist-norm/cc_onco556.ann	Carcinoma poco diferenciado de célula grande	8012/33
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesiones a nivel pancreático	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesiones renal	8000/6
train-set-to-publish/cantemist-norm/cc_onco556.ann	lesiones focales hipervasculares hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco223.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco223.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco223.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco223.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco223.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco223.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco223.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco223.ann	Adenocarcinoma de 2,4 cm bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco15.ann	Hipernefroma	8312/3
train-set-to-publish/cantemist-norm/cc_onco15.ann	adenocarcinoma de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco15.ann	adenocarcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco15.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco15.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco15.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco15.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco15.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco15.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco15.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco15.ann	pT3NxMx	8000/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco636.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco636.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco636.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco636.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco636.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco636.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco636.ann	cT3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	carcinoma lobulillar	8520/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco696.ann	tumoral a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	metastásica por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	CLI	8520/3
train-set-to-publish/cantemist-norm/cc_onco696.ann	adenopatías en regiones supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	lesión orbitaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	Carcinoma lobulillar infiltrante estadio IV (por afectación orbitaria)	8520/6
train-set-to-publish/cantemist-norm/cc_onco696.ann	cáncer de origen desconocido	8000/9
train-set-to-publish/cantemist-norm/cc_onco666.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco666.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco666.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco666.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco666.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco666.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco666.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco666.ann	timoma	8580/3
train-set-to-publish/cantemist-norm/cc_onco666.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco666.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco666.ann	timoma tipo A	8581/3
train-set-to-publish/cantemist-norm/cc_onco666.ann	timoma tipo A	8580/3
train-set-to-publish/cantemist-norm/cc_onco666.ann	angiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco666.ann	angiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco666.ann	angiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco226.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco226.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco226.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco226.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco226.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco226.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	progresa a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	progresión iridiana	8000/6
train-set-to-publish/cantemist-norm/cc_onco226.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco226.ann	enfermedad pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	Metastasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco362.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco362.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco362.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco362.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco362.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco362.ann	carcinoma no queratinizante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco362.ann	Carcinoma nasofaríngeo estadio IV con metástasis	8010/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	carcinoma nasofaríngeo estadio IV con metástasis	8010/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	proceso medular proliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco362.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	LOEs hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	focos blasticos en columna	8000/6
train-set-to-publish/cantemist-norm/cc_onco362.ann	focos blasticos oseos	8000/6
train-set-to-publish/cantemist-norm/cc_onco860.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco860.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco860.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco860.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco860.ann	ADC pulmonar metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco860.ann	afectación nodular pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco946.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco946.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco946.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco946.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco946.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco946.ann	metástasis por adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	lesión en vulva	8000/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	lesión en labio mayor	8000/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	lesión vulvar	8000/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	lesión vulvar	8000/6
train-set-to-publish/cantemist-norm/cc_onco946.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco672.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	carcinoma de mama ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco672.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	Lesión lítica subcondral	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	lesión lítica subcondral	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	micronódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	nódulos pulmonares milimétricos bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	cT3N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco672.ann	foco óseo en cabeza femoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	Implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco547.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco547.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco547.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	Carcinoma pulmonar multicéntrico	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco547.ann	implante muscular	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	Carcinoma epidermoide de pulmón multicéntrico	8070/3/H
train-set-to-publish/cantemist-norm/cc_onco547.ann	implantes musculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco547.ann	neoplásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco129.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco129.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco129.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	neoplásicas	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco129.ann	afectación osteolítica	8000/6
train-set-to-publish/cantemist-norm/cc_onco129.ann	adenocarcinoma pobremente diferenciado con células en anillo de sello	8490/33
train-set-to-publish/cantemist-norm/cc_onco129.ann	sin un tumor primario conocido	8000/9
train-set-to-publish/cantemist-norm/cc_onco413.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco413.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco413.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco413.ann	carcinoma infiltrante grado histológico II	8010/32/H
train-set-to-publish/cantemist-norm/cc_onco413.ann	metástasis hepáticas por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco413.ann	Carcinoma infiltrante mama izquierda grado histológico 2	8010/32/H
train-set-to-publish/cantemist-norm/cc_onco413.ann	carcinoma ductal infiltrante de mama hormonosensible con afectación a distancia	8500/6
train-set-to-publish/cantemist-norm/cc_onco728.ann	carcinoma vesical urotelial en estadio pT2N1M1	8120/6
train-set-to-publish/cantemist-norm/cc_onco134.ann	carcinoma escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco134.ann	carcinoma urotelial	8120/3
train-set-to-publish/cantemist-norm/cc_onco134.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco134.ann	diferenciación escamosa	8070/3
train-set-to-publish/cantemist-norm/cc_onco134.ann	sarcomatoides	8033/3
train-set-to-publish/cantemist-norm/cc_onco134.ann	carcinoma sarcomatoide de vejiga pT3aN0M1	8033/6
train-set-to-publish/cantemist-norm/cc_onco134.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco134.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco134.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco687.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco687.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco687.ann	melanoma metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	metástasis de melanoma maligno	8720/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	sarcoma de partes blandas	8800/3
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumor de tipo desmoide	8821/1
train-set-to-publish/cantemist-norm/cc_onco687.ann	tumor maligno de la vaina nerviosa periférica, epitelioide, G-3 de la OMS	9540/33
train-set-to-publish/cantemist-norm/cc_onco687.ann	Tumor maligno de la vaina nerviosa periférica epitelioide grado 3	9540/33
train-set-to-publish/cantemist-norm/cc_onco687.ann	metástasis cutánea pobremente diferenciada	8000/63
train-set-to-publish/cantemist-norm/cc_onco687.ann	TMVNP	9540/3
train-set-to-publish/cantemist-norm/cc_onco687.ann	lesiones de la zona frontal	8000/6
train-set-to-publish/cantemist-norm/cc_onco687.ann	lesión frontal	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	encondroma	9220/0
train-set-to-publish/cantemist-norm/cc_onco133.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumoración de partes blandas de naturaleza mixta probablemente mesenquimal	8990/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumor mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	neoformación mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumor mesenquimal maligno	8800/3
train-set-to-publish/cantemist-norm/cc_onco133.ann	Tumor mesenquimal maligno	8800/3
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumor mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	tumor fusocelular	8032/1
train-set-to-publish/cantemist-norm/cc_onco133.ann	histiocitoma fibroso maligno	8830/3
train-set-to-publish/cantemist-norm/cc_onco133.ann	sarcoma pleomórfico de alto grado	8802/34
train-set-to-publish/cantemist-norm/cc_onco133.ann	sarcoma pleomórfico de alto grado	8802/34
train-set-to-publish/cantemist-norm/cc_onco133.ann	Nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco133.ann	siembra hematógena pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	Melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco682.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco682.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco682.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco682.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco682.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	nevus	8720/0
train-set-to-publish/cantemist-norm/cc_onco682.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco682.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco682.ann	carcinoma epidermoide in situ	8070/2
train-set-to-publish/cantemist-norm/cc_onco682.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco682.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco791.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco791.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco791.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco791.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco791.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco791.ann	miofibroblastoma	8825/0
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco967.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco967.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco967.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco967.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinoma lobulillar infiltrante tipo mixto (ductal y lobulillar)	8524/3
train-set-to-publish/cantemist-norm/cc_onco967.ann	carcinoma lobulillar infiltrante tipo mixto (ductal y lobulillar)	8524/3
train-set-to-publish/cantemist-norm/cc_onco967.ann	masas ováricas	8000/6
train-set-to-publish/cantemist-norm/cc_onco967.ann	masas ováricas	8000/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco577.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco577.ann	melanoma de células fusiformes desmoplásico	8745/3
train-set-to-publish/cantemist-norm/cc_onco577.ann	melanoma de células fusiformes	8772/3
train-set-to-publish/cantemist-norm/cc_onco577.ann	melanoma no desmoplásico	8720/3/H
train-set-to-publish/cantemist-norm/cc_onco577.ann	Melanoma con enfermedad metastásica	8720/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	M1c	8000/6
train-set-to-publish/cantemist-norm/cc_onco577.ann	lesiones cutáneas y pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco300.ann	N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco300.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco300.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco300.ann	metastasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco300.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco300.ann	melanoma maligno nodular	8721/3
train-set-to-publish/cantemist-norm/cc_onco300.ann	Melanoma cutáneo metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	Carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco984.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco984.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco984.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco984.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco984.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	T3cN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	ypT3cN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	adenocarcinoma seroso papilar de alto grado	8460/34
train-set-to-publish/cantemist-norm/cc_onco984.ann	Omental Cake	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	implantes omentales	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	afectación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	afectación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco984.ann	enfermedad a nivel pélvico y hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco158.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco158.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco158.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	suelta de globos	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	suelta de globos	8000/6
train-set-to-publish/cantemist-norm/cc_onco158.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco158.ann	neoplásica de estirpe epitelial	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco416.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	Osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco416.ann	hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco416.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco416.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco416.ann	Oligodendroglioma anaplásico de la WHO III	9451/3
train-set-to-publish/cantemist-norm/cc_onco416.ann	Carcinoma ductal infiltrante grado II	8500/32
train-set-to-publish/cantemist-norm/cc_onco416.ann	(LOE) hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	lesión única en región temporo-occipital	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	LOE cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco416.ann	oligodendroglioma anaplásico de la WHO III	9451/3
train-set-to-publish/cantemist-norm/cc_onco482.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco482.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco482.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco482.ann	tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco482.ann	tumor maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	infiltración de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	neuroblastoma	9500/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	neuroblastoma	9500/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	tumor desmoide	8821/1
train-set-to-publish/cantemist-norm/cc_onco307.ann	Ca	8000/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	Ca. Microcítico	8002/3
train-set-to-publish/cantemist-norm/cc_onco307.ann	metástasis óseas de neuroblastoma	9500/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	Neuroblastoma abdominal intervenido con recidiva metastásica	9500/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	afectación sacra	8000/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	afectación de médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	masa de partes blandas prevertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco307.ann	lesión sacra	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	Carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco216.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	adenocarcinoma (ADC) de pulmón, estadio IV (cT2bN2M1b)	8140/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco216.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco216.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	lesiones blásticas en cuerpos vertebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	progresión exclusiva a nivel meníngeo	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	nódulos en mama	8000/6
train-set-to-publish/cantemist-norm/cc_onco216.ann	CLM	8010/9
train-set-to-publish/cantemist-norm/cc_onco216.ann	CLM	8010/9
train-set-to-publish/cantemist-norm/cc_onco74.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibroma	9540/0
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibromatosis	9540/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibromatosis	9540/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibromas múltiples	9540/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	sarcoma pleomorfico de alto grado	8802/34
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumor maligno de la vaina nerviosa periférica	9540/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	TMVNP	9540/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibromas múltiples	9540/1
train-set-to-publish/cantemist-norm/cc_onco74.ann	neurofibromas	9540/0
train-set-to-publish/cantemist-norm/cc_onco74.ann	TMVNP	9540/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	TMVNP con diferenciación rabdomiosarcomatosa	9561/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	tumor de tritón	9561/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	metástasis única con tumor	8000/6
train-set-to-publish/cantemist-norm/cc_onco74.ann	TMVNP	9540/3
train-set-to-publish/cantemist-norm/cc_onco74.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco74.ann	extensión local y a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco914.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco914.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco914.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco914.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco914.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco914.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco914.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco914.ann	sarcoma retroperitoneal primario, con metástasis	8800/6
train-set-to-publish/cantemist-norm/cc_onco914.ann	neoplasia adrenal cortical de rasgos oncocíticos	8370/1
train-set-to-publish/cantemist-norm/cc_onco738.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco738.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco738.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco738.ann	neurofibroma	9540/0
train-set-to-publish/cantemist-norm/cc_onco738.ann	neurofibroma	9540/0
train-set-to-publish/cantemist-norm/cc_onco738.ann	neurofibromatosis	9540/1
train-set-to-publish/cantemist-norm/cc_onco738.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco738.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco738.ann	implantes subcapsulares hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco738.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinoma de ovario (seroso de alto grado)	8441/34
train-set-to-publish/cantemist-norm/cc_onco738.ann	neurinoma	9560/0
train-set-to-publish/cantemist-norm/cc_onco738.ann	carcinoma seroso residual de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco738.ann	YpT2aN0Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco738.ann	tumoración sólido-quística	8452/1
train-set-to-publish/cantemist-norm/cc_onco698.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	carcinoma neuroendocrino	8246/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	carcinoma neuroendocrino	8246/3
train-set-to-publish/cantemist-norm/cc_onco698.ann	tumor neuroendocrino de alto grado	8240/34
train-set-to-publish/cantemist-norm/cc_onco698.ann	carcinoma neuroendocrino de alto grado	8240/34
train-set-to-publish/cantemist-norm/cc_onco698.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	pT3pN2aM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco698.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco698.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco698.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco698.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco167.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco167.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco167.ann	Tumor óseo de células gigantes grado 3 de Sanerkin	9250/33
train-set-to-publish/cantemist-norm/cc_onco167.ann	Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo	9250/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	infiltración esofágica	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	tumor de células gigantes	8003/3
train-set-to-publish/cantemist-norm/cc_onco167.ann	masa mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	Masa medistínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco167.ann	enfermedad a nivel mediastínico	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco344.ann	sarcomatoide	8033/3
train-set-to-publish/cantemist-norm/cc_onco344.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco344.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco344.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco344.ann	OS de bajo grado	9180/31
train-set-to-publish/cantemist-norm/cc_onco344.ann	Osteosarcoma de bajo grado	9180/31
train-set-to-publish/cantemist-norm/cc_onco344.ann	osteosarcoma de bajo grado (de 4x3 cm) fusocelular, esclerosante, con formación de matriz ósea, bien diferenciado	9180/31/H
train-set-to-publish/cantemist-norm/cc_onco344.ann	tumor fibroso esclerosante de bajo grado	8815/11/H
train-set-to-publish/cantemist-norm/cc_onco344.ann	metastasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	sarcoma de alto grado	8800/34
train-set-to-publish/cantemist-norm/cc_onco344.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco344.ann	sarcoma pleomorfo indiferenciado de alto grado en estadio IV (metástasis	8802/64
train-set-to-publish/cantemist-norm/cc_onco344.ann	Sarcoma pleomorfo indiferenciado	8802/34
train-set-to-publish/cantemist-norm/cc_onco344.ann	neoformación típica sarcomatoide de partes blandas	8800/1
train-set-to-publish/cantemist-norm/cc_onco344.ann	Sarcoma pleomorfo de alto grado	8802/34
train-set-to-publish/cantemist-norm/cc_onco344.ann	Metastasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	Osteosarcoma bajo grado	9180/31
train-set-to-publish/cantemist-norm/cc_onco344.ann	sarcoma de alto grado en progresión a nivel pulmonar	8800/64
train-set-to-publish/cantemist-norm/cc_onco344.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	osteosarcoma de bajo grado (de 4x3 cm) fusocelular	8004/3
train-set-to-publish/cantemist-norm/cc_onco344.ann	celularidad tumoral	8001/1
train-set-to-publish/cantemist-norm/cc_onco344.ann	enfermedad pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	recaida pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	nodulo pulmunar	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	lesiones a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco344.ann	enfermedad a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco173.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco173.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco173.ann	meningioma	9530/0
train-set-to-publish/cantemist-norm/cc_onco173.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	T4cN3M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	lesiones líticas en columna dorsal	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	metástasis dural del carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	metástasis dural de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	lesión dural	8000/6
train-set-to-publish/cantemist-norm/cc_onco173.ann	lesión extraaxial occipital	8000/6
train-set-to-publish/cantemist-norm/cc_onco939.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco939.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco939.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco939.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco939.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco939.ann	osteosarcoma de células pequeñas de alto grado	9185/34
train-set-to-publish/cantemist-norm/cc_onco939.ann	Osteosarcoma de células pequeñas (de Hutter) estadio IV (afectación cerebral	9185/6
train-set-to-publish/cantemist-norm/cc_onco939.ann	suelta de globos	8000/6
train-set-to-publish/cantemist-norm/cc_onco939.ann	Nódulo leptomeníngeo	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	carcinoma de células renales	8312/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	carcinoma urotelial	8120/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	hipernefroma	8312/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	hipernefroma de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco863.ann	Carcinoma renal de células claras estadio IV (metástasis	8310/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	lesión lítica en escápula	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	lesión lítica de escápula	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	lesión de apófisis	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco863.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco219.ann	afectacion cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	hemangiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco219.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	Adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	8140/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	CNMP	8046/3
train-set-to-publish/cantemist-norm/cc_onco219.ann	Carcinoma no microcítico de pulmón (CNMP) estadio IV (afectación pulmonar bilateral	8046/6
train-set-to-publish/cantemist-norm/cc_onco219.ann	afectación pulmonar y ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco314.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco314.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco314.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco314.ann	tumor del seno endodermico	9071/3
train-set-to-publish/cantemist-norm/cc_onco314.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco314.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco314.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco314.ann	TCGNS (seno endodérmico)	9071/3
train-set-to-publish/cantemist-norm/cc_onco314.ann	pT1cN0cM1bS2	8000/6
train-set-to-publish/cantemist-norm/cc_onco314.ann	TCGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco314.ann	tumor germinal no seminomatoso	9065/3
train-set-to-publish/cantemist-norm/cc_onco314.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco314.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco744.ann	carcinoma de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco744.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco744.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco744.ann	carcinoma microcítico de pulmón, enfermedad extensa (hígado	8041/6
train-set-to-publish/cantemist-norm/cc_onco744.ann	cáncer de pulmón microcítico metastásico	8041/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco828.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco828.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco828.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco828.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco828.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	neoproliferativo diseminado	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	carcinoma renal de células claras con grado nuclear I de Führman	8310/31
train-set-to-publish/cantemist-norm/cc_onco828.ann	neoplasia renal estadio IV por afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	diseminación intracraneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco828.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco25.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco25.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco25.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco25.ann	afectación pulmonar, ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco25.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	adenopático supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco759.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco759.ann	lesión en región supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma de pulmón neuroendocrino de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma de pulmón neuroendocrino	8246/3
train-set-to-publish/cantemist-norm/cc_onco759.ann	carcinoma microcítico de pulmón, enfermedad extensa por afectación supraclavicular	8041/6
train-set-to-publish/cantemist-norm/cc_onco759.ann	lesión retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	hepatocarcinoma	8170/3
train-set-to-publish/cantemist-norm/cc_onco417.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	metástasis de colangiocarcinoma	8160/6
train-set-to-publish/cantemist-norm/cc_onco417.ann	metástasis pulmonares de colangiocarcinoma	8160/6
train-set-to-publish/cantemist-norm/cc_onco218.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco218.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco218.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco363.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco363.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco363.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco363.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco363.ann	cáncer no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco363.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco363.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco837.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco837.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	metástasis de carcinoma poco diferenciado de células pequeñas	8041/33
train-set-to-publish/cantemist-norm/cc_onco837.ann	Carcinoma microcítico de pulmón estadio IV por afectación suprarrenal	8041/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	carcinoma microcítico de pulmón estadio IV por afectación suprarrenal	8041/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	Adenopatías mediastínicas bilaterales y supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	Nódulo de 31 mm en la suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	implantes leptomeníngeos	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	lesión nodular a nivel del tallo hipofisario	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	lesión nodular en tallo hipofisario	8000/6
train-set-to-publish/cantemist-norm/cc_onco837.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco493.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco493.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco493.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco493.ann	cáncer no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco493.ann	enfermedad pulmonar y hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco493.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco493.ann	Adenocarcinoma de pulmón E-IVa (c T4N3M1a)	8140/6
train-set-to-publish/cantemist-norm/cc_onco278.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco278.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco278.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco278.ann	adenomatosa con displasia de alto grado	8140/04
train-set-to-publish/cantemist-norm/cc_onco278.ann	Adenocarcinoma de unión rectosigmoidea estenosante (con endoprótesis), moderadamente diferenciado con células en anillo de sello	8490/32
train-set-to-publish/cantemist-norm/cc_onco278.ann	metástásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco352.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco352.ann	TUMOR MIOFIBROBLASTICO INFLAMATORIO	8825/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	liposarcoma desdiferenciado	8858/3
train-set-to-publish/cantemist-norm/cc_onco352.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	tumor miofibroblástico inflamatorio	8825/1
train-set-to-publish/cantemist-norm/cc_onco352.ann	tumor estromal gastro-intestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco326.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco326.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco326.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco326.ann	colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco326.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco326.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco326.ann	cTxNxM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco326.ann	ypT3N0/M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	adenocarcinoma de tipo intestinal compatible con afectación metastásica	8144/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	recidiva paracardíaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco326.ann	progresión paracardíaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco14.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco14.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco14.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco14.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco14.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco762.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco762.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco762.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco762.ann	adenocarcinoma gástrico moderadamente diferenciado de tipo intestinal	8144/32
train-set-to-publish/cantemist-norm/cc_onco762.ann	infiltración hepática por adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	LOE hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	lesión a nivel de cúpula hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco762.ann	lesión hipermetabólica en cúpula hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco922.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco922.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco922.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	poliposis adenomatosa familiar	8220/0
train-set-to-publish/cantemist-norm/cc_onco922.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	fibromatosis mesentérica de tipo desmoide	8821/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	tumores desmoides	8821/1
train-set-to-publish/cantemist-norm/cc_onco922.ann	PAF	8220/0
train-set-to-publish/cantemist-norm/cc_onco922.ann	PAF	8220/0
train-set-to-publish/cantemist-norm/cc_onco922.ann	linfoma B difuso de células grandes, inmunofenotipo germinal	9680/3/H
train-set-to-publish/cantemist-norm/cc_onco922.ann	afectación a nivel abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	masas intraperitoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	masas a nivel abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco922.ann	Linfoma difuso de células grandes B (LCGB) tipo centrogerminal	9680/3/H
train-set-to-publish/cantemist-norm/cc_onco496.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco496.ann	metástasis de carcinoma microcítico	8041/6
train-set-to-publish/cantemist-norm/cc_onco496.ann	adenocarcinoma de pulmón estadio IV por metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco496.ann	lesión subpleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco255.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco255.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco255.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco255.ann	T2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco57.ann	carcinoma papilar	8050/3
train-set-to-publish/cantemist-norm/cc_onco57.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco57.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco57.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco57.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco57.ann	carcinoma papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco57.ann	Carcinoma papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco57.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco57.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco816.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco816.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco816.ann	adenopatías mediastínicas, hiliares, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	implantes mesentéricos	8000/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	metástasis de ADK	8140/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	ADK de pulmón en estadio IV (T2N3M1)	8140/6
train-set-to-publish/cantemist-norm/cc_onco816.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco318.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco318.ann	GIST con fenotipo epitelioide con metástasis	8936/6
train-set-to-publish/cantemist-norm/cc_onco318.ann	Tumor del estroma gastrointestina epitelioide, G1	8936/61
train-set-to-publish/cantemist-norm/cc_onco318.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco318.ann	GIST con metástasis	8936/6
train-set-to-publish/cantemist-norm/cc_onco318.ann	GIST con fenotipo epitelioide	8804/3
train-set-to-publish/cantemist-norm/cc_onco318.ann	Tumor del estroma gastrointestina epitelioide	8804/3
train-set-to-publish/cantemist-norm/cc_onco54.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco54.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco54.ann	diseminación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	adenocarcinoma de colon estadio IV (hepáticas)	8140/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	Adenocarcinoma de colon estadio IV (hepáticas	8140/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	Progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	recidiva hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	lesiones micronodulares pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco993.ann	lesiones lumbares	8000/6
train-set-to-publish/cantemist-norm/cc_onco506.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco506.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	Nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco379.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco379.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco379.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	metástasis de carcinoma ductal infiltrante	8500/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	Carcinoma ductal infiltrante de mama derecha estadio IV (metástasis	8500/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesión lítica en húmero	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesión lítica en tercio medio humeral	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	enfermedad a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	enfermedad cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones supra e infratentoriales	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	infiltración leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco379.ann	lesiones similares milimétricas en ilíaco	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	metástasis ósea con masa de partes blandas de Carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	Tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco364.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco364.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco364.ann	Carcinoma (ca.) renal de células claras, estadio pT1b G2	8310/32
train-set-to-publish/cantemist-norm/cc_onco364.ann	ca.	8010/3
train-set-to-publish/cantemist-norm/cc_onco364.ann	recaída a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	masa prevertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	lesión en L2	8000/6
train-set-to-publish/cantemist-norm/cc_onco364.ann	Recaída a distancia con ILE 5.9 años de Ca. renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco558.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	carcinoma ductal infiltrante grado histológico 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco558.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco558.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco558.ann	carcinoma ductal infiltrante bilateral luminal A estadio IV por enfermedad bilateral, ósea	8500/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco558.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco558.ann	nódulos espiculados pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco35.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco35.ann	carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco35.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco35.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco35.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco35.ann	lesiones líticas óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	masa ovárica	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	carcinoma metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	lesión en el párpado	8000/6
train-set-to-publish/cantemist-norm/cc_onco35.ann	enfermedad pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco120.ann	Metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco120.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco120.ann	mioma	8895/0
train-set-to-publish/cantemist-norm/cc_onco120.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco120.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco120.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco120.ann	pT3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco120.ann	implante secundario	8000/6
train-set-to-publish/cantemist-norm/cc_onco120.ann	metástasis de adenocarcinoma con diferención mucinosa	8480/6
train-set-to-publish/cantemist-norm/cc_onco120.ann	Carcinoma epitelial maligno indiferenciado con componente mucinoso	8070/34/H
train-set-to-publish/cantemist-norm/cc_onco120.ann	tumoración epitelial maligna indiferenciada con componente mucinoso	8070/34/H
train-set-to-publish/cantemist-norm/cc_onco120.ann	carcinoma epitelial maligno indiferenciado con componente mucinoso	8070/34/H
train-set-to-publish/cantemist-norm/cc_onco535.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco535.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco535.ann	adenocarcinoma Gleason 7	8140/32
train-set-to-publish/cantemist-norm/cc_onco535.ann	adenocarcinoma Gleason 7	8140/32
train-set-to-publish/cantemist-norm/cc_onco535.ann	T3bN0 con estudio de extensión negativo	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	adenocarcinoma Gleason 8	8140/33
train-set-to-publish/cantemist-norm/cc_onco535.ann	adenocarcinoma Gleason 8	8140/33
train-set-to-publish/cantemist-norm/cc_onco535.ann	cáncer prostático resistente a castración metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	CPRCm	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco535.ann	lesión invasiva en la base del hueso occipital	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	carcinoma de células cromófobas, grado 4 de Furhman	8270/34
train-set-to-publish/cantemist-norm/cc_onco211.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	recidiva retroperitoneal y suprarrenal de carcinoma cromófobo	8270/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	lesión suprarenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	nódulos retroperitoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco211.ann	nódulos peritonales	8000/6
train-set-to-publish/cantemist-norm/cc_onco573.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco573.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco573.ann	adenocarcinoma mal diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco573.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco585.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco585.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco585.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco585.ann	carcinoma epidermoide de pulmón cT4 N3 M1b	8070/6
train-set-to-publish/cantemist-norm/cc_onco585.ann	neoplásica	8000/3
train-set-to-publish/cantemist-norm/cc_onco585.ann	neoplásica	8000/3
train-set-to-publish/cantemist-norm/cc_onco998.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco998.ann	carcinoma urotelial de alto grado	8120/34
train-set-to-publish/cantemist-norm/cc_onco998.ann	carcinoma urotelial de vejiga de alto grado	8120/3
train-set-to-publish/cantemist-norm/cc_onco998.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco998.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco998.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco998.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco998.ann	nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco919.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco919.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC de próstata pT3b, Gleason 3 + 4	8140/32
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	diseminación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco919.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco919.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco919.ann	metástasis de ADC pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco947.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco947.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco947.ann	diseminación linfática única de un adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco947.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco947.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco947.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco947.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco947.ann	adenocarcinoma de colon con células en anillo de sello, grado histológico III	8490/33
train-set-to-publish/cantemist-norm/cc_onco947.ann	pT3pN2bM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	diseminación broncovascular y linfática	8000/6
train-set-to-publish/cantemist-norm/cc_onco947.ann	Progresión pulmonar de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco721.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	adenocarcinoma de pulmón T4 N2 M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	progresión mínima en pulmón y hueso	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	progresión pulmonar y ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco721.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco382.ann	carcinoma escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco382.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco382.ann	papiloma	8050/0
train-set-to-publish/cantemist-norm/cc_onco382.ann	lesión escamosa intraepitelial de alto grado	8077/2
train-set-to-publish/cantemist-norm/cc_onco382.ann	SHIL	8077/2
train-set-to-publish/cantemist-norm/cc_onco382.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco382.ann	progresión pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco662.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco662.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco662.ann	intratumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	sarcoma	8800/3
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	neoplasia maligna pleomórfica	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco662.ann	cT4cN0cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco662.ann	celularidad tumoral	8001/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	neoplasia de estirpe mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco662.ann	adenocarcinomas	8140/3
train-set-to-publish/cantemist-norm/cc_onco662.ann	diseminación sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco662.ann	progresión sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco662.ann	sarcoma (alto grado histológico)	8800/34
train-set-to-publish/cantemist-norm/cc_onco788.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco788.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	neoplasia de pulmón en estadio IV (T4N3M1b)	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	adenocarcinoma de pulmón estadio IV, con afectación hepática	8140/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	enfermedad a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco788.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco788.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco788.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco694.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco694.ann	adenocarcinoma pulmonar de célula no pequeña	8046/3
train-set-to-publish/cantemist-norm/cc_onco694.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	Metástasis única hepática de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	metastásica de la lesión por adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	Carcinoma de célula no pequeña	8046/3
train-set-to-publish/cantemist-norm/cc_onco694.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	enfermedad a otros niveles: hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	implante en colon	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	lesión focal hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco694.ann	lesiones esclerosas desde cuerpo vertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco778.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco778.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco778.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco778.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco778.ann	sarcoma sinovial monofásico	9040/3/H
train-set-to-publish/cantemist-norm/cc_onco778.ann	sarcoma sinovial	9040/3
train-set-to-publish/cantemist-norm/cc_onco778.ann	sarcoma sinovial monofásico	9040/3/H
train-set-to-publish/cantemist-norm/cc_onco778.ann	sarcoma sinovial de patrón fusocelular monofásico	9041/3
train-set-to-publish/cantemist-norm/cc_onco411.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco411.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco411.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco411.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco411.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco411.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco411.ann	neoplasia mucinosa papilar intraductal con displasia de alto grado	8453/2
train-set-to-publish/cantemist-norm/cc_onco411.ann	Adenocarcinoma de páncreas estadio IV, con infiltración del retroperitoneo	8140/6
train-set-to-publish/cantemist-norm/cc_onco411.ann	adenocarcinoma de páncreas metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco87.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	CDI, Grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco87.ann	pT1cN2aM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco87.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco973.ann	condrosarcoma	9220/3
train-set-to-publish/cantemist-norm/cc_onco973.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco973.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco973.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco973.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco973.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco973.ann	tumor de estirpe sarcomatoide de alto grado	8800/34
train-set-to-publish/cantemist-norm/cc_onco973.ann	condrosarcoma desdiferenciado de alto grado	9243/34
train-set-to-publish/cantemist-norm/cc_onco973.ann	recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco973.ann	condrosarcoma de alto grado	9220/34
train-set-to-publish/cantemist-norm/cc_onco973.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco973.ann	condrosarcoma de alto grado	9220/34
train-set-to-publish/cantemist-norm/cc_onco973.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco973.ann	progresión subcutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco973.ann	lesión en dedo índice	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco513.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco513.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco513.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco513.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco513.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco513.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco513.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco513.ann	cáncer de pulmón no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco513.ann	células neoplásicas de estirpe epitelial	8001/1/H
train-set-to-publish/cantemist-norm/cc_onco513.ann	M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	afectación tumoral costal	8000/6
train-set-to-publish/cantemist-norm/cc_onco513.ann	masa de pared costal	8000/6
train-set-to-publish/cantemist-norm/cc_onco409.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco409.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco409.ann	Adenocarcinoma de pulmón cT1NxM1a	8140/6
train-set-to-publish/cantemist-norm/cc_onco409.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco409.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco409.ann	enfermedad a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco409.ann	enfermedad radiológica (pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco980.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco980.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco980.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco491.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco491.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco491.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco491.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco491.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco491.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco491.ann	ADC tubular infiltrante	8211/3/H
train-set-to-publish/cantemist-norm/cc_onco491.ann	adenoma tubulovelloso	8263/3
train-set-to-publish/cantemist-norm/cc_onco491.ann	neoformativa	8000/3
train-set-to-publish/cantemist-norm/cc_onco491.ann	ADC tubular infiltrante moderadamente diferenciado	8211/32/H
train-set-to-publish/cantemist-norm/cc_onco491.ann	ADC de colon derecho, G2, estadio IV (hepática	8140/6
train-set-to-publish/cantemist-norm/cc_onco491.ann	lesión dudosa en el lóbulo hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco491.ann	nódulos subcentimétricos en todos los lóbulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco187.ann	Rabdomiosarcoma pleomórfico	8901/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco187.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco187.ann	rabdomiosarcoma pleomórfico	8901/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	rabdomiosarcoma pleomórfico	8901/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	sarcoma pleomórfico	8802/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	sarcoma pleomórfico	8802/3
train-set-to-publish/cantemist-norm/cc_onco187.ann	rabdomiosarcomas	8900/3
train-set-to-publish/cantemist-norm/cc_onco387.ann	enfermedad linfoproliferativa	9970/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco387.ann	linfoma difuso de alto grado	9591/34
train-set-to-publish/cantemist-norm/cc_onco387.ann	Linfoma Difuso de Célula Grande B	9680/3
train-set-to-publish/cantemist-norm/cc_onco387.ann	LINFOMA HODGKIN PREDOMINIO LINFOCÍTICO	9651/3
train-set-to-publish/cantemist-norm/cc_onco387.ann	enfermedad de Hodgkin predominio linfocítico	9651/3
train-set-to-publish/cantemist-norm/cc_onco517.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco517.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco517.ann	melanoma cutáneo maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco517.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco517.ann	lesiones líticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco517.ann	recidiva de melanoma maligno	8720/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	carcinoma renal de celulas claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco222.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco222.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco222.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	Carcinoma renal de células claras grado 3 de Fuhrman	8310/33
train-set-to-publish/cantemist-norm/cc_onco222.ann	macroadenoma hipofisario	8272/0
train-set-to-publish/cantemist-norm/cc_onco222.ann	macroadenoma hipofisario	8272/0
train-set-to-publish/cantemist-norm/cc_onco222.ann	macroadenoma hipofisario	8272/0
train-set-to-publish/cantemist-norm/cc_onco222.ann	Metástasis cerebral de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	realces leptomeníngeos	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco222.ann	masa adrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco820.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco820.ann	carcinoma mixto	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco820.ann	endometrioide bien diferenciado	8380/31
train-set-to-publish/cantemist-norm/cc_onco820.ann	tumor de células claras	8005/3
train-set-to-publish/cantemist-norm/cc_onco820.ann	diseminación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco820.ann	progresión tumoral a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco799.ann	carcinoma de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco799.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco799.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco799.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco799.ann	focos osteoblásticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco799.ann	carcinoma microcítico estadio IV (enfermedad extendida)	8041/6
train-set-to-publish/cantemist-norm/cc_onco288.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco288.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco288.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco288.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco288.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco288.ann	LOEs hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco288.ann	lóbulo hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco288.ann	melanoma mucoso nasal y progresión masiva metastásica	8746/6
train-set-to-publish/cantemist-norm/cc_onco288.ann	melanoma mucoso	8746/3
train-set-to-publish/cantemist-norm/cc_onco288.ann	melanoma mucoso nasal y progresión masiva metastásica	8746/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco720.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco720.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco720.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco720.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco720.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco720.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco720.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco720.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco720.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco720.ann	pT2N2cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	Adenocarcinoma de próstata Gleason 6	8140/31
train-set-to-publish/cantemist-norm/cc_onco720.ann	cT1cN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco720.ann	adenocarcinoma de tipo ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco720.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco769.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	epitelioma basocelular	8090/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	epitelioma basocelular	8090/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	fibroadenoma	9010/0
train-set-to-publish/cantemist-norm/cc_onco769.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco769.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco769.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco769.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco769.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco769.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco769.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco769.ann	adenocarcinoma colorrectal bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco769.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	pT3N1aM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco769.ann	carcinoma con diferenciación neuroendocrina	8574/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	diferenciación escamosa	8070/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	neuroendocrina	8574/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	diferenciación neuroendocrina del epitelioma basocelular	8574/3
train-set-to-publish/cantemist-norm/cc_onco769.ann	carcinoma con morfología basaloide	8090/3
train-set-to-publish/cantemist-norm/cc_onco741.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco741.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco741.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco741.ann	Ca papilar infiltrante	8503/3
train-set-to-publish/cantemist-norm/cc_onco741.ann	T2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	nódulo de la suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	metástasis de ADC	8140/6
train-set-to-publish/cantemist-norm/cc_onco741.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco1000.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco1000.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco1000.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco1000.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco1000.ann	linfoma difuso de células grandes B	9680/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	LDCGB	9680/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	LDCGB	9680/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	LDCGB	9680/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	LDCGB	9680/3
train-set-to-publish/cantemist-norm/cc_onco1000.ann	linfoma de células grandes B difuso subtipo ABC	9680/3/H
train-set-to-publish/cantemist-norm/cc_onco1000.ann	lesión de pared torácica	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	glucagonoma estadio IV (T3N0M1	8152/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumor neuroendocrino con un grado de diferenciación 2	8249/3
train-set-to-publish/cantemist-norm/cc_onco646.ann	tumor neuroendocrino de 4,2 cm, con un grado 2 de diferenciación	8249/3
train-set-to-publish/cantemist-norm/cc_onco646.ann	glucagonoma	8152/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	metastásica tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	metástasis de carcinoma neuroendocrino	8246/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	glucagonoma	8152/1
train-set-to-publish/cantemist-norm/cc_onco646.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco646.ann	nódulos a nivel de tejido celular subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco726.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco726.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco726.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco726.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco726.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco726.ann	malignas	8000/3
train-set-to-publish/cantemist-norm/cc_onco726.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco726.ann	lesiones pulmonares y en glándulas suprarrenales	8000/6
train-set-to-publish/cantemist-norm/cc_onco726.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco103.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco103.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco103.ann	carcinoma urotelial papilar de bajo grado	8120/31
train-set-to-publish/cantemist-norm/cc_onco103.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	mesotelioma epitelial	9052/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	carcinoma neuroendocrino de célula grande	8013/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	carcinoma neuroendocrino de células grandes metastásico	8013/6
train-set-to-publish/cantemist-norm/cc_onco103.ann	mesotelioma pleural maligno	9050/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco103.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco103.ann	lesiones pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco103.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	tumoral	8000/3
train-set-to-publish/cantemist-norm/cc_onco103.ann	progresión a nivel pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	CPT	8260/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	Tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco174.ann	carcinoma ductal infiltrante (CDI) grado 1	8500/31
train-set-to-publish/cantemist-norm/cc_onco174.ann	carcinoma intraductal (CDIS) 8 mm de bajo grado	8500/21
train-set-to-publish/cantemist-norm/cc_onco174.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco174.ann	carcinoma papilar invasivo	8050/3/H
train-set-to-publish/cantemist-norm/cc_onco174.ann	CDIS	8500/2
train-set-to-publish/cantemist-norm/cc_onco174.ann	adenopatia (ADP) supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	metástasis (M1) de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	ganglios supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	cT0N3M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	afectación retropectoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	carcinoma papilar tiroidal	8260/3
train-set-to-publish/cantemist-norm/cc_onco174.ann	M1 ganglionar por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	metaplasia de células de Hürthle	8290/0
train-set-to-publish/cantemist-norm/cc_onco174.ann	ADP supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	ADP SPCL	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	Nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	Nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco174.ann	ADP SCLD	8000/6
train-set-to-publish/cantemist-norm/cc_onco578.ann	carcinoma neuroendocrino de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco578.ann	carcinoma neuroendocrino indiferenciado	8246/34
train-set-to-publish/cantemist-norm/cc_onco578.ann	adenocarcinoma de próstata Gleason 5 + 4	8140/34
train-set-to-publish/cantemist-norm/cc_onco351.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco351.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco351.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco351.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco351.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco351.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco351.ann	lesiones a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	osteosarcoma osteoide osteoblástico grado IV	9180/34
train-set-to-publish/cantemist-norm/cc_onco351.ann	pT1pN0cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	Osteosarcoma osteoide osteoblástico con recaída local y pulmonar	9180/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco351.ann	metástasis de osteosarcoma	9180/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco351.ann	Lesión ocupante de espacio cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco817.ann	Neoplasia sólido-quística	8452/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco817.ann	neoplasia primaria cerebral de estirpe glial	9380/3
train-set-to-publish/cantemist-norm/cc_onco817.ann	ependimoma variante de células claras grado II según la Organización Mundial de la Salud	9391/32
train-set-to-publish/cantemist-norm/cc_onco71.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco71.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco71.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco71.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco71.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco71.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco71.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco71.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco71.ann	cáncer de mama metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	neoplasia primaria renal sin descartar metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	metástasis de carcinoma ductal	8500/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	carcinoma de células cromófobas	8270/3
train-set-to-publish/cantemist-norm/cc_onco71.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	lesión supra-acetabular cadera	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	lesión costal izquierda (partes blandas)	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	masa localizada en polo superior del riñón	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	lesiones blásticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco71.ann	lesión lítica L4-L5	8000/6
train-set-to-publish/cantemist-norm/cc_onco541.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco541.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco541.ann	Linfoma cutáneo primario T	9709/3
train-set-to-publish/cantemist-norm/cc_onco541.ann	micosis fungoide	9700/3
train-set-to-publish/cantemist-norm/cc_onco541.ann	T1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco541.ann	linfoma cutáneo primario T tipo micosis fungoide con nódulos de transformación a células grandes CD30 +	9718/3
train-set-to-publish/cantemist-norm/cc_onco541.ann	micosis fungoide	9700/3
train-set-to-publish/cantemist-norm/cc_onco541.ann	linfoma T de células grandes	9718/3
train-set-to-publish/cantemist-norm/cc_onco541.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco330.ann	Adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco330.ann	Adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco330.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco330.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco330.ann	Metástasis de carcinoma ductal	8500/6
train-set-to-publish/cantemist-norm/cc_onco330.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco330.ann	cáncer inflamatorio	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco330.ann	tumor neurogénico	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco330.ann	tumor neurogénico	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco330.ann	Cáncer inflamatorio	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco587.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco587.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco587.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco587.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco587.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco32.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco32.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco32.ann	adenocarcinoma de recto-sigma KRAS nativo, con metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco32.ann	adenocarcinoma de sigma ypT3 N1b M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco32.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco826.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco826.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco826.ann	Recaída múltiple a nivel de tracto digestivo (esofágica y rectal) de carcinoma lobulillar	8520/6
train-set-to-publish/cantemist-norm/cc_onco826.ann	metástasis de carcinoma lobulillar	8520/6
train-set-to-publish/cantemist-norm/cc_onco826.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco826.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco826.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco826.ann	adenopatías axilares o supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco826.ann	afectación visceral	8000/6
train-set-to-publish/cantemist-norm/cc_onco826.ann	progresión esofágica	8000/6
train-set-to-publish/cantemist-norm/cc_onco961.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco961.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco961.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco961.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco961.ann	Tumor rabdoide-teratoide atípico grado IV de la Organización Mundial de la Salud (OMS)	9508/34
train-set-to-publish/cantemist-norm/cc_onco271.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco271.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco271.ann	tumor de células fusiformes	8004/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco271.ann	celularidad maligna	8001/3
train-set-to-publish/cantemist-norm/cc_onco271.ann	implantes peritoneales múltiples	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco704.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco704.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco704.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco704.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco704.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco704.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco704.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco20.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco20.ann	hepatocarcinoma	8170/3
train-set-to-publish/cantemist-norm/cc_onco20.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco20.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco20.ann	Lesión escamosa intraepitelial (SIL) de bajo grado	8077/0
train-set-to-publish/cantemist-norm/cc_onco20.ann	CIN I	8077/0
train-set-to-publish/cantemist-norm/cc_onco20.ann	SIL	8077/0
train-set-to-publish/cantemist-norm/cc_onco377.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco377.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco377.ann	adenocarcinoma mucosecretor	8481/3
train-set-to-publish/cantemist-norm/cc_onco377.ann	Adenocarcinoma pancreático de bajo grado	8140/31
train-set-to-publish/cantemist-norm/cc_onco377.ann	pT2pN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco377.ann	Adenocarcinoma de pancreas de bajo grado	8140/31
train-set-to-publish/cantemist-norm/cc_onco377.ann	pT2pN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco467.ann	Melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco467.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco467.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco467.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco467.ann	recidiva intestinal de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco893.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco893.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco893.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco893.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco893.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco893.ann	Angiosarcoma cutáneo convencional de 4,5 cm, grado histológico 3 (según sistema de gradación de la FNCLCC)	9120/33
train-set-to-publish/cantemist-norm/cc_onco893.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco893.ann	metástasis de angiosarcoma	9120/6
train-set-to-publish/cantemist-norm/cc_onco893.ann	nódulo subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco39.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco39.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco39.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco39.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco39.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco39.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco39.ann	tumoración previsiblemente benigna	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco457.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco457.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco457.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco457.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco457.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco457.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco457.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	neoplásicas	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma gástrico tipo intestinal, grado 3	8144/33
train-set-to-publish/cantemist-norm/cc_onco457.ann	adenocarcinoma gástrico pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco457.ann	masa biliopancreática	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	tumor neuroendocrino (TNE) G1	8240/31
train-set-to-publish/cantemist-norm/cc_onco192.ann	Metástasis retroocular de tumor neuroendocrino	8240/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE grado I	8240/31
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE G1	8240/31
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	tumor de características neuroendocrinas	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco192.ann	nódulo de 1,2 cm de localización retroorbitaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco192.ann	nódulo de localización posterior al globo ocular	8000/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco49.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco49.ann	carcinoma lobulillar	8520/3
train-set-to-publish/cantemist-norm/cc_onco49.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	carcinoma lobulillar infiltrante grado II de Nottingham	8520/32
train-set-to-publish/cantemist-norm/cc_onco49.ann	Carcinoma lobulillar	8520/3
train-set-to-publish/cantemist-norm/cc_onco49.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco49.ann	metástasis de carcinoma lobulillar	8520/6
train-set-to-publish/cantemist-norm/cc_onco49.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco850.ann	cT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco850.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco850.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco850.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco850.ann	cáncer de mama ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco850.ann	SCHMO	8000/3
train-set-to-publish/cantemist-norm/cc_onco850.ann	SCHMO	8000/3
train-set-to-publish/cantemist-norm/cc_onco157.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco157.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	pT3aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	metástasis subcutánea de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	melanoma diagnosticado en el año 1992, metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	melanoma metastásico	8720/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco157.ann	nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco157.ann	nódulo peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco233.ann	Carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco233.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco233.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco233.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco233.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco233.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco233.ann	metástasis de carcinoma seroso de alto grado	8441/64
train-set-to-publish/cantemist-norm/cc_onco233.ann	implantes en omento	8000/6
train-set-to-publish/cantemist-norm/cc_onco317.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco317.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco317.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco317.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco317.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco317.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco317.ann	neoformación pulmonar maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco317.ann	T4N1MO	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco974.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	adenocarcinoma Gleason 8	8140/33
train-set-to-publish/cantemist-norm/cc_onco974.ann	adenocarcinoma de próstata Gleason 8	8140/33
train-set-to-publish/cantemist-norm/cc_onco974.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	infiltración de médula ósea por carcinoma de próstata con diferenciación neuroendocrina	8574/6
train-set-to-publish/cantemist-norm/cc_onco974.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco196.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco196.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco196.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco196.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco196.ann	tumor maligno de la vaina nerviosa	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco196.ann	Tumor maligno de la vaina nerviosa	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco327.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco327.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco327.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco327.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	Adenocarcinoma acinar bien diferenciado	8550/31
train-set-to-publish/cantemist-norm/cc_onco327.ann	Cistoadenocarcinoma de ovario mucinosos bien diferenciado	8470/31
train-set-to-publish/cantemist-norm/cc_onco327.ann	(LOEs) en riñón	8000/6
train-set-to-publish/cantemist-norm/cc_onco327.ann	LOEs renales	8000/6
train-set-to-publish/cantemist-norm/cc_onco327.ann	carcinoma multifocal	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasias pancreáticas exocrinas	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco327.ann	tumor primario sería de estirpe exocrina	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasia de páncreas de orígen mixto	8154/3
train-set-to-publish/cantemist-norm/cc_onco327.ann	Adenocarcinoma Acinar Endocrino	8154/3
train-set-to-publish/cantemist-norm/cc_onco327.ann	lesiones renales	8000/6
train-set-to-publish/cantemist-norm/cc_onco327.ann	neoplasias de estirpe endocrinas	8150/1
train-set-to-publish/cantemist-norm/cc_onco327.ann	Adenocarcinoma Acinar Endocrino	8154/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco109.ann	tumoral a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	CM	8000/3
train-set-to-publish/cantemist-norm/cc_onco109.ann	pT2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	adenopatía (ADP) en la región supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	ADP supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	metástasis de CDI	8500/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	lesión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	lesión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	metástasis de CDI	8500/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	oligometastásica de CDI	8500/6
train-set-to-publish/cantemist-norm/cc_onco109.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco425.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco425.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco425.ann	timoma tipo B1	8583/1
train-set-to-publish/cantemist-norm/cc_onco425.ann	timoma tipo B2 invasor	8584/3
train-set-to-publish/cantemist-norm/cc_onco425.ann	implantes intraabdominales	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco425.ann	lesiones pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	progresión pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	progresión a nivel pleuropulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	enfermedad locorregional y pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco425.ann	enfermedad a nivel pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco766.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco766.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco766.ann	neoplásicas	8000/1
train-set-to-publish/cantemist-norm/cc_onco766.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco559.ann	cáncer de colon derecho metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	adenocarcinoma de sigma con metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	adenocarcinoma de tipo colorrectal bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco559.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	progresión tumoral a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco559.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco988.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco988.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco988.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco988.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco988.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco988.ann	fibromatosis	8000/0
train-set-to-publish/cantemist-norm/cc_onco988.ann	Fibromatosis	8000/0
train-set-to-publish/cantemist-norm/cc_onco634.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco634.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco634.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	implante peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	metástasis de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco634.ann	tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco634.ann	carcinoma de células claras de 1,4cm pT1pN0M0, grado IV de Fuhrman	8310/34
train-set-to-publish/cantemist-norm/cc_onco634.ann	pT1pN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	masa abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	recidiva a nivel perihepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	carcinoma renal de células claras metastásico	8310/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	CCRm	8310/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	masa en la pared abdominal	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco634.ann	nódulos subcutáneos	8000/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco675.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco675.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco675.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco675.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco675.ann	osteosarcoma esclerosante	9180/3/H
train-set-to-publish/cantemist-norm/cc_onco675.ann	tumoral a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	Osteosarcoma metastásico	9180/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	neoplasia mesenquimal	8800/1
train-set-to-publish/cantemist-norm/cc_onco675.ann	metástasis de osteosarcoma osteoblástico	9180/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	lesiones en pulmón	8000/6
train-set-to-publish/cantemist-norm/cc_onco675.ann	masa pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco783.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco783.ann	neoplasia tímica	8580/1
train-set-to-publish/cantemist-norm/cc_onco783.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco783.ann	neoplásica metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco783.ann	neoplásico con afectación metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	Metástasis de Adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	metastasica	8000/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	metástasis de Adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	neoplasico	8000/1
train-set-to-publish/cantemist-norm/cc_onco302.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco302.ann	pT1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco302.ann	adenocarcinoma de células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco302.ann	adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	8140/6
train-set-to-publish/cantemist-norm/cc_onco302.ann	metástasis de carcinoma neuroendocrino de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco396.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco396.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco396.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco396.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco396.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco396.ann	adenocarcinoma de pulmón T4N3M1c	8140/6
train-set-to-publish/cantemist-norm/cc_onco64.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco64.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco64.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco64.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco64.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco64.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco64.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco64.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco64.ann	carcinoma ductal infiltrante con patrón sólido predominantemente grado histológico 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco64.ann	carcinoma ductal infiltrante con patrón sólido	8230/3
train-set-to-publish/cantemist-norm/cc_onco64.ann	Carcinoma ductal infiltrante de mama izquierda de 2 cm, grado 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco64.ann	cT2cN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	NET metastásico	8240/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	tumor de bajo grado	8000/11
train-set-to-publish/cantemist-norm/cc_onco583.ann	tumor neuroendocrino de intestino delgado metastásico	8240/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco583.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	Carcinoma indiferenciado de célula grande	8012/34
train-set-to-publish/cantemist-norm/cc_onco7.ann	adenocarcinoma estadio IV B (cTx, cN3, cM1b	8140/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	CPCNP	8041/3
train-set-to-publish/cantemist-norm/cc_onco7.ann	afectación pulmonar, adenopática mediastínica, hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco7.ann	lesiones osteoblásticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco370.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco370.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco370.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco370.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco370.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco370.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco370.ann	neo-formación	8000/1
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco370.ann	adenocarcinoma ductal bien diferenciado	8500/31
train-set-to-publish/cantemist-norm/cc_onco370.ann	implantes, 2 de ellos en intestino delgado	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	implante subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	metástasis por adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco370.ann	enfermedad (PE) pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	angiomiolipoma	8860/0
train-set-to-publish/cantemist-norm/cc_onco269.ann	implante tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco269.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco269.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco269.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco269.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco269.ann	Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural	8441/63
train-set-to-publish/cantemist-norm/cc_onco269.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco269.ann	Adenocarcinoma seroso G3	8441/33
train-set-to-publish/cantemist-norm/cc_onco269.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco269.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco269.ann	masa residual retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	masa mesentérica	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	afectación meníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco269.ann	lesiones intraparenquimatosas	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco34.ann	teratoma quístico	9080/0
train-set-to-publish/cantemist-norm/cc_onco34.ann	teratoma con degeneración maligna, con metástasis	9080/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	teratoma maligno mediastínico estadio IV (metástasis	9080/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco34.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco459.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco459.ann	neoplasia renal izquierda primaria con metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	carcinoma renal de células claras grado de Fuhrman I	8310/31
train-set-to-publish/cantemist-norm/cc_onco459.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	carcinoma renal de células claras bifocal grado nuclear II (Fuhrman)	8310/32
train-set-to-publish/cantemist-norm/cc_onco459.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco459.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco345.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco345.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco345.ann	neoplasia de alto grado de malignidad	8000/34
train-set-to-publish/cantemist-norm/cc_onco345.ann	tumor astrocitario de alto grado	9401/3
train-set-to-publish/cantemist-norm/cc_onco345.ann	Ca microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco345.ann	Carcinoma microcítico de pulmón hiliar derecho, con metástasis	8041/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	microcítico de pulmón mestastásico	8041/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	(LOE ) frontal	8000/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	LOE cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco345.ann	recidiva tumoral a nivel craneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco758.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco758.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco758.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco758.ann	neoplasia pulmonar metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	afectación suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	adenopático supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	afectación de glándula suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	neoplasia pulmonar metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco758.ann	linfoma folicular, grado 3A	9698/3
train-set-to-publish/cantemist-norm/cc_onco758.ann	malignas	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	linfoma folicular grado 3A estadio IVA (metástasis	9698/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	consolidaciones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco758.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco808.ann	hemangiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco808.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco808.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco808.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco808.ann	tumor Phyllodes	9020/1
train-set-to-publish/cantemist-norm/cc_onco808.ann	carcinoma infiltrante con grado histológico III	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco808.ann	(LOE) en el hígado	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	LOE hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco808.ann	metástasis hepática de carcinoma neuroendocrino bien diferenciado	8246/61
train-set-to-publish/cantemist-norm/cc_onco808.ann	tumores neuroendocrinos	8240/3
train-set-to-publish/cantemist-norm/cc_onco808.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma de uraco estadio IV por recaída peritoneal	8140/6
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	afectación secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco284.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco284.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco284.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco284.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco284.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma de patrón mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	carcinoma urotelial de bajo grado	8120/31
train-set-to-publish/cantemist-norm/cc_onco284.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco284.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco284.ann	adenocarcinoma de patrón mucinoso, con presencia de células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	"adenocarcinoma mucinoso (coloide) con componente de células ""en anillo de sello"""	8490/3
train-set-to-publish/cantemist-norm/cc_onco284.ann	afectación peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco528.ann	carcinoma escamoso	8070/3
train-set-to-publish/cantemist-norm/cc_onco528.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco528.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco528.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco528.ann	diseminación neoplásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco528.ann	carcinoma escamoso no queratinizante, mal diferenciado	8072/33
train-set-to-publish/cantemist-norm/cc_onco528.ann	cT3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco528.ann	carcinoma escamoso no queratinizante, mal diferenciado	8072/33
train-set-to-publish/cantemist-norm/cc_onco528.ann	carcinoma escamoso in situ	8070/2
train-set-to-publish/cantemist-norm/cc_onco528.ann	pT4N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco528.ann	neoproliferativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco714.ann	Leucemia aguda mieloblástica	9872/3
train-set-to-publish/cantemist-norm/cc_onco714.ann	condrosarcoma	9220/3
train-set-to-publish/cantemist-norm/cc_onco714.ann	condrosarcoma	9220/3
train-set-to-publish/cantemist-norm/cc_onco714.ann	sarcomas	8800/3
train-set-to-publish/cantemist-norm/cc_onco714.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco714.ann	Leucemia aguda mieloblástica (fenotipo sugestivo de M3)	9866/3
train-set-to-publish/cantemist-norm/cc_onco714.ann	leucemia aguda mieloblástica M3	9866/3
train-set-to-publish/cantemist-norm/cc_onco516.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco516.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco516.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco516.ann	carcinoma indiferenciado de célula pequeña infiltrante	8041/34/H
train-set-to-publish/cantemist-norm/cc_onco516.ann	carcinoma neuroendocrino de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco516.ann	carcinoma neuroendocrino de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco516.ann	Carcinoma neuroendocrino de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco27.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	adenocarcinoma seroso papilar	8460/3
train-set-to-publish/cantemist-norm/cc_onco27.ann	Carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco27.ann	tumor mülleriano mixto maligno	8950/3
train-set-to-publish/cantemist-norm/cc_onco27.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco27.ann	sarcoma indiferenciado de alto grado	8805/34
train-set-to-publish/cantemist-norm/cc_onco27.ann	Carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco27.ann	carcinoma intraepitelial	8010/2
train-set-to-publish/cantemist-norm/cc_onco27.ann	Carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco27.ann	carcinoma intraepitelial	8010/2
train-set-to-publish/cantemist-norm/cc_onco27.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco27.ann	adenocarcinoma seroso de alto grado, siendo un estadio UICC pT3c pN1 pM1	8441/64
train-set-to-publish/cantemist-norm/cc_onco27.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco27.ann	implantes miliares a nivel del peritoneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco27.ann	implante de epiplón	8000/6
train-set-to-publish/cantemist-norm/cc_onco27.ann	implantes en el peritoneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco872.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco872.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco872.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco872.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco872.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco872.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco872.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco872.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco872.ann	tumor indiferenciado, con grado nuclear (G) alto (G3)	8000/34
train-set-to-publish/cantemist-norm/cc_onco707.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco707.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco707.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco707.ann	adenocarcinoma infiltrante	8140/3/H
train-set-to-publish/cantemist-norm/cc_onco707.ann	adenocarcinoma infiltrante bien diferenciado	8140/31/H
train-set-to-publish/cantemist-norm/cc_onco707.ann	adenoma maligno	8140/3
train-set-to-publish/cantemist-norm/cc_onco707.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco707.ann	maligna de alto grado	8000/34
train-set-to-publish/cantemist-norm/cc_onco707.ann	infiltración ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco707.ann	infiltración ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco707.ann	lesión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco328.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco328.ann	mioma	8895/0
train-set-to-publish/cantemist-norm/cc_onco328.ann	pT3N2b(+9/23)M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco794.ann	T1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco794.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco794.ann	carcinoma de células renales tipo células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco794.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco794.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco794.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco794.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco794.ann	carcinoma de células renales tipo células claras, estadio patológico pT1b, grado nuclear Fuhrman III/IV	8312/34
train-set-to-publish/cantemist-norm/cc_onco794.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco794.ann	enfermedad radiológica pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	carcinoma renal de células claras con infiltración capsular, grado 2 de Fuhrman	8310/32
train-set-to-publish/cantemist-norm/cc_onco971.ann	neoplasia renal metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	cM1	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco971.ann	progresión local y pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco488.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco488.ann	carcinoma de las células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco488.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco488.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	metástasis por carcinoma neuroendocrino de células pequeñas	8041/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	carcinoma de las células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco488.ann	Carcinoma de células de Merkel estadio IV por implante rectovaginal	8247/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco488.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco50.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco50.ann	Tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco50.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco50.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco50.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco50.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco50.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco50.ann	carcinoma ductal infiltrante (CDI) grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco50.ann	carcinoma ductal infiltrante grado 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco50.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco50.ann	Angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	fibrosarcoma	8810/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	histiocitoma fibroso maligno	8830/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco286.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco286.ann	mieloma	9732/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	osteosarcoma	9180/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco286.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco286.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco286.ann	Linfoma de Hodgkin difuso centroblástico	9680/3
train-set-to-publish/cantemist-norm/cc_onco286.ann	tumoración fibroblástica	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco286.ann	pT1-2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco286.ann	pT1-2N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco286.ann	neoproliferativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	T2N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	Carcinoma de pulmón no microcítico (CPNM) de tipo epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	CPNM	8046/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	Carcinoma de pulmón no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplasia mucinosa	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplasia sólido-quística	8452/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	neoplasia sólido-quística	8452/1
train-set-to-publish/cantemist-norm/cc_onco923.ann	metástasis de carcinoma escamoso moderadamente diferenciado	8070/62
train-set-to-publish/cantemist-norm/cc_onco923.ann	masas nodulares sólidas de situación suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	masas suprarrenales	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	CA epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	CA epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco923.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	masa de la suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	lesión sólida en suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	lesión hipodensa en cuerpo de páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	MTS de CA epidermoide	8070/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	masa en la cola del páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco923.ann	masa pancreática	8000/6
train-set-to-publish/cantemist-norm/cc_onco5.ann	T1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco5.ann	Tumor Miofibroblástico inflamatorio	8825/1
train-set-to-publish/cantemist-norm/cc_onco5.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco5.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco5.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco5.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco5.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco5.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco5.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco5.ann	celularidad tumoral	8001/1
train-set-to-publish/cantemist-norm/cc_onco864.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco864.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	T3N2M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	implante retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	lesiones subcutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metástasis solitaria intramedular de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	implante mesentérico	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	Nódulo retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	enfermedad a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	lesión medular	8000/6
train-set-to-publish/cantemist-norm/cc_onco864.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	T3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco4.ann	carcinoma de células escamosas	8070/3
train-set-to-publish/cantemist-norm/cc_onco4.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco4.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco4.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco4.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco4.ann	lesiones pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	carcinoma tímico	8586/3
train-set-to-publish/cantemist-norm/cc_onco4.ann	carcinoma tímico	8586/3
train-set-to-publish/cantemist-norm/cc_onco4.ann	adenocarcinoma de colon bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco4.ann	carcinoma escamoso pulmonar metastásico	8070/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	carcinoma tímico escamoso con afectación pleural	8586/6
train-set-to-publish/cantemist-norm/cc_onco4.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	carcinoma adenoide quístico	8200/3
train-set-to-publish/cantemist-norm/cc_onco633.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco633.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	síndrome mieloproliferativo crónico	9960/3
train-set-to-publish/cantemist-norm/cc_onco633.ann	trombocitemia esencial	9962/3
train-set-to-publish/cantemist-norm/cc_onco633.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco633.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco633.ann	carcinoma adenoide quístico grado 2	8200/32
train-set-to-publish/cantemist-norm/cc_onco633.ann	pT2N1miM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	nódulos diafragmáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	pleura visceral y parietal con lesiones	8000/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	adenoide quístico	8200/3
train-set-to-publish/cantemist-norm/cc_onco633.ann	carcinoma adenoide quístico metastásico	8200/6
train-set-to-publish/cantemist-norm/cc_onco633.ann	recaída sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco940.ann	adenocarcinoma de próstata grado combinado Gleason 6	8140/31
train-set-to-publish/cantemist-norm/cc_onco940.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	metastásicas vertebrales por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	neoplásica	8000/3
train-set-to-publish/cantemist-norm/cc_onco940.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	afectación casi completa de los cuerpos vertebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco940.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco613.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco613.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco613.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco613.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco613.ann	invasión de 4ª a 6ª vértebras	8000/6
train-set-to-publish/cantemist-norm/cc_onco59.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco59.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco59.ann	liposarcoma desdiferenciado de 27 cm, grado 2	8858/32
train-set-to-publish/cantemist-norm/cc_onco59.ann	liposarcoma retroperitoneal desdiferenciado grado 2	8858/32
train-set-to-publish/cantemist-norm/cc_onco59.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco79.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco79.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco79.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco79.ann	metástasis de carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	metástasis de carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco79.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco79.ann	pT1aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	carcinoma de células claras de patrón tubuloquístico	8310/3/H
train-set-to-publish/cantemist-norm/cc_onco79.ann	carcinoma de ovario de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco79.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	carcinoma concordante con origen ovárico metastásico	8010/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	lesión en el seno cardiofrénico	8000/6
train-set-to-publish/cantemist-norm/cc_onco79.ann	carcinoma de células claras de patrón tubuloquístico asociado a áreas de patrón adenofibroso	8313/3
train-set-to-publish/cantemist-norm/cc_onco531.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco531.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	micrometastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	Recaída locorregional, ganglionar y pulmonar de melanoma maligno	8720/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	Adenopatías patológicashipervasculares supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco531.ann	adenopatías laterocervicales bilaterales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco168.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco168.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco168.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco168.ann	linfoma difuso de células B	9591/3
train-set-to-publish/cantemist-norm/cc_onco168.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco168.ann	Adenocarcinoma de sigma diseminado	8140/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco605.ann	diseminación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	neoplasia de estirpe germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco605.ann	neoplasia de origen germinal diseminada	9064/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	coriocarcinoma primario mediastínico diseminado	9100/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	nódulos hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	nódulos tumorales hemorrágicos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco605.ann	nódulos únicos en riñón	8000/6
train-set-to-publish/cantemist-norm/cc_onco815.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco815.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco815.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco815.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco815.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco815.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco815.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco815.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco815.ann	cTxcN2cM 1	8000/1
train-set-to-publish/cantemist-norm/cc_onco823.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco823.ann	tumor maligno de crecimiento bifásico	8000/3/H
train-set-to-publish/cantemist-norm/cc_onco823.ann	metástasis de SS	9040/6
train-set-to-publish/cantemist-norm/cc_onco823.ann	Sarcoma sinovial primario cardiaco de alto grado	9040/34
train-set-to-publish/cantemist-norm/cc_onco823.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco823.ann	lesión de 5 cm entre esófago y ventrículo	8000/6
train-set-to-publish/cantemist-norm/cc_onco96.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco96.ann	mixoma	8840/0
train-set-to-publish/cantemist-norm/cc_onco96.ann	rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco96.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco96.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco96.ann	tumor de células redondas	8041/1
train-set-to-publish/cantemist-norm/cc_onco102.ann	Adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	Carcinoma de células grandes	8012/3
train-set-to-publish/cantemist-norm/cc_onco102.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	cáncer de pulmón no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco102.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco102.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco102.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco102.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco102.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco102.ann	metástasis de carcinoma de células grandes	8012/6
train-set-to-publish/cantemist-norm/cc_onco102.ann	T1N3M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco194.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco194.ann	carcinoma basocelular	8090/3
train-set-to-publish/cantemist-norm/cc_onco194.ann	carcinoma neuroendocrino	8246/3
train-set-to-publish/cantemist-norm/cc_onco194.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco194.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco194.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco194.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco194.ann	tumor mixto	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco194.ann	adenocarcinoma indiferenciado	8140/34
train-set-to-publish/cantemist-norm/cc_onco194.ann	adecarcinoma indiferenciado	8140/34
train-set-to-publish/cantemist-norm/cc_onco194.ann	adenocarcinoma pobremente diferenciado grado 3 difuso con células en anillo de sello	8490/33
train-set-to-publish/cantemist-norm/cc_onco194.ann	tumor una diferenciación neuroendocrina	8240/3
train-set-to-publish/cantemist-norm/cc_onco194.ann	adenocarcinoma pobremente diferenciado con células en anillo de sello	8490/33
train-set-to-publish/cantemist-norm/cc_onco194.ann	adenocarcinoma pobremente diferenciado grado 3 difuso	8145/33
train-set-to-publish/cantemist-norm/cc_onco194.ann	tumor mixto: adenocarcinoma pobremente diferenciado con células en anillo de sello y carcinoma neuroendocrino	8244/3
train-set-to-publish/cantemist-norm/cc_onco276.ann	Neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco276.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco276.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco276.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco276.ann	sarcoma cardiaco metastásico	8800/6
train-set-to-publish/cantemist-norm/cc_onco276.ann	tumor cardíaco de estirpe mesenquimal	8800/3
train-set-to-publish/cantemist-norm/cc_onco276.ann	angiosarcoma epiteloide	8804/3
train-set-to-publish/cantemist-norm/cc_onco276.ann	angiosarcoma cardíaco estadio IV (metástasis	9120/6
train-set-to-publish/cantemist-norm/cc_onco276.ann	enfermedad pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco442.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco442.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco442.ann	adenocarcinoma de pulmón estadio IV (T1bN3M1b)	8140/6
train-set-to-publish/cantemist-norm/cc_onco610.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco610.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco610.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco610.ann	Adenocarcinoma de pulmón lóbulo superior derecho (cT1acN2pM1b)	8140/6
train-set-to-publish/cantemist-norm/cc_onco610.ann	adenocarcinoma de 1,5 cm y metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco610.ann	estadio IV por cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco610.ann	lesión temporoparietal	8000/6
train-set-to-publish/cantemist-norm/cc_onco111.ann	Carcinoma de células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco111.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco111.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco111.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco111.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco111.ann	tumor de células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco111.ann	tumor de células de Merkel	8247/3
train-set-to-publish/cantemist-norm/cc_onco111.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco1.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco1.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco1.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco897.ann	TNEp	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	TNEp	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	TNEp	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	TNEp	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco897.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	hemangioblastoma	9161/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	hemangioblastoma	9161/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	hemangioblastomas	9161/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	hemangioblastomas	9161/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	hemangioblastomas	9161/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco897.ann	carcinoma renal de células claras multicéntrico	8310/3/H
train-set-to-publish/cantemist-norm/cc_onco897.ann	angiomiolipomas	8860/0
train-set-to-publish/cantemist-norm/cc_onco897.ann	Tumor neuroendocrino pancreático bien diferenciado	8240/3
train-set-to-publish/cantemist-norm/cc_onco897.ann	angiomiolipomas	8860/0
train-set-to-publish/cantemist-norm/cc_onco291.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco291.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco291.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco291.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco291.ann	rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco291.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco291.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco291.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco291.ann	leucemia linfoblástica aguda L1 de células B	9835/36
train-set-to-publish/cantemist-norm/cc_onco291.ann	leucemia linfobástica aguda	9835/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	rabdomiosarcoma alveolar	8920/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	adenopatías cervicales, supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco291.ann	rabdomiosarcoma alveolar	8920/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	leucemia	9800/3
train-set-to-publish/cantemist-norm/cc_onco291.ann	rabdomiosarcoma alveolar	8920/3
train-set-to-publish/cantemist-norm/cc_onco423.ann	carcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco423.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco423.ann	tumor endometrial mülleriano mixto	8950/3
train-set-to-publish/cantemist-norm/cc_onco423.ann	tumor mülleriano mixto	8950/3
train-set-to-publish/cantemist-norm/cc_onco423.ann	sarcoma de alto grado con diferenciación rabdomioblástica	8800/34/H
train-set-to-publish/cantemist-norm/cc_onco423.ann	progresión peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco423.ann	recaída a nivel peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco350.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco350.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco350.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco350.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco350.ann	pT3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	nódulos hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	lesiones blásticas óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	captación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	lesiones nodulares hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco350.ann	lesiones blásticas en cuerpos vertebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	TCG	9064/3
train-set-to-publish/cantemist-norm/cc_onco188.ann	TCGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco188.ann	carcinoma embrionario	9070/3
train-set-to-publish/cantemist-norm/cc_onco188.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	micronódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco188.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco188.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco188.ann	tumor de células germinales (TCG) mixto	9064/3/H
train-set-to-publish/cantemist-norm/cc_onco188.ann	tumor de células germinales no seminomatoso (TCGNS) T2 N3 M1a	9065/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	tumor del seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco188.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco188.ann	lesión retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco188.ann	masa retroperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco82.ann	celulas neoplasicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco82.ann	meningioma	9530/0
train-set-to-publish/cantemist-norm/cc_onco82.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco82.ann	meduloblastoma desmoplásico nodular grado IV de la OMS	9471/34
train-set-to-publish/cantemist-norm/cc_onco301.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco301.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco301.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco301.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco301.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco301.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco301.ann	cordoma	9370/3
train-set-to-publish/cantemist-norm/cc_onco301.ann	cordoma	9370/3
train-set-to-publish/cantemist-norm/cc_onco301.ann	cordoma	9370/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	TCG	9064/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	Tumor de células germinales testicular estadio III por enfermedad retroperitoneal	9064/6
train-set-to-publish/cantemist-norm/cc_onco148.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco148.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumor seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	TCG mixto	9064/3/H
train-set-to-publish/cantemist-norm/cc_onco148.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumor germinal maligno	9064/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	tumor de seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco148.ann	masa pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco148.ann	afectación pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco485.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco485.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco485.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco485.ann	leucemia	9800/3
train-set-to-publish/cantemist-norm/cc_onco485.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco485.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco485.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco485.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco485.ann	metástasis adenocarcinoma poco diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco485.ann	progresión pulmonar bilateral	8000/6
train-set-to-publish/cantemist-norm/cc_onco777.ann	Adenocarcinoma mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco777.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco777.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco777.ann	adenocarcinoma mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco777.ann	adenocarcinoma mucinoso bien diferenciado	8480/31
train-set-to-publish/cantemist-norm/cc_onco777.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco777.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco777.ann	pT4NxM1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco777.ann	derrame pleural maligno	8000/6
train-set-to-publish/cantemist-norm/cc_onco777.ann	cáncer de pulmón de células no pequeñas	8002/3
train-set-to-publish/cantemist-norm/cc_onco553.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco553.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	melanoma maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco553.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	progresión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco553.ann	progresión franca de la enfermedad adenopática, peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	cistoadenoma	8440/0
train-set-to-publish/cantemist-norm/cc_onco870.ann	hemangiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco870.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	tumor folicular	8330/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	Struma ovárico maligno	9090/3
train-set-to-publish/cantemist-norm/cc_onco870.ann	Struma ovárico metastatizado	9090/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	Struma ovarii	9090/1
train-set-to-publish/cantemist-norm/cc_onco870.ann	Teratoma maligno con diferenciación folicular (Struma ovarii) con afectación hepática	9090/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	lesión focal hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	foco hipermetabólico a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	metástasis de estruma ovárico maligno	9090/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	lesiones ocupantes de espacio localizadas en parénquima hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco870.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	carcinoma no célula pequeña	8046/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	carcinoma sarcomatoide	8033/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco916.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco916.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco916.ann	tumor maligno con presencia de células fusiformes	8004/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	neoplasia de origen pulmonar de características sarcomatoides con metástasis	8033/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	tumores de estirpe sarcomatoide	8033/1
train-set-to-publish/cantemist-norm/cc_onco916.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	CPNCP	8046/3
train-set-to-publish/cantemist-norm/cc_onco916.ann	CPNCP en estadio IV por afectación ósea	8046/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	implante tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	nódulo en espacio pararrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	lesión adrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	nódulo en el espacio pararrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco916.ann	masa suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco22.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco22.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco22.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco22.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco22.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco22.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	Lesión focal hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco247.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco247.ann	Adenocarcinoma rectal T3N1M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	lesión segmento VI hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	lesión ocupante de espacio en segmento VI hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco247.ann	lesión en el segmento VI hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	afectación secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	carcinoma neuroendocrino de célula grande	8013/3
train-set-to-publish/cantemist-norm/cc_onco679.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco679.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco679.ann	macroadenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco679.ann	carcinoma no célula pequeña, pobremente diferenciado	8046/33
train-set-to-publish/cantemist-norm/cc_onco679.ann	carcinoma neuroendocrino de células grandes	8013/3
train-set-to-publish/cantemist-norm/cc_onco679.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	diseminación a nivel infradiafragmático	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	implantes a nivel subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	lesiones subcutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	lesiones parenquimatosas	8000/6
train-set-to-publish/cantemist-norm/cc_onco679.ann	lesión pituitaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco795.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco795.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco795.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco795.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco225.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco225.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco225.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco225.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco225.ann	CDI grado histológico III	8500/33
train-set-to-publish/cantemist-norm/cc_onco225.ann	pT1N3M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco225.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco525.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco525.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco525.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco525.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco525.ann	adenocarcinoma enteroide bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco525.ann	adenocarcinoma enteroide bien diferenciado con 10 % de componente mucosecretor	8481/3
train-set-to-publish/cantemist-norm/cc_onco525.ann	adenocarcinoma enteroide bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco525.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco525.ann	diseminación tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco394.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco394.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco394.ann	adenocarcinoma mucinoso bien diferenciado	8480/31
train-set-to-publish/cantemist-norm/cc_onco394.ann	Adenocarcinoma mucinoso de uraco estadio IV por afectación peritoneal	8480/6
train-set-to-publish/cantemist-norm/cc_onco394.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco394.ann	adenocarcinoma mucinoso bien diferenciado, con aisladas células en anillo de sello	8490/31
train-set-to-publish/cantemist-norm/cc_onco394.ann	progresión peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco453.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco453.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco453.ann	sarcomatoide	8033/1
train-set-to-publish/cantemist-norm/cc_onco453.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco453.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco453.ann	tumoral pobremente diferenciada	8000/13
train-set-to-publish/cantemist-norm/cc_onco453.ann	neoplasia fusocelular	8004/1
train-set-to-publish/cantemist-norm/cc_onco453.ann	carcinoma urotelial de alto grado con diferenciación sarcomatoide estadio IV (pT4N2M1)	8122/64
train-set-to-publish/cantemist-norm/cc_onco453.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco453.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco453.ann	enfermedad a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco202.ann	hemangioblastoma	9161/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	neoplasia germinal intratubular	9064/2
train-set-to-publish/cantemist-norm/cc_onco202.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	nevus melanocítico lentiginoso	8720/0/H
train-set-to-publish/cantemist-norm/cc_onco202.ann	N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	Carcinoma germinal de testículo no seminomatoso	9065/3
train-set-to-publish/cantemist-norm/cc_onco202.ann	pT1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	yolk-sac	9071/3
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumores de estirpe germinal mixtos	9085/3
train-set-to-publish/cantemist-norm/cc_onco202.ann	metástasis del tumor	8000/6
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumor primario de origen germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco202.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco202.ann	teratoma maligno mixto con áreas de carcinoma embrionario	9081/3
train-set-to-publish/cantemist-norm/cc_onco235.ann	Melanoma Nodular	8721/3
train-set-to-publish/cantemist-norm/cc_onco235.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco235.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco235.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco235.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco235.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	glioblastoma	9440/3
train-set-to-publish/cantemist-norm/cc_onco181.ann	glioblastoma multiforme	9440/3
train-set-to-publish/cantemist-norm/cc_onco181.ann	glioblastoma multiforme	9440/3
train-set-to-publish/cantemist-norm/cc_onco181.ann	glioblastoma multiforme	9440/3
train-set-to-publish/cantemist-norm/cc_onco181.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco181.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco905.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco905.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco905.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco905.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco371.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco371.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco371.ann	carcinoma ductal infiltrante de mama grado I	8500/31
train-set-to-publish/cantemist-norm/cc_onco371.ann	carcinoma ductal infiltrante grado I	8500/31
train-set-to-publish/cantemist-norm/cc_onco647.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco647.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco647.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco647.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco647.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco647.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco647.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco647.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco647.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco647.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	Metástasis en trígono retromolar de un adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco647.ann	lesión exofítica en trígono retromolar	8000/6
train-set-to-publish/cantemist-norm/cc_onco597.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco597.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco597.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco597.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco597.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco597.ann	diseminación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco597.ann	progresión radiológica a nivel peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco597.ann	nódulos hipodensos en ambos lóbulos hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco213.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco213.ann	carcinoma no de células pequeñas	8046/3
train-set-to-publish/cantemist-norm/cc_onco213.ann	metástasis pulmonar de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	adenocarcinoma compatible con metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	Metástasis intratraqueal de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	nódulo de 2,3 cm en el LSD	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	lesión en intratraqueal	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco213.ann	lesión traqueal	8000/6
train-set-to-publish/cantemist-norm/cc_onco804.ann	Teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco804.ann	hepatocarcinoma	8170/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco804.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco804.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco804.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco804.ann	diferenciación neuroendocrina	8574/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	metástasis de carcinoma hepatoide	8576/6
train-set-to-publish/cantemist-norm/cc_onco804.ann	variante hepatoide de tumor germinal tipo seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	Carcinoma hepatoide	8576/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	carcinoma hepatoide	8576/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	tumor del seno endodérmico hepatoide	9071/3
train-set-to-publish/cantemist-norm/cc_onco804.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco804.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco262.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco262.ann	metastásis	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco262.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco262.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco262.ann	adenocarcinoma papilar	8260/3
train-set-to-publish/cantemist-norm/cc_onco262.ann	pM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	metástasis por tumor carcinoide atípico	8240/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	carcinoide pulmonar atipico	8240/3
train-set-to-publish/cantemist-norm/cc_onco262.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	metástasis de tumor carcinoide atípico	8240/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	TNE	8240/3
train-set-to-publish/cantemist-norm/cc_onco262.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	lesión acetabular sugestiva de implante	8000/6
train-set-to-publish/cantemist-norm/cc_onco262.ann	PE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco968.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco968.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco968.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco968.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco968.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco968.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco968.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco968.ann	Carcinoma ductal infiltrante de mama derecha, cT3N1M1	8500/6
train-set-to-publish/cantemist-norm/cc_onco968.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco481.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco481.ann	rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco481.ann	Rabdomiosarcoma	8900/3
train-set-to-publish/cantemist-norm/cc_onco481.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco481.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco481.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco481.ann	N1 cervical y supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco67.ann	Carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	Tumor mulleriano mixto maligno	8950/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco67.ann	adenocarcinoma seroso de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco67.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco67.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco67.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco67.ann	tumor mulleriano mixto maligno	8950/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco67.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco67.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco67.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco67.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	sarcoma pleomorfo	8802/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	carcinosarcoma	8980/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	sarcoma pleomorfo	8802/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	enfermedad a nivel peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco67.ann	recaída local y peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco67.ann	síndrome de Lynch	8010/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco509.ann	adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco509.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	leiomiosarcoma	8890/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	leiomiosarcoma	8890/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	leiomiosarcoma	8890/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco509.ann	tumor fusocelular maligno	8004/3
train-set-to-publish/cantemist-norm/cc_onco509.ann	leiomiosarcoma de alto grado	8890/34
train-set-to-publish/cantemist-norm/cc_onco582.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	nevus	8720/0
train-set-to-publish/cantemist-norm/cc_onco582.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco582.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	NEM	8000/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	NEM2	8000/3
train-set-to-publish/cantemist-norm/cc_onco582.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	LOE hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco582.ann	lesiones sospechosas en mama	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	adenocarcinoma de recto inferior, estadio IV (2 metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	cT3N0M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	Adenocarcinoma de recto inferior, estadio IV (2 metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	cT3N0M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	adenocarcinoma de origen colorrectal ypT3N0 (0/17)M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco83.ann	metastático	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco83.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco83.ann	progresiones a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	adenocarcinoma metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco163.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco163.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco163.ann	carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco163.ann	Ib1N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	cT2N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	implante dural	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	Adenocarcinoma de colon de novo con afectación metastásica	8140/6
train-set-to-publish/cantemist-norm/cc_onco163.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco163.ann	lesiones cutáneas	8000/6
train-set-to-publish/cantemist-norm/cc_onco81.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco81.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco81.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco81.ann	adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco81.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco81.ann	leucemia mieloblástica aguda	9872/3
train-set-to-publish/cantemist-norm/cc_onco957.ann	glioblastoma multiforme	9440/3
train-set-to-publish/cantemist-norm/cc_onco957.ann	glioblastoma multiforme	9440/3
train-set-to-publish/cantemist-norm/cc_onco957.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco957.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco957.ann	células neoplásicas	8001/1
train-set-to-publish/cantemist-norm/cc_onco957.ann	metástasis de tumor glial de alto grado	9380/64
train-set-to-publish/cantemist-norm/cc_onco957.ann	metástasis de tumor glial de alto grado	9380/6
train-set-to-publish/cantemist-norm/cc_onco957.ann	Metástasis ganglionares cervicales bilaterales de un glioblastoma multiforme	9440/6
train-set-to-publish/cantemist-norm/cc_onco957.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco957.ann	diseminación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco957.ann	diseminación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco957.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco957.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco957.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco957.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco250.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco250.ann	neoformación maligna, con rasgos neuroendocrinos	8240/3
train-set-to-publish/cantemist-norm/cc_onco250.ann	Tumor neuroendocrino grado 2	8240/32
train-set-to-publish/cantemist-norm/cc_onco250.ann	tumor bien diferenciado	8000/11
train-set-to-publish/cantemist-norm/cc_onco250.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco250.ann	carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco250.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco250.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco250.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco298.ann	cancer	8000/3
train-set-to-publish/cantemist-norm/cc_onco298.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco298.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco298.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco298.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco298.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco298.ann	pororcarcinoma ecrino	8409/3
train-set-to-publish/cantemist-norm/cc_onco298.ann	metástasis de porocarcinoma	8409/6
train-set-to-publish/cantemist-norm/cc_onco298.ann	porocarcinoma ecrino	8409/3
train-set-to-publish/cantemist-norm/cc_onco298.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco298.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco700.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco700.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco700.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco700.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco700.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco700.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco700.ann	carcinoma ductal infiltrante, grado II	8500/32
train-set-to-publish/cantemist-norm/cc_onco700.ann	Carcinoma ductal infiltrante de mama E IV por afectación ganglionar axilar, hepática	8500/6
train-set-to-publish/cantemist-norm/cc_onco700.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco700.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco700.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco800.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco800.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco800.ann	carcinoma escamoso de alto grado	8070/34
train-set-to-publish/cantemist-norm/cc_onco800.ann	carcinoma escamoso moderadamente diferenciado, infiltrante	8070/32/H
train-set-to-publish/cantemist-norm/cc_onco800.ann	rpT4NxM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco800.ann	celularidad maligna	8001/3
train-set-to-publish/cantemist-norm/cc_onco800.ann	carcinoma pobremente diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco800.ann	cT1bN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco800.ann	pT1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco962.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco962.ann	adenopatías cervicales y supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	adenopatías cervicales y supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco962.ann	lesiones focales en los segmentos II y VI hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	carcinoma de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco743.ann	carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco743.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco743.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco743.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco743.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco743.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	T4N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	T2aN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	T2aN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	carcinoma metastásico de células pequeñas	8041/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	Metástasis tiroidea de carcinoma microcítico de pulmón	8041/6
train-set-to-publish/cantemist-norm/cc_onco743.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco169.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco169.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco169.ann	células tumorales malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco169.ann	CTM	8001/3
train-set-to-publish/cantemist-norm/cc_onco169.ann	adenocarcinoma de pulmón derecho metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco169.ann	CTM	8001/3
train-set-to-publish/cantemist-norm/cc_onco169.ann	carcinomatosa	8010/9
train-set-to-publish/cantemist-norm/cc_onco169.ann	MC	8010/9
train-set-to-publish/cantemist-norm/cc_onco169.ann	MC	8010/9
train-set-to-publish/cantemist-norm/cc_onco572.ann	Melanocitoma	8726/0
train-set-to-publish/cantemist-norm/cc_onco572.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanocitoma de grado intermedio	8726/02
train-set-to-publish/cantemist-norm/cc_onco572.ann	tumorales con afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	melanocitoma de grado intermedio	8726/02
train-set-to-publish/cantemist-norm/cc_onco572.ann	Schwannoma melanocítico maligno	9560/3
train-set-to-publish/cantemist-norm/cc_onco572.ann	schwannomas	9560/0
train-set-to-publish/cantemist-norm/cc_onco572.ann	schwannomas	9560/0
train-set-to-publish/cantemist-norm/cc_onco572.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	lesiones cervicales	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	invasión vertebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	invasión mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco572.ann	lesión en fosa clavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco91.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco91.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco91.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco91.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco91.ann	adenopatías sospechosas a nivel supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco622.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco622.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco622.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco622.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco622.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco622.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco622.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco622.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco622.ann	realce meníngeo	8000/6
train-set-to-publish/cantemist-norm/cc_onco654.ann	Carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco654.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco654.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco654.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco654.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco654.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco654.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco654.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco654.ann	neurilemoma	9560/0
train-set-to-publish/cantemist-norm/cc_onco654.ann	mesotelioma maligno	9050/3
train-set-to-publish/cantemist-norm/cc_onco654.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco654.ann	mesotelioma convencional de patrón túbulo papilar	9050/3/H
train-set-to-publish/cantemist-norm/cc_onco654.ann	mesotelioma monofásico	9050/3/H
train-set-to-publish/cantemist-norm/cc_onco654.ann	mesotelioma	9050/3
train-set-to-publish/cantemist-norm/cc_onco654.ann	Mesotelioma maligno inguinal monofásico	9050/3/H
train-set-to-publish/cantemist-norm/cc_onco654.ann	progresión peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco654.ann	infiltración peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco654.ann	infiltración peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco654.ann	sarcomatoides	9051/3
train-set-to-publish/cantemist-norm/cc_onco755.ann	angioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco755.ann	carcinoma de células renales	8312/3
train-set-to-publish/cantemist-norm/cc_onco755.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco755.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco755.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco755.ann	cT3aN0Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	carcinoma de células renales tipo células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco755.ann	metástasis en parénquima testicular de carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	progresión a nivel testicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco755.ann	lesión de aspecto lítico D11	8000/6
train-set-to-publish/cantemist-norm/cc_onco55.ann	neoplasia intratubular de células germinales	9064/2
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor germinal no seminoma	9065/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor quemado	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco55.ann	sarcoma	8800/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	sarcoma	8800/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	sarcoma	8800/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	metástasis de carcinoma embrionario	9070/6
train-set-to-publish/cantemist-norm/cc_onco55.ann	sarcoma retroperitoneal de alto grado	8800/34
train-set-to-publish/cantemist-norm/cc_onco55.ann	sarcoma retroperitoneal de alto grado	8800/34
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumor maligno de la vaina nerviosa periférica), grado histológico 3	9540/33
train-set-to-publish/cantemist-norm/cc_onco55.ann	Sarcoma de partes blandas	8800/3
train-set-to-publish/cantemist-norm/cc_onco55.ann	neoplásico de alto grado	8000/14
train-set-to-publish/cantemist-norm/cc_onco55.ann	síndrome linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco55.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco723.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco723.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco723.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	sarcomas	8800/3
train-set-to-publish/cantemist-norm/cc_onco723.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco723.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco723.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco723.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	realces leptomeníngeos	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	enfermedad periférica	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	enfermedad a nivel periférico	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	8140/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	lesiones nodulares supra e infratentoriales	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	Progresión tumoral en el sistema nervioso central	8000/6
train-set-to-publish/cantemist-norm/cc_onco723.ann	progresión en SNC	8000/6
train-set-to-publish/cantemist-norm/cc_onco420.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco420.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco420.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	timoma tipo A	8581/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	Timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco420.ann	timoma	8580/1
train-set-to-publish/cantemist-norm/cc_onco537.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco537.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco537.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco537.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco537.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco537.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco537.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco537.ann	Neuroblastoma poco diferenciado (clasificación INPC/OMS2017) con afectación ganglionar retroperitoneal y hepática	9500/63
train-set-to-publish/cantemist-norm/cc_onco537.ann	neuroblastoma poco diferenciado	9500/33
train-set-to-publish/cantemist-norm/cc_onco537.ann	peritumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco366.ann	CARCINOMA MICROCITICO	8041/3
train-set-to-publish/cantemist-norm/cc_onco366.ann	carcinoma no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco366.ann	cTxN3M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco366.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	carcinoma medular	8510/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco232.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco232.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco232.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco232.ann	Cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco944.ann	afectación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco944.ann	linfoma Burkitt like IIB	9687/3/H
train-set-to-publish/cantemist-norm/cc_onco944.ann	enfermedad de Paget extramamaria	8542/3
train-set-to-publish/cantemist-norm/cc_onco361.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco361.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco361.ann	fibromiomas	8890/0
train-set-to-publish/cantemist-norm/cc_onco361.ann	MOLA HIDATIFORME	9100/0
train-set-to-publish/cantemist-norm/cc_onco361.ann	enfermedad extrauterina	8000/6
train-set-to-publish/cantemist-norm/cc_onco361.ann	Mola hidatiforme invasiva	9100/1
train-set-to-publish/cantemist-norm/cc_onco361.ann	MOLA HIDATIFORME INVASIVA	9100/1
train-set-to-publish/cantemist-norm/cc_onco275.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco275.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco275.ann	Adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco275.ann	Hemangioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco275.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco275.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco275.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco275.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco275.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco374.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco374.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco374.ann	adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco374.ann	cáncer de pulmón no microcítico	8046/3
train-set-to-publish/cantemist-norm/cc_onco374.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco374.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco374.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco374.ann	pT2aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco374.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco374.ann	cTxcN2pM1	8000/6
train-set-to-publish/cantemist-norm/cc_onco374.ann	progresión tumoral a nivel mediastínico, pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco374.ann	implantes en pectoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco490.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco490.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco490.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco490.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco490.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco490.ann	implante pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	carcinoma mal diferenciado de célula no pequeña	8046/33
train-set-to-publish/cantemist-norm/cc_onco490.ann	carcinoma pulmonar mal diferenciado de célula no pequeña	8046/33
train-set-to-publish/cantemist-norm/cc_onco490.ann	cM1c	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	infiltración ósea neoplásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	implantes pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	lesión de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	Lesiones en lóbulo hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco490.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco986.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco986.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco986.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco986.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco986.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco986.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco986.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco986.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco986.ann	Carcinoma papilar seroso de ovario de alto grado	8461/34
train-set-to-publish/cantemist-norm/cc_onco986.ann	adenopatías supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco986.ann	recaída mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	carcinoma de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco900.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco900.ann	metástasis por carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	metástasis por carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco900.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco900.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco900.ann	Carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco900.ann	Carcinoma renal de células claras E.II (pT2, G1)	8310/31
train-set-to-publish/cantemist-norm/cc_onco900.ann	carcinoma renal de células claras bilateral con metástasis	8310/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	enfermedad a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	metastásica de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	implante tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	Melanoma maligno de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesión suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesiones pancreáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesiones en el polo inferior del riñón	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesión en segmento 4 hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesiones en cola de páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesión milimétrica en hígado	8000/6
train-set-to-publish/cantemist-norm/cc_onco900.ann	lesión milimétrica en páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco593.ann	Colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco593.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco593.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco593.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco593.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco593.ann	colangiocarcinoma	8160/3
train-set-to-publish/cantemist-norm/cc_onco840.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco840.ann	pT4N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco840.ann	melanoma cutáneo maligno	8720/3
train-set-to-publish/cantemist-norm/cc_onco840.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco840.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco677.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco677.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco677.ann	carcinoma epidermoide	8070/3
train-set-to-publish/cantemist-norm/cc_onco677.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco677.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco677.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco677.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco677.ann	carcinoma microinvasivo	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco677.ann	diseminación a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco677.ann	carcinoma epidermoide moderadamente diferenciado	8070/32
train-set-to-publish/cantemist-norm/cc_onco859.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco859.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco859.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco859.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	micrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco859.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco859.ann	carcinoma ductal infiltrante grado 2	8500/32
train-set-to-publish/cantemist-norm/cc_onco859.ann	comedocarcinoma	8501/3
train-set-to-publish/cantemist-norm/cc_onco859.ann	macrometástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	Carcinoma ductal infiltrante de mama subtipo luminal B, estadio IV por afectación ósea	8500/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco859.ann	enfermedad de Paget del pezón	8540/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco251.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco251.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco251.ann	Carcinoma ductal infiltrante pobremente diferenciado	8500/33
train-set-to-publish/cantemist-norm/cc_onco251.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	carcinoma ductal microinfiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco251.ann	carcinoma intraductal residual, ambos pobremente diferenciados	8500/23
train-set-to-publish/cantemist-norm/cc_onco10.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco10.ann	Neoplasia pulmonar T4N0M1b	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	Carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco10.ann	Carcinoma indiferenciado de pulmón T4N0M1b	8020/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	Carcinoma indiferenciado de pulmón T4N0M1b	8020/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco10.ann	oligometástasica	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	Carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco10.ann	implante	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	lesión adrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco10.ann	lesión cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco430.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco430.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco430.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco430.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco430.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco430.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco430.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco430.ann	cT2N2M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco430.ann	cT2N2M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco885.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	carcinoma embrionario	9070/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco885.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco885.ann	tumor del seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	tumor germinal	9064/3
train-set-to-publish/cantemist-norm/cc_onco885.ann	tumor mixto de células germinales no seminomatoso	9065/3/H
train-set-to-publish/cantemist-norm/cc_onco885.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco395.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	T3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	carcinoma urotelial	8120/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	malignas	8000/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco395.ann	T3-4N0-2M1a	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	afectación bipulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	afectación bipulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinoma broncopulmonar bien diferenciado, de patrón lepídico/acinar/papilar	8140/31/H
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinomas	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	ADC de pulmón lepídico	8140/3/H
train-set-to-publish/cantemist-norm/cc_onco395.ann	cT4a cN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco395.ann	CPNM	8046/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	adenocarcinomas	8140/3
train-set-to-publish/cantemist-norm/cc_onco395.ann	ADC lepídico	8140/3/H
train-set-to-publish/cantemist-norm/cc_onco395.ann	T4N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco84.ann	Carcinoma microcítico	8041/3
train-set-to-publish/cantemist-norm/cc_onco84.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco84.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco84.ann	carcinoma indiferenciado de células pequeñas	8041/34
train-set-to-publish/cantemist-norm/cc_onco84.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco84.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco84.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco84.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco84.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco84.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco84.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco84.ann	carcinoma indiferenciado de células pequeñas, de aspecto neuroendocrino	8574/34
train-set-to-publish/cantemist-norm/cc_onco90.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco90.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco90.ann	Adenocarcinoma de páncreas estadio IV por metástasis	8140/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	lesión a nivel de hemisferio cerebeloso	8000/6
train-set-to-publish/cantemist-norm/cc_onco90.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco40.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco40.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco40.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco40.ann	carcinoma ductal infiltrante de mama derecha de 3,7 cm, grado histológico II de Nottingham	8500/32
train-set-to-publish/cantemist-norm/cc_onco40.ann	lesión única de 1 cm en hemisferio	8000/6
train-set-to-publish/cantemist-norm/cc_onco40.ann	lesión cerebelosa	8000/6
train-set-to-publish/cantemist-norm/cc_onco99.ann	Carcinoma ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma ductal	8500/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma intraductal de alto grado	8500/24
train-set-to-publish/cantemist-norm/cc_onco99.ann	fibroadenoma	9010/0
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma ductal pobremente diferenciado	8500/33
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma inflamatorio	8530/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma inflamatorio	8530/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma intraductal sólido de alto grado	8230/24
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumor phyllodes, histológicamente benigno	9020/0
train-set-to-publish/cantemist-norm/cc_onco99.ann	pT4cN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco99.ann	Carcinoma ductal inflamatorio	8530/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	Tumor phyllodes benigno	9020/0
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma intraductal sólido de alto grado	8230/24
train-set-to-publish/cantemist-norm/cc_onco99.ann	carcinoma ductal inflamatorio	8530/3
train-set-to-publish/cantemist-norm/cc_onco99.ann	pT4cN1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco99.ann	tumor phyllodes benigno	9020/0
train-set-to-publish/cantemist-norm/cc_onco566.ann	ADC	8140/3
train-set-to-publish/cantemist-norm/cc_onco566.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco566.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco566.ann	carcinoma renal de tipo células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco566.ann	lesiones nodulares pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco566.ann	suelta de globo	8000/6
train-set-to-publish/cantemist-norm/cc_onco566.ann	cáncer renal metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco705.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco705.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco705.ann	adenocarcinoma moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco705.ann	adenopatías hipermetabólicas retrocrurales derechas, retroperitoneales y supraclaviculares	8000/6
train-set-to-publish/cantemist-norm/cc_onco705.ann	carcinoma de cérvix estadio IV (adenopatías supraclaviculares	8010/6
train-set-to-publish/cantemist-norm/cc_onco705.ann	infiltración mesorrectal	8000/6
train-set-to-publish/cantemist-norm/cc_onco705.ann	infiltración mesorrectal	8000/6
train-set-to-publish/cantemist-norm/cc_onco908.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco908.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco908.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco908.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco908.ann	adenocarcinoma de pulmón estadio IV por afectación cerebral	8140/6
train-set-to-publish/cantemist-norm/cc_onco908.ann	lesiones cerebrales	8000/6
train-set-to-publish/cantemist-norm/cc_onco908.ann	LOES frontales	8000/6
train-set-to-publish/cantemist-norm/cc_onco199.ann	T1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco199.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco199.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco199.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco199.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco199.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco199.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco199.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco199.ann	carcinoma papilar de células claras multifocal con extensas áreas de necrosis, grado de Fuhrman 2	8050/32/H
train-set-to-publish/cantemist-norm/cc_onco199.ann	Metástasis mediastínica de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco199.ann	masa mediastínica	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco58.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco58.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco58.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco58.ann	implantes pericárdicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	adenocarcinoma de pulmón, estadio IV (cT4N2M1b)	8140/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	masa de 35 mm en la glándula suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco58.ann	enfermedad tanto a nivel cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco312.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco312.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco312.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco312.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco312.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco312.ann	lesión intrabronquial	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	carcinoma de células claras metastásico	8310/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	Recaída sistémica (pulmonar e intrabronquial) de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	progresión pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	implantes renales y en glándula suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	progresión radiológica a nivel óseo	8000/6
train-set-to-publish/cantemist-norm/cc_onco312.ann	enfermedad pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco888.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco888.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco888.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	enfermedad secundaria	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco888.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	enfermedad hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco888.ann	lesiones focales hipermetabólicas en bazo	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	carcinoma de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco779.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	metastásicos	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	metástasis de carcinoma de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco779.ann	carcinoma renal de células claras (Fuhrman grado 1) de 9 cm (pT3a pN0 pM1)	8310/61
train-set-to-publish/cantemist-norm/cc_onco779.ann	carcinoma renal de células claras metastásico	8310/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	afectación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	progresión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulo de 1,5 cm en la glándula suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	lesión cutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulo subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulo subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulo subcutáneo	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco779.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco189.ann	schwannoma	9560/0
train-set-to-publish/cantemist-norm/cc_onco189.ann	schwannoma	9560/0
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco189.ann	tumor maligno de la vaina nerviosa periférica	9540/3
train-set-to-publish/cantemist-norm/cc_onco189.ann	neurofibrosarcoma	9540/3
train-set-to-publish/cantemist-norm/cc_onco189.ann	Tumor neuroectodérmico primitivo periférico	9364/3
train-set-to-publish/cantemist-norm/cc_onco189.ann	Ewing	9260/3
train-set-to-publish/cantemist-norm/cc_onco189.ann	PNET	9364/3
train-set-to-publish/cantemist-norm/cc_onco732.ann	angioma	9120/0
train-set-to-publish/cantemist-norm/cc_onco732.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco732.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco732.ann	CDI de mama izquierda multifocal, grado 1	8500/3
train-set-to-publish/cantemist-norm/cc_onco732.ann	CDI de mama izquierda multifocal	8500/3/H
train-set-to-publish/cantemist-norm/cc_onco732.ann	adenoma tubular con displasia de bajo grado	8211/0/H
train-set-to-publish/cantemist-norm/cc_onco732.ann	"adenocarcinoma difuso, pobremente diferenciado, con células ""en anillo de sello"""	8490/33
train-set-to-publish/cantemist-norm/cc_onco732.ann	adenocarcinoma difuso	8145/3
train-set-to-publish/cantemist-norm/cc_onco732.ann	metástasis colónicas de CDI	8500/6
train-set-to-publish/cantemist-norm/cc_onco732.ann	metastásica colónica y ganglionar de CDI	8500/6
train-set-to-publish/cantemist-norm/cc_onco732.ann	lesiones líticas en sacro	8000/6
train-set-to-publish/cantemist-norm/cc_onco732.ann	pT2pN1aM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco869.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis hepáticas de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	metástasis hepáticas de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	adenocarcinoma colorrectal moderadamente diferenciado	8140/32
train-set-to-publish/cantemist-norm/cc_onco869.ann	implantes tumorales	8000/6
train-set-to-publish/cantemist-norm/cc_onco869.ann	implantes de menor tamaño en fascia	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	carcinoma de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	carcinoma de células pequeñas	8041/3
train-set-to-publish/cantemist-norm/cc_onco544.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco544.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco544.ann	adenocarcinoma de pulmón cT2b N3 M1b	8140/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	progresión a nivel local, así como, sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	progresión a nivel del SNC	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	afectación cerebral	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	afectación del sistema nervioso central	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	lesión cerebelosa	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	afectación del SNC	8000/6
train-set-to-publish/cantemist-norm/cc_onco544.ann	afectación en glándula suprarrenal	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	adenocarcinoma de tipo intestinal	8144/3
train-set-to-publish/cantemist-norm/cc_onco324.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco324.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco324.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco324.ann	hemangiomas	9120/0
train-set-to-publish/cantemist-norm/cc_onco324.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco324.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco324.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco324.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco324.ann	adenocarcinoma de cuerpo gástrico de tipo intestinal	8144/3
train-set-to-publish/cantemist-norm/cc_onco324.ann	lesión hipodensa del segmento VI hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	adenocarcinoma mal diferenciado (4 cm) de tipo intestinal	8144/33
train-set-to-publish/cantemist-norm/cc_onco324.ann	lesión del segmento VI hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco324.ann	metástasis de carcinoma mal diferenciado	8010/63
train-set-to-publish/cantemist-norm/cc_onco185.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco185.ann	Tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco185.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco185.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco185.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco185.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco185.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	carcinoma ductal infiltrante Grado II-III	8500/33
train-set-to-publish/cantemist-norm/cc_onco185.ann	linitis plástica	8142/3
train-set-to-publish/cantemist-norm/cc_onco185.ann	linitis plástica	8142/3
train-set-to-publish/cantemist-norm/cc_onco185.ann	carcinoma lobulillar de alto grado (pleomórfico) metastásico	8520/64/H
train-set-to-publish/cantemist-norm/cc_onco185.ann	Carcinoma infiltrante mixto (lobulillar con áreas de ductal) grado 2	8522/32
train-set-to-publish/cantemist-norm/cc_onco185.ann	celularidad tumoral	8001/1
train-set-to-publish/cantemist-norm/cc_onco185.ann	carcinoma de mama infiltrante mixto (lobulillar clásico con áreas de ductal) estadio ypT2ypN2pM1	8522/6
train-set-to-publish/cantemist-norm/cc_onco185.ann	linitis plástica	8142/3
train-set-to-publish/cantemist-norm/cc_onco143.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco143.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco143.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco143.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco143.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco143.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco143.ann	pT1N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco143.ann	leucemia aguda mieloide con displasia trilineal de la clasificación de la OMS	9895/3
train-set-to-publish/cantemist-norm/cc_onco143.ann	LAM	9861/3
train-set-to-publish/cantemist-norm/cc_onco936.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco936.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco936.ann	carcinoma infiltrante NOS, grado II	8010/32/H
train-set-to-publish/cantemist-norm/cc_onco936.ann	implantes meníngeos	8000/6
train-set-to-publish/cantemist-norm/cc_onco936.ann	Carcinoma infiltrante	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco936.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco936.ann	diseminación pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco936.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco936.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	adenoma	8140/0
train-set-to-publish/cantemist-norm/cc_onco736.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	tumor carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco736.ann	tumorlet	8040/1
train-set-to-publish/cantemist-norm/cc_onco736.ann	tumor carcinoide	8240/3
train-set-to-publish/cantemist-norm/cc_onco736.ann	tumorlet	8040/1
train-set-to-publish/cantemist-norm/cc_onco736.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco736.ann	neoplasia de páncreas con metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco736.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	nódulos pulmonares bilaterales	8000/6
train-set-to-publish/cantemist-norm/cc_onco736.ann	nódulo hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco31.ann	GIST	8936/3
train-set-to-publish/cantemist-norm/cc_onco31.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumor del estroma gastrointestinal	8936/3
train-set-to-publish/cantemist-norm/cc_onco31.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco31.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco706.ann	mesotelioma	9050/3
train-set-to-publish/cantemist-norm/cc_onco706.ann	T4N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco706.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco38.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco38.ann	adenocarcinoma mucinoso	8480/3
train-set-to-publish/cantemist-norm/cc_onco38.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco38.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco38.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco38.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco38.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco38.ann	cistoadenoma mucinoso	8470/0
train-set-to-publish/cantemist-norm/cc_onco38.ann	pseudomixoma peritonei	8480/6
train-set-to-publish/cantemist-norm/cc_onco38.ann	pseudomixoma peritoneal	8480/6
train-set-to-publish/cantemist-norm/cc_onco38.ann	teratoma maduro quístico	9080/0
train-set-to-publish/cantemist-norm/cc_onco38.ann	enfermedad diseminada	8000/6
train-set-to-publish/cantemist-norm/cc_onco38.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco38.ann	progresión pélvica	8000/6
train-set-to-publish/cantemist-norm/cc_onco435.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco435.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco435.ann	PE a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	Carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco160.ann	carcinoma de células escamosas	8070/3
train-set-to-publish/cantemist-norm/cc_onco160.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco160.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco160.ann	carcinoma de células escamosas bien diferenciado infiltrante	8070/31/H
train-set-to-publish/cantemist-norm/cc_onco160.ann	metástasis de carcinoma de células escamosas	8070/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	Nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	nódulo del LSD	8000/6
train-set-to-publish/cantemist-norm/cc_onco160.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco37.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco37.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco37.ann	angiosarcoma epitelioide	8804/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	angiosarcoma epitelioide	8804/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	Angiosarcoma epitelioide	8804/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	Angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco37.ann	nodulares subpleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco37.ann	lesiones pleurales	8000/6
train-set-to-publish/cantemist-norm/cc_onco37.ann	lesión subpleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	carcinoma de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco562.ann	implante tumoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco562.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	miomatoso	8895/0
train-set-to-publish/cantemist-norm/cc_onco562.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco562.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco562.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco562.ann	carcinoma renal de células claras (CCRc), estadio II (pT2) G1 de Fuhrman	8310/31
train-set-to-publish/cantemist-norm/cc_onco562.ann	CCRc	8310/3
train-set-to-publish/cantemist-norm/cc_onco562.ann	metástasis tiroidea por CCRc	8310/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	Carcinoma renal de células claras, Fuhrman 2, estadio IV (metástasis	8310/62
train-set-to-publish/cantemist-norm/cc_onco562.ann	metástasis procedentes de CCRc	8310/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	CCRc	8310/3
train-set-to-publish/cantemist-norm/cc_onco562.ann	metástasis por carcinoma de células claras, Fuhrman 2	8310/62
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulo hipoecoico en lóbulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	(LOE) de 15 mm hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	LOE en segmento hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulo hipoecoico en lóbulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	LOE de 15 mm hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulos heterogéneos en cuerpo y cola de páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulo mamario	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulos heterogéneos en cuerpo y cola de páncreas	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	recaída local y a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco562.ann	nódulo mamario	8000/6
train-set-to-publish/cantemist-norm/cc_onco985.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco985.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco985.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco985.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco985.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco985.ann	adenocarcinoma endometrioide pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco985.ann	neoplasia de endometrio tipo I estadio IB grado 3	8000/33
train-set-to-publish/cantemist-norm/cc_onco985.ann	adenocarcinoma pobremente diferenciado	8140/33
train-set-to-publish/cantemist-norm/cc_onco985.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco985.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco985.ann	nódulos peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco208.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco208.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco208.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco208.ann	pT1N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco208.ann	adenocarcinoma de sigma bien diferenciado	8140/31
train-set-to-publish/cantemist-norm/cc_onco208.ann	recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	neoformativa	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	Adenocarcinoma de sigma ,estadio IV, por afectación oligometastásica	8140/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	recaída pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	recaída precoz pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	nódulo tiroideo	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	RP pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	enfermedad estable tiroidea	8000/6
train-set-to-publish/cantemist-norm/cc_onco208.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco983.ann	CPT	8260/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	CPT estadio IV por afectación ósea	8260/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	enfermedad ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	progresión ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco983.ann	síndrome mielodisplásico	9989/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	síndrome mielodisplásico	9989/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	síndrome mielodisplásico	9989/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	síndrome mielodisplásico	9989/3
train-set-to-publish/cantemist-norm/cc_onco983.ann	síndrome mielodisplásico	9989/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco676.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco676.ann	mieloma	9732/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	mieloma leucemizante	9733/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	mieloma múltiple	9732/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	carcinoma de tiroides de células de Hürthle	8290/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	CCH	8290/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	CCH estadio IVc (pT3NxM1	8290/6
train-set-to-publish/cantemist-norm/cc_onco676.ann	CCH	8290/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	Carcinoma de tiroides de células de Hürthle	8290/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	CCH	8290/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	neoplasia de células plasmáticas	9731/3
train-set-to-publish/cantemist-norm/cc_onco676.ann	leucemia de células plasmáticas	9733/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	METÁSTASIS	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	METÁSTASIS	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	Melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco265.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	pT3aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco265.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	Melanoma maligno de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	extensión de enfermedad a otras localizaciones	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	MELANOMA MALIGNO	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	T3aN1bM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	MELANOMA MALIGNO	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	T3aN1bM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	MELANOMA MALIGNO	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	MELANOMA MALIGNO	8720/3
train-set-to-publish/cantemist-norm/cc_onco265.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	masa de partes blandas a nível de región dorsal	8000/6
train-set-to-publish/cantemist-norm/cc_onco265.ann	lesión nodular a nivel de extremidad	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco918.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco918.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco918.ann	melanoma avanzado con afectación hepática	8720/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	recidiva hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco918.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco918.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco918.ann	(LOE) hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco918.ann	LOE de nueva aparición en segmento VIII	8000/6
train-set-to-publish/cantemist-norm/cc_onco925.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco925.ann	linfangitis carcinomatosa	8000/3
train-set-to-publish/cantemist-norm/cc_onco925.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco925.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco925.ann	adenocarcinoma de pulmón T2 N1 M1	8140/6
train-set-to-publish/cantemist-norm/cc_onco925.ann	afectación pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco925.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco925.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco924.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco924.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco924.ann	angiosarcoma	9120/3
train-set-to-publish/cantemist-norm/cc_onco924.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco924.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco924.ann	neoplasias	8000/1
train-set-to-publish/cantemist-norm/cc_onco924.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco924.ann	angiosarcomas	9120/3
train-set-to-publish/cantemist-norm/cc_onco924.ann	pT2aN0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco924.ann	angiosarcoma moderadamente diferenciado	9120/32
train-set-to-publish/cantemist-norm/cc_onco230.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco230.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco230.ann	carcinoma ductal infiltrante, grado I	8500/31
train-set-to-publish/cantemist-norm/cc_onco230.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	adenocarcinoma infiltrante de bajo grado histológico (grado II)	8140/32
train-set-to-publish/cantemist-norm/cc_onco230.ann	adenocarcinoma de colon estadío IV (pTxNxM1)	8140/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	lesión lítica	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco230.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	Implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco761.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco761.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco761.ann	tumor del seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco761.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco761.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco761.ann	diseminación intraperitoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma inmaduro	9080/3
train-set-to-publish/cantemist-norm/cc_onco761.ann	variantes hepatoide	9071/3
train-set-to-publish/cantemist-norm/cc_onco761.ann	glandular de tipo endometrioide	8380/0
train-set-to-publish/cantemist-norm/cc_onco761.ann	Implantes en cúpulas diafragmáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	implantes subcentimétricos	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma de características histológicas maduras	9080/0
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma de características maduras	9080/0
train-set-to-publish/cantemist-norm/cc_onco761.ann	teratoma de características maduras	9080/0
train-set-to-publish/cantemist-norm/cc_onco761.ann	neoplásico maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco761.ann	implantes subcentimétricos	8000/6
train-set-to-publish/cantemist-norm/cc_onco761.ann	omental cake	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	implante pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco982.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco982.ann	adenocarcinoma de colón-recto con células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco982.ann	T3dN2M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	Adenocarcinoma de recto de células en anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco982.ann	afectación ganglionar, ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	adenocarcinoma de recto metastásico	8140/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	enfermedad en médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	infiltración generalizada de la médula ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	afectación en esqueleto	8000/6
train-set-to-publish/cantemist-norm/cc_onco982.ann	masa de partes blandas	8000/6
train-set-to-publish/cantemist-norm/cc_onco909.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco909.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco909.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco909.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco909.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco909.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco909.ann	linfoma B difuso de células grandes	9680/3
train-set-to-publish/cantemist-norm/cc_onco909.ann	Linfoma difuso de células grandes B	9680/3
train-set-to-publish/cantemist-norm/cc_onco909.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco408.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco408.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco408.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco408.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco408.ann	adenocarcinoma seroso de ovario de alto grado	8441/34
train-set-to-publish/cantemist-norm/cc_onco408.ann	letálides	8000/6
train-set-to-publish/cantemist-norm/cc_onco128.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco128.ann	lipoma	8850/0
train-set-to-publish/cantemist-norm/cc_onco128.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco128.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco128.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco128.ann	miomas	8895/0
train-set-to-publish/cantemist-norm/cc_onco128.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco128.ann	tumor neuroendocrino de páncreas (TNEP) grado 3	8240/33
train-set-to-publish/cantemist-norm/cc_onco128.ann	TNEP	8240/3
train-set-to-publish/cantemist-norm/cc_onco128.ann	TNEP	8240/3
train-set-to-publish/cantemist-norm/cc_onco128.ann	TNEP	8240/3
train-set-to-publish/cantemist-norm/cc_onco128.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco128.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco119.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco119.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco119.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco119.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco119.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco119.ann	carcinoma grado nuclear 2	8010/32
train-set-to-publish/cantemist-norm/cc_onco119.ann	CDI grado 1	8500/31
train-set-to-publish/cantemist-norm/cc_onco119.ann	T4bN1M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	progresión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	enfermedad sistémica	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco119.ann	progresión pleural	8000/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco200.ann	carcinoma renal de células claras multicéntrico	8310/3/H
train-set-to-publish/cantemist-norm/cc_onco200.ann	carcinoma renal de células claras multicéntrico	8310/3/H
train-set-to-publish/cantemist-norm/cc_onco200.ann	carcinoma renal de células claras	8310/3
train-set-to-publish/cantemist-norm/cc_onco200.ann	feocromocitoma	8700/0
train-set-to-publish/cantemist-norm/cc_onco200.ann	hemangioblastoma	9161/1
train-set-to-publish/cantemist-norm/cc_onco200.ann	hemangioblastoma	9161/1
train-set-to-publish/cantemist-norm/cc_onco200.ann	hemangioblastomas	9161/1
train-set-to-publish/cantemist-norm/cc_onco200.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco200.ann	tumoraciones	8000/1
train-set-to-publish/cantemist-norm/cc_onco200.ann	neurinoma	9560/0
train-set-to-publish/cantemist-norm/cc_onco200.ann	metástasis múltiples de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	metástasis de carcinoma renal de células claras	8310/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	cistoadenoma papilar	8450/0
train-set-to-publish/cantemist-norm/cc_onco200.ann	tumor de mayor tamaño de 5 cm, grado nuclear de Fuhrman II	8000/12
train-set-to-publish/cantemist-norm/cc_onco200.ann	masa palpable en el testículo	8000/6
train-set-to-publish/cantemist-norm/cc_onco200.ann	afectación de epidídimo	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco446.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco446.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco446.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco446.ann	pT4N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	implantes mesentéricos	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	lesión subcutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	lesión subcutánea	8000/6
train-set-to-publish/cantemist-norm/cc_onco446.ann	lesiones ocupantes de espacio supratentoriales	8000/6
train-set-to-publish/cantemist-norm/cc_onco164.ann	Tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco164.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco164.ann	carcinoma intraductal de alto grado	8500/24
train-set-to-publish/cantemist-norm/cc_onco164.ann	metástasis de acenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco164.ann	Carcinoma intraductal	8500/2
train-set-to-publish/cantemist-norm/cc_onco164.ann	cT4dNxM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco164.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco164.ann	metastásicas	8000/6
train-set-to-publish/cantemist-norm/cc_onco16.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco16.ann	linfoma	9590/3
train-set-to-publish/cantemist-norm/cc_onco16.ann	linfoma cerebral primario de célula T	9702/3
train-set-to-publish/cantemist-norm/cc_onco745.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco745.ann	carcinoma de mama ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco745.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco745.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco745.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco745.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco745.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	M1	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	enfermedad pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	lesiones pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco671.ann	nódulo pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumor neuroendocrino	8240/3
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumor neuroendocrino de bajo grado de origen desconocido, metastásico	8240/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco671.ann	cáncer de mama triple negativo metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	metástasis por carcinoma neuroendocrino de bajo grado	8246/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	T3N2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco671.ann	Tumor neuroendocrino de bajo grado con metástasis	8240/6
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinoma poco diferenciado	8010/33
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco463.ann	carcinomatosis	8010/9
train-set-to-publish/cantemist-norm/cc_onco463.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco463.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco463.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco463.ann	pT2pN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco463.ann	implantes de aspecto neoplásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco463.ann	cáncer de mama estadio IV con metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco463.ann	enfermedad a nivel peritoneal	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco175.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco175.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco175.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	nódulos hipodensos hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	nódulos hipodensos en ambos lóbulos hepáticos	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco175.ann	lesiones focales hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco280.ann	Enfermedad de Hodgkin	9650/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	Neoplasia maligna	8000/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	linfoma no Hodgkin	9591/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	mielofibrosis	9961/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco280.ann	síndrome linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco280.ann	sarcoma de células dendríticas foliculares	9758/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	Sarcoma de células dendríticas foliculares estadio IV (por infiltración de MO y lesiones óseas)	9758/6
train-set-to-publish/cantemist-norm/cc_onco280.ann	Linfoma de Hodgkin clásico tipo esclerosis nodular	9663/3
train-set-to-publish/cantemist-norm/cc_onco280.ann	lesiones líticas óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco280.ann	adenopatías a nivel lateterocervical, supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco280.ann	adenopática supra e infradiafragmática de predominio supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco895.ann	cT4N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco895.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco895.ann	carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco895.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco895.ann	enfermedad a distancia	8000/6
train-set-to-publish/cantemist-norm/cc_onco895.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco895.ann	metástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco895.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco895.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco895.ann	micrometástasis de carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco948.ann	carcinoma neuroendocrino	8246/3
train-set-to-publish/cantemist-norm/cc_onco948.ann	carcinoma neuroendocrino de célula pequeña	8041/3
train-set-to-publish/cantemist-norm/cc_onco948.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco948.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco948.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco948.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco948.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco948.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco948.ann	carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco948.ann	carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco948.ann	carcinoma indiferenciado	8020/3
train-set-to-publish/cantemist-norm/cc_onco890.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco890.ann	cT3N0M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco890.ann	maligno	8000/3
train-set-to-publish/cantemist-norm/cc_onco890.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco890.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco890.ann	adenoma prostático grado 2	8140/02
train-set-to-publish/cantemist-norm/cc_onco890.ann	adenocarcinoma prostático Gleason 5	8140/31
train-set-to-publish/cantemist-norm/cc_onco890.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco890.ann	angiosarcoma de alto grado	9120/34
train-set-to-publish/cantemist-norm/cc_onco193.ann	cM0	8000/6
train-set-to-publish/cantemist-norm/cc_onco193.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco193.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco193.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco193.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco193.ann	metástasis de melanoma	8720/6
train-set-to-publish/cantemist-norm/cc_onco193.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco193.ann	melanoma de extensión superficial	8743/3
train-set-to-publish/cantemist-norm/cc_onco193.ann	fibroadenomas	9010/0
train-set-to-publish/cantemist-norm/cc_onco193.ann	enfermedad pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco193.ann	melanoma avanzado por metástasis	8720/6
train-set-to-publish/cantemist-norm/cc_onco193.ann	nódulos en pulmón	8000/6
train-set-to-publish/cantemist-norm/cc_onco193.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco588.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	metastásico	8000/6
train-set-to-publish/cantemist-norm/cc_onco588.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco588.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco588.ann	neoplásico	8000/1
train-set-to-publish/cantemist-norm/cc_onco588.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco588.ann	tumores	8000/1
train-set-to-publish/cantemist-norm/cc_onco588.ann	pólipos adenomatosos	8210/0
train-set-to-publish/cantemist-norm/cc_onco588.ann	adenoma tubular de intestino grueso con displasia moderada-severa	8211/0/H
train-set-to-publish/cantemist-norm/cc_onco588.ann	carcinoma de células de anillo de sello	8490/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	tumor de Klastkin	8160/3
train-set-to-publish/cantemist-norm/cc_onco588.ann	Colangiocarcinoma extrahepático moderadamente diferenciado	8160/32
train-set-to-publish/cantemist-norm/cc_onco588.ann	implantes peritoneales	8000/6
train-set-to-publish/cantemist-norm/cc_onco588.ann	recaída peritoneal de colangiocarcinoma	8160/6
train-set-to-publish/cantemist-norm/cc_onco588.ann	lesiones nodulares en epiplón	8000/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	CDI	8500/3
train-set-to-publish/cantemist-norm/cc_onco989.ann	M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco989.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco989.ann	metástasis por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	metástasis por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	neoplasia	8000/1
train-set-to-publish/cantemist-norm/cc_onco989.ann	CDI de mama izquierda grado 3	8500/33
train-set-to-publish/cantemist-norm/cc_onco989.ann	metastásica	8000/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	lesión hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	recaída única hepática por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	recaída pectoral	8000/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	CDI de mama perfil luminal B en recaída sistémica	8500/6
train-set-to-publish/cantemist-norm/cc_onco989.ann	recaída de partes blandas por carcinoma	8010/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	afectación ósea	8000/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	neoplásica	8000/1
train-set-to-publish/cantemist-norm/cc_onco907.ann	proceso linfoproliferativo	9970/1
train-set-to-publish/cantemist-norm/cc_onco907.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco907.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco907.ann	adenocarcinoma de próstata Gleason 2 + 2	8140/31
train-set-to-publish/cantemist-norm/cc_onco907.ann	adenomas tubulovellosos	8263/0
train-set-to-publish/cantemist-norm/cc_onco907.ann	neoplasia gástrica infiltrante	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco907.ann	"carcinoma difuso de ""células en anillo de sello"""	8490/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	carcinoma difuso	8145/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	celularidad metastásica	8001/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	lesiones blásticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco907.ann	linitis plástica	8142/3
train-set-to-publish/cantemist-norm/cc_onco907.ann	lesión lítica	8000/6
train-set-to-publish/cantemist-norm/cc_onco814.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco814.ann	neoformativo	8000/1
train-set-to-publish/cantemist-norm/cc_onco814.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco814.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco814.ann	meduloblastoma clásico de localización vermiana, grado IV de la OMS	9470/34
train-set-to-publish/cantemist-norm/cc_onco814.ann	diseminación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco814.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco814.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco814.ann	meduloblastoma clásico de localización vermiana grado IV de la OMS	9470/34
train-set-to-publish/cantemist-norm/cc_onco814.ann	afectación leptomeníngea	8000/6
train-set-to-publish/cantemist-norm/cc_onco814.ann	realces leptomeníngeos	8000/6
train-set-to-publish/cantemist-norm/cc_onco663.ann	Carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	carcinoma lobulillar	8520/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco663.ann	células tumorales	8001/1
train-set-to-publish/cantemist-norm/cc_onco663.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco663.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco663.ann	carcinoma lobulillar de mama izquierda grado 2	8520/32
train-set-to-publish/cantemist-norm/cc_onco663.ann	neoplásicos	8000/1
train-set-to-publish/cantemist-norm/cc_onco849.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco849.ann	melanoma	8720/3
train-set-to-publish/cantemist-norm/cc_onco849.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco849.ann	recaída hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco849.ann	diseminación	8000/6
train-set-to-publish/cantemist-norm/cc_onco849.ann	lesiones hepáticas	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	afectación hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	carcinoma	8010/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	lesiones oseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	lesiones óseas	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	mieloma	9732/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	mieloma múltiple	9732/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	mieloma múltiple	9732/3
train-set-to-publish/cantemist-norm/cc_onco44.ann	recaída hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	tumorales	8000/1
train-set-to-publish/cantemist-norm/cc_onco44.ann	carcinoma ductal infiltrante de mama izquierda grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco44.ann	carcinoma ductal infiltrante de mama izquierda grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco44.ann	carcinoma ductal infiltrante grado III	8500/33
train-set-to-publish/cantemist-norm/cc_onco44.ann	pT3ypN2M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	lesiones hipodensas a nivel hepático	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	micronódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	LOE hepática	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	infiltración hepática por plasmocitoma	9731/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	cT3N1M0	8000/6
train-set-to-publish/cantemist-norm/cc_onco44.ann	afectación iliaca	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco110.ann	células malignas	8001/3
train-set-to-publish/cantemist-norm/cc_onco110.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	metástasis de adenocarcinoma	8140/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	tumoral	8000/1
train-set-to-publish/cantemist-norm/cc_onco110.ann	Adenocarcinoma	8140/3
train-set-to-publish/cantemist-norm/cc_onco110.ann	Mx	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	lesión pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	progresión a nivel pulmonar	8000/6
train-set-to-publish/cantemist-norm/cc_onco110.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco768.ann	TGNS	9065/3
train-set-to-publish/cantemist-norm/cc_onco768.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco768.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco768.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco768.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco768.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco768.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco768.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco768.ann	suelta de globos	8000/6
train-set-to-publish/cantemist-norm/cc_onco768.ann	tumor primitivo	8000/1/H
train-set-to-publish/cantemist-norm/cc_onco768.ann	carcinoma escamoso pobremente diferenciado	8070/33
train-set-to-publish/cantemist-norm/cc_onco768.ann	metástasis de tumor con diferenciación germinal de tipo trofoblástico	9064/6/H
train-set-to-publish/cantemist-norm/cc_onco768.ann	tumor germinal no seminomatoso mixto	9065/3/H
train-set-to-publish/cantemist-norm/cc_onco768.ann	tumor de seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco768.ann	Tumor germinal no seminomatoso (TGNS) mixto	9065/3/H
train-set-to-publish/cantemist-norm/cc_onco768.ann	tumor de seno endodérmico	9071/3
train-set-to-publish/cantemist-norm/cc_onco768.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	carcinoma embrionario	9070/3
train-set-to-publish/cantemist-norm/cc_onco845.ann	coriocarcinoma	9100/3
train-set-to-publish/cantemist-norm/cc_onco845.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	neoformación	8000/1
train-set-to-publish/cantemist-norm/cc_onco845.ann	seminoma	9061/3
train-set-to-publish/cantemist-norm/cc_onco845.ann	teratoma	9080/1
train-set-to-publish/cantemist-norm/cc_onco845.ann	teratoma maduro	9080/0
train-set-to-publish/cantemist-norm/cc_onco845.ann	tumor	8000/1
train-set-to-publish/cantemist-norm/cc_onco845.ann	tumor del saco vitelino	9071/3
train-set-to-publish/cantemist-norm/cc_onco845.ann	tumoración	8000/1
train-set-to-publish/cantemist-norm/cc_onco845.ann	adenopatía supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	adenopatía necrótica supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	TCG mixto	9085/3
train-set-to-publish/cantemist-norm/cc_onco845.ann	TCG mixto de teste derecho estadio pT3cN3cM1a	9085/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	enfermedad ganglionar (supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	adenopático supraclavicular	8000/6
train-set-to-publish/cantemist-norm/cc_onco845.ann	nódulos pulmonares	8000/6
train-set-to-publish/cantemist-norm/cc_onco644.ann	Carcinoma ductal infiltrante	8500/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	Carcinoma lobulillar infiltrante	8520/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	Metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco644.ann	cáncer	8000/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	malignidad	8000/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	metástasis	8000/6
train-set-to-publish/cantemist-norm/cc_onco644.ann	carcinoma ductal infiltrante, grado 2-3 con focos de diferenciación mucinosa	8523/33
train-set-to-publish/cantemist-norm/cc_onco644.ann	carcinoma lobulillar invasivo de alto grado	8520/34
train-set-to-publish/cantemist-norm/cc_onco644.ann	carcinoma invasivo	8010/3/H
train-set-to-publish/cantemist-norm/cc_onco644.ann	carcinoma de tipo lobulillar	8500/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	metástasis de su neoplasia	8000/6
train-set-to-publish/cantemist-norm/cc_onco644.ann	carcinoma de tipo lobulillar	8500/3
train-set-to-publish/cantemist-norm/cc_onco644.ann	lesiones conocidas en ambas mamas y a nivel óseo	8000/6
